<SEC-DOCUMENT>0001493152-25-021913.txt : 20251112
<SEC-HEADER>0001493152-25-021913.hdr.sgml : 20251112
<ACCEPTANCE-DATETIME>20251112160757
ACCESSION NUMBER:		0001493152-25-021913
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20251112
FILED AS OF DATE:		20251112
DATE AS OF CHANGE:		20251112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MILESTONE SCIENTIFIC INC.
		CENTRAL INDEX KEY:			0000855683
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				133545623
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14053
		FILM NUMBER:		251472704

	BUSINESS ADDRESS:	
		STREET 1:		220 SOUTH ORANGE AVENUE
		CITY:			LIVINGSTON
		STATE:			NJ
		ZIP:			07039
		BUSINESS PHONE:		(973) 535-2717

	MAIL ADDRESS:	
		STREET 1:		220 SOUTH ORANGE AVENUE
		CITY:			LIVINGSTON
		STATE:			NJ
		ZIP:			07039

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MILESTONE SCIENTIFIC INC/NJ
		DATE OF NAME CHANGE:	19970409

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	U S OPPORTUNITY SEARCH INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>formdef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:MLSS="http://milestonescientific.com/20241231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_ECD%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_MLSS_milestonescientific.com_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240101_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0000855683 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_065_Ratio_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000004" name="dei:EntityCentralIndexKey">0000855683</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0011" name="dei:DocumentType">DEF 14A</ix:nonNumeric>
  <ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0024" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0025" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0030" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0031" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_ecd_PeoMember_custom_ValueReportedUnderStockAwardsInSCTMember" id="xdx2ixbrl0045" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_ecd_PeoMember_custom_ValueReportedUnderStockAwardsInSCTMember" id="xdx2ixbrl0046" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_ecd_PeoMember_custom_FVOfUnvestedEquityAwardsAtYearEndMember" id="xdx2ixbrl0048" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_ecd_PeoMember_custom_FVOfUnvestedEquityAwardsAtYearEndMember" id="xdx2ixbrl0049" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_ecd_PeoMember_custom_FVOfVestedAwardsAsOfVestingDateMember" id="xdx2ixbrl0051" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_ecd_PeoMember_custom_FVOfVestedAwardsAsOfVestingDateMember" id="xdx2ixbrl0052" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_ecd_PeoMember_custom_FVOfVestedAwardsAsOfVestingDateMember" id="xdx2ixbrl0054" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_ecd_PeoMember_custom_FVOfVestedAwardsAsOfVestingDateMember" id="xdx2ixbrl0055" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="mlss-20241231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="ecd:RestatementDateAxis">
            <ecd:RestatementDateAxis.domain>2021-12-31</ecd:RestatementDateAxis.domain>
          </xbrldi:typedMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_ecd_PeoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_ecd_PeoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_ecd_PeoMember_custom_ValueReportedUnderStockAwardsInSCTMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">MLSS:ValueReportedUnderStockAwardsInSCTMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_ecd_PeoMember_custom_ValueReportedUnderStockAwardsInSCTMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">MLSS:ValueReportedUnderStockAwardsInSCTMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_ecd_PeoMember_custom_FVOfUnvestedEquityAwardsAtYearEndMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">MLSS:FVOfUnvestedEquityAwardsAtYearEndMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_ecd_PeoMember_custom_FVOfUnvestedEquityAwardsAtYearEndMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">MLSS:FVOfUnvestedEquityAwardsAtYearEndMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_ecd_PeoMember_custom_FVOfVestedAwardsAsOfVestingDateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">MLSS:FVOfVestedAwardsAsOfVestingDateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_ecd_PeoMember_custom_FVOfVestedAwardsAsOfVestingDateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">MLSS:FVOfVestedAwardsAsOfVestingDateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Ratio">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000020" toRefs="Footnote000032"/>
  <ix:relationship fromRefs="Fact000026" toRefs="Footnote000032"/>
  <ix:relationship fromRefs="Fact000021" toRefs="Footnote000035"/>
  <ix:relationship fromRefs="Fact000027" toRefs="Footnote000035"/>
  <ix:relationship fromRefs="xdx2ixbrl0024" toRefs="Footnote000036"/>
  <ix:relationship fromRefs="xdx2ixbrl0030" toRefs="Footnote000036"/>
  <ix:relationship fromRefs="xdx2ixbrl0025" toRefs="Footnote000037"/>
  <ix:relationship fromRefs="xdx2ixbrl0031" toRefs="Footnote000037"/>
  <ix:relationship fromRefs="Fact000022" toRefs="Footnote000038"/>
  <ix:relationship fromRefs="Fact000028" toRefs="Footnote000038"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MILESTONE
SCIENTIFIC AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
DC 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90E_edei--DocumentType_dxL_c20240101__20241231_zn3mT0QlFC87" title="::XDX::DEF 14A"><span style="-sec-ix-hidden: xdx2ixbrl0011">SCHEDULE
14A</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Proxy
Statement Pursuant to Section 14(a) of the Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exchange
Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
by the Registrant &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
by a Party other than the Registrant &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary
Proxy Statement</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Confidential,
for use of the Commission Only (as permitted by Rule 14a-6(e) (2))</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9746; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive
Proxy Statement</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive
Additional Materials</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
Material Pursuant to &#167;240.14a-12</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_906_edei--EntityRegistrantName_c20240101__20241231_zRvJnNjDk91d"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000012" name="dei:EntityRegistrantName">Milestone
Scientific Inc.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
of Registrant as Specified in its Charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Person(s) Filing Proxy Statement, if Other Than the Registrant)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
of Filing Fee (Check all boxes that apply):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    fee required.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee
    paid previously with preliminary materials</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee
    computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Milestone
Scientific Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notice
of Annual Meeting of Stockholders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>To
be held on December 18, 2025</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders of Milestone Scientific Inc.:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTICE
IS HEREBY GIVEN that the Annual Meeting of Stockholders (the &#8220;Meeting&#8221;) of Milestone Scientific Inc. (&#8220;Milestone&#8221;
or the &#8220;Company&#8221;) will be held in a <b>virtual-only </b>meeting format conducted via live audio webcast located at <span style="text-decoration: underline">www.virtualshareholdermeeting.com/MLSS2025</span>
on December 18, 2025 at 9:00 a.m. (ET).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following items are scheduled for consideration and action at the Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Election
    of six (6) directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval
    to amend the Corporation&#8217;s Restated Certificate of Incorporation, increasing the number of authorized shares of Common Stock
    from 100,000,000 shares to 125,000,000;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ratification
    of the appointment of CBIZ CPAs P.C. as the Company&#8217;s independent auditors for the fiscal year ending December 31, 2025; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
    other business as may legally come before the Meeting and any adjournments or postponements thereof.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors has fixed the close of business on November 4, 2025, as the record date for determining the stockholders having the
right to notice of and to vote at the Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Attending
the Virtual Meeting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in the proxy materials for the Meeting, you are entitled to attend and participate in the virtual Meeting if you were a stockholder
of record as of the close of business on November 4, 2025, the record date, or if you hold a legal proxy for the Meeting provided by
your bank, broker-dealer, or other similar organization. The accompanying proxy materials include instructions on how to participate
in the Meeting and how to vote your shares of the Company&#8217;s stock in the Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
attending the Meeting will be in a listen-only mode. However, virtual attendees will be able to vote and submit questions during the
Meeting using the virtual Meeting website.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
vote is important. Whether or not you plan to attend the Meeting, you are encouraged to vote as soon as possible to ensure that your
shares are represented at the Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Important
Notice Regarding the Internet Availability of Proxy Material for the Annual Meeting of Stockholders to be Held on December 18, 2025.
This Proxy Statement, the Proxy Card, and our Annual Report for 2024 are available at: www.virtualshareholdermeeting.com/MLSS2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
order of the Board of Directors</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neal
Goldman</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
of the Board</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Roseland,
New Jersey</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
12, 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPORTANT:
Every stockholder, whether he or she expects to attend the Annual Meeting, is urged to execute the proxy and return it promptly in the
enclosed business reply envelope. Sending in your proxy will not prevent you from voting your stock at the Annual Meeting if you desire
to do so, as your proxy is revocable at your option. We would appreciate your giving this matter your prompt attention.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MILESTONE
SCIENTIFIC INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROXY
STATEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
Annual Meeting of Stockholders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>To
be Held on December 18, 2025</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
proxy is solicited on behalf of the Board of Directors (which we refer to as our &#8220;Board&#8221;) of Milestone Scientific Inc., a
Delaware corporation (which we refer to as &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; or the &#8220;Company&#8221;), for
use at our 2025 Annual Meeting of Stockholders (which we refer to as the &#8220;Annual Meeting&#8221;) to be held on Thursday December
18, 2025 at 9:00 a.m. Eastern time, or at any continuation, postponement or adjournment thereof, for the purposes discussed in this Proxy
Statement. Proxies are solicited to allow all stockholders of record to vote on matters properly presented at the Annual Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Important
                                            Notice Regarding the Availability of Proxy Materials for the Stockholders</b>&#8217;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Meeting
    to Be Held Via the Internet at </b><span style="text-decoration: underline">www.virtualshareholdermeeting.com/MLSS2025</span></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>on
    Thursday, December 18, 2025 at 9:00 a.m. local time.</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Annual Report, Notice of Meeting, and Proxy Statement</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are
    available at &#8211; www.proxyvote.com</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to mail this Proxy Statement, the proxy card, and the Notice of Annual Meeting on or about November 7, 2025, to all stockholders
of record entitled to vote at the Annual Meeting. If you would like a hard copy of the Annual Report, Notice of Meeting, Proxy Statement
and Proxy Card for this Annual Meeting, or any future stockholder meetings, mailed or emailed to you, please contact us at 425 Eagle
Rock Avenue, Roseland, NJ 07068, at our web page www.milestonescientific.com or, telephone us at 973-535-2717.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
VOTING AND VOTE REQUIRED</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Record
Date and Quorum</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Only
stockholders of record at the close of business on November 4, 2025 (the &#8220;Record Date&#8221;) are entitled to notice of and vote
at the Annual Meeting. On the Record Date, there were 78,628,913 outstanding shares of common stock, par value $.001 per share (&#8220;Common
Stock&#8221;). Each share of Common Stock is entitled to one vote. Shares represented by each properly executed, unrevoked proxy received
in time for the Annual Meeting will be voted as specified. A quorum will be present at the Annual Meeting if stockholders owning not
less than one-third of the shares issued and outstanding on the Record Date are present at the meeting in person or by proxy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Voting
of Proxies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
persons acting as proxies pursuant to the enclosed proxy will vote the shares represented as directed in the signed proxy. Unless otherwise
directed in the proxy, the proxyholders will vote the shares represented by the proxy: (i) for the election of the six (6) director nominees
named in this Proxy Statement; (ii) for the approval to amend the Corporation&#8217;s Restated Certificate of Incorporation increasing
the number of authorized shares of Common Stock from 100,000,000 shares to 125,000,000 shares; (iii) for the ratification of the appointment
of CBIZ CPSs P.C. as the Milestone Scientific&#8217;s independent auditors for the fiscal year ending December 31, 2025; and (iv) in
the proxyholders&#8217; discretion, on any other business that may come before the meeting and any adjournments thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are a stockholder of record, which means your shares are in your name, you may vote your shares as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    vote in person, attend the Annual Meeting and the 16-digit control number found on your proxy card to register and vote.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    vote through the Internet, go to <span style="text-decoration: underline">www.proxyvote.com</span> to complete an electronic proxy card. You will be asked to provide the
    control number on the proxy card delivered to you. Your Internet vote must be received by 11:59 p.m., Eastern Time on December 17,
    2025 to be counted.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    vote using the proxy card delivered to you, simply complete, sign, and date the proxy card and return it promptly in the envelope
    provided or use a touch-tone telephone to transmit your voting instructions by calling 1-800-579-1639. If you return your signed
    proxy card to us before the Annual Meeting, we will vote your shares as you direct.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you hold your shares of common stock in street name, which means that your shares are held of record by a broker, bank or other nominee,
you will receive instructions from your broker, bank or other nominee on how to vote your shares by either (i) attending the Annual Meeting
and voting in person; (ii) through the Internet; or (iii) otherwise instructing the broker, bank or other nominee on how to vote your
shares. Please note that if you hold your shares of common stock in street name, in order to vote your shares in person at the Annual
Meeting, you will need to obtain from your broker, bank or other nominee, a valid legal proxy from your broker, bank or other nominee
authorizing you to vote your shares at the Annual Meeting. After obtaining a valid legal proxy from your broker, bank or other agent,
to then register to vote at the Annual Meeting, you must submit proof of your legal proxy reflecting the number of your shares along
with your name and email address and mail to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 50%">&#160;</td>
  <td style="text-align: left; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VOTE BY MAIL</span></td>
  </tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vote Processing, c/o Broadridge,</span></td>
  </tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51 Mercedes Way</span></td>
  </tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td style="text-align: left">Edgewood, NY 11717</td>
  </tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
information regarding the rules and procedures for participating in the Annual Meeting will be provided at the meeting website.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
inspector of elections appointed for the Annual Meeting will tabulate votes cast by proxy or in person at the Annual Meeting. The inspector
of elections will also determine whether a quorum is present. In order to constitute a quorum for the conduct of business at the Annual
Meeting, a one-third in voting power of all of the shares of the stock entitled to vote at the Annual Meeting must be present in person
or represented by proxy at the Annual Meeting. Shares that abstain from voting on any proposal, or that are represented by broker non-votes
(as defined below), will be treated as shares that are present and entitled to vote at the Annual Meeting for purposes of determining
whether a quorum is present.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are a beneficial owner of shares held in street name and you do not instruct your broker, bank, or other agent how to vote your shares,
your broker, bank, or other agent may still be able to vote your shares at its discretion. In this regard, under the rules of the New
York Stock Exchange, or NYSE American, brokers, banks, and other securities intermediaries that are subject to NYSE American rules may
use their discretion to vote your &#8220;uninstructed&#8221; shares with respect to matters considered to be &#8220;routine&#8221; under
NYSE American rules, but not with respect to &#8220;non-routine&#8221; matters. When a beneficial owner of shares held in &#8220;street
name&#8221; does not give instructions to the broker or nominee holding the shares as to how to vote on matters deemed by the NYSE American
to be &#8220;non-routine,&#8221; the broker or nominee cannot vote the shares. These unvoted shares are counted as &#8220;broker non-votes.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the election of directors (Proposal 1) and the approval to increase the authorized number of shares of common stock (Proposal
2) will be considered non-routine matters. For Proposal 1 broker non-votes will not be counted as votes cast and will have no effect
on the result of the vote; however for Proposal 2, broker non-votes will not be counted as votes cast but will have the effect of a vote
against the proposal because of the requirement to have the proposal approved by a majority of the issued and outstanding shares of common
stock. We believe that the ratification of the appointment of CBIZ CPAs P.C. as our independent registered public accounting firm
(Proposal 3) will be considered to be a routine matter on which a broker, bank or other agent has discretionary authority to vote.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Voting
Requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Election
of Directors</b>. The election of the director nominees will require a plurality of the votes cast at the Annual Meeting. With respect
to the election of directors, votes may be cast in favor of or withheld with respect to each nominee. Votes that are withheld will be
excluded entirely from the vote and will have no effect on the outcome of the vote.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Approval
to Amend the Restated Certificate of Incorporation to increase the number of Authorized Shares of Common Stock from 100,000,000 to 125,000,000.
</b>The affirmative vote of the majority of the shares issued and outstanding cast by stockholders entitled to vote at the Annual Meeting
is required to approve this matter. An abstention will be treated as &#8220;present&#8221; for quorum purposes. Abstention&#8217;s and
broker non-votes will have the same effect as an against vote on the matter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ratification
of the appointment of Independent Auditors.</b> The affirmative vote of a majority of the votes cast at the Annual Meeting by stockholders
entitled to vote at the Annual Meeting is required to approve this matter. An abstention will be treated as &#8220;present&#8221; for
quorum purposes. Abstention&#8217;s will have the same effect as an against vote on the matter and broker non-votes will have no effect
on the matter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revocability
of Proxy. </b>A proxy may be revoked by the stockholder giving the proxy at any time before it is voted by delivering oral or written
notice to the Corporate Secretary of Milestone Scientific at or prior to the Annual Meeting, and a prior proxy is automatically revoked
by a stockholder giving a subsequent proxy or attending and voting at the Annual Meeting. Attendance at the Annual Meeting in and of
itself does not revoke a prior proxy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expenses
of Solicitation</b>. Our Board is soliciting proxies for the Annual Meeting from our stockholders. We will bear the entire cost of soliciting
proxies from our stockholders. In addition to the solicitation of proxies by delivery of this Proxy Statement through the Internet or
by mail, we will request that brokers, banks and other nominees that hold shares of our common stock, which are beneficially owned by
our stockholders, forward proxies and proxy materials to those beneficial owners and secure those beneficial owners&#8217; voting instructions.
We will reimburse those record holders for their reasonable expenses. We may use several of our regular employees, who will not be specially
compensated, to solicit proxies from our stockholders, either personally or by Internet, facsimile or special delivery letter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will also consider any other business that properly comes before the Annual Meeting, or any adjournment or postponement thereof. As of
the record date, we are not aware of any other matters to be submitted for consideration at the Annual Meeting. If any other matters
are properly brought before the Annual Meeting, the persons named as your proxy will vote the shares as recommended by our Board, or
if no recommendation is given, in their own discretion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholder
List</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
list of stockholders eligible to vote at the Annual Meeting will be available for inspection, for any purpose germane to the Annual Meeting,
at the Annual Meeting and at principal executive office of the Company during regular business hours for a period of no less than ten
(10) days prior to the Annual Meeting.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Forward-Looking
Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Proxy Statement contains &#8220;forward-looking statements&#8221; (as defined in the Private Securities Litigation Reform Act of 1995).
These statements are based on our current expectations and involve risks and uncertainties, which may cause results to differ materially
from those set forth in the statements. The forward-looking statements may include statements regarding actions to be taken by us. We
undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Forward-looking statements should be evaluated together with the many uncertainties that affect our business, particularly those mentioned
in the risk factors in Item 1A of our 2024 Annual Report on Form 10-K and in our Quarterly Reports on Form 10-Q and our Current Reports
on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPOSAL
1</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ELECTION
OF DIRECTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(ITEM
1 ON THE PROXY CARD)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board currently consists of six (6) members, four (4) of whom are independent under the listing standards for independence of the NYSE
American and under Rule 10A-3 under the Securities Exchange Act of 1934, as amended (which we refer to as the &#8220;Exchange Act&#8221;).
Based upon the recommendation of the Nominating and Corporate Governance Committee of our Board, our Board determined to nominate each
of the Company&#8217;s current directors: Benedetta I. Casamento, Neal Goldman, Eric Hines,  Dr. Didier Demesmin, Shanth Thiyagalingam,
and Dr. Dawood Sayed for election at the Annual Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board and the Nominating Committee believe the directors nominated collectively have the experience, qualifications, attributes and skills
to effectively oversee the management of the Company, including a high degree of personal and professional integrity, an ability to exercise
sound business judgment on a broad range of issues, sufficient experience and background to have an appreciation of the issues facing
the Company, a willingness to devote the necessary time to Board duties, a commitment to representing the best interests of the Company
and our stockholders and a dedication to enhancing stockholder value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
director elected at the Annual Meeting will serve a one (1) year term until the Company&#8217;s next annual meeting and until his or
her successor is duly elected and qualified or until his or her earlier death, resignation, or removal. Unless otherwise instructed,
the proxyholders will vote the proxies received by them for the six (6) nominees named below. If any of the nominees is unable or declines
to serve as a director at the time of the Annual Meeting, the proxies will be voted for any nominee designated by the present Board to
fill the vacancy. It is not expected that any of the nominees named below will be unable or will decline to serve as a director. If additional
persons are nominated for election as directors, the proxyholders intend to vote all proxies received by them in a manner to assure the
election of as many of the nominees listed below as possible. In such event, the specific nominees to be voted for will be determined
by the proxyholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Set forth below are the names, ages and positions
of our director nominees as of the date of this Proxy Statement (1):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NAME</b></span></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGE</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>POSITION</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DIRECTOR
    SINCE</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benedetta
    Casamento</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="margin: 0">Chairman of the Board of Directors</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neal
    Goldman</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="margin: 0">Vice Chairman of the Board</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric
    Hines</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="margin: 0">Chief Executive Officer and Director</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Didier Demesmin</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shanth
                                            Thiyagalingam</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Dawood Sayed</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) As of the date of this Proxy Statement,
Neal Goldman is Chairman of the Board of Directors; however, upon their election, Benedetta Casamento will become Chairman of the Board
of Directors and Neal Goldman Vice Chairman.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Recommendation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OUR
BOARD RECOMMENDS A VOTE &#8220;FOR&#8221; EACH OF THE SIX (6) NOMINEES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
DIRECTOR NAMED IN THIS PROXY STATEMENT.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vacancies
on our Board, including any vacancy created by an increase in the size of our Board, may be filled by a majority of the directors remaining
in office (even though less than a quorum of our Board) or a sole remaining director, or by the stockholders. A director elected by our
Board to fill a vacancy will serve until the next annual meeting of stockholders and until such director&#8217;s successor is elected
and qualified, or until such director&#8217;s earlier retirement, resignation, disqualification, removal, or death.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Information
about Director Nominees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is biographical information for each director nominee and a summary of the specific qualifications, attributes, skills and
experiences which led our Board to conclude that each nominee should serve on our Board at this time. There are no family relationships
among any of the directors or executive officers of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Benedetta
I. Casamento,  Director</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benedetta
Casamento has served as a director of the Company since April 2022. Since August 2017, Ms. Casamento has served as a consultant
and a board member specializing in strategy, finance, and operations. Ms. Casamento previously served as Chairman and President
of Allyke, Inc., an artificial intelligence company creating digital imagery insights for retail and other industries, from June 2016
to August 2017. From December 2014 to April 2016, she served as Chief Executive Officer of Calypso St. Barth, a luxury boutique retailer
of women&#8217;s apparel and accessories. Prior to her role as CEO at Calypso St. Barth, Ms. Casamento served as a consultant to private
equity firms with portfolio interests in retail and fashion from July 2012 to December 2014. Ms. Casamento previously served as Executive
Vice President, Finance &amp; Operations of The Talbots, Inc. (&#8220;Talbots&#8221;), a specialty retailer and direct marketer of women&#8217;s
apparel, accessories, and shoes, from March 2009 to July 2012. Prior to joining Talbots, Ms. Casamento served in various leadership roles
within Liz Claiborne Inc. from February 1999 to November 2008, culminating in her position as President of Liz Claiborne Brands. Ms.
Casamento started her career at Saks Fifth Avenue. Our Board has determined that Ms. Casamento&#8217;s extensive business experience,
as well as her background in accounting and finance, qualifies her to serve on the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neal
Goldman, Chairman of the Board</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neal
Goldman has been a director of Milestone Scientific since 2019 and has served as Chairman of the Board since January 2024. Mr.
Goldman is the President and Founder of Goldman Capital Management, Inc., a family office since 2018, which was previously an investment
advisory firm founded in 1985. He was First Vice President of Research at Shearson Lehman Hutton. He has also held senior positions as
a money manager and research analyst with a variety of firms including Neuberger Berman, Moseley Hallgarten Estabrook and Weeden, Bruns
Nordeman, and Russ and Company. Mr. Goldman serves as Chairman of Charles &amp; Colvard, Ltd. since 2016 and served on the board
of Imageware Systems, Inc. until November 2020. He also serves on the board of Deep-Down Inc. Prior to their respective acquisitions,
he served on the boards of Blyth Industries and IPASS Corporation. Mr. Goldman received his B.A. degree in Economics from The City University
of New York (City College). Mr. Goldman&#8217;s professional experience and financial background have given him the expertise needed
to serve as one of our directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr.
Didier Demesmin, Director</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Demesmin has been a director of Milestone Scientific since 2024. He is currently the Chief Executive Officer and Medical Director of
University Pain Medicine Center, a position he has held since 2007. Since March 2006, Dr. Demesmin has held the position of Director
of the Pain Management Department at St. Peter&#8217;s University Hospital. He is also a physician in the Departments of Pain Medicine
at JFK Medical Center (since March 2007), Robert Wood Johnson University Hospital (since January 2008), Somerset Medical Center (since
February 2009), Hudson Regional Hospital (since December 2010), and Saint Barnabas Hospital (since November 2013). Dr. Demesmin is also
a Clinical Instructor in the Department of Medicine at Rutgers Robert Wood Johnson Medical School (since August 2006), a Clinical Assistant
Professor in the Department of Physical Medicine and Rehabilitation at Rutgers Robert Wood Johnson Medical School (since July 2013),
the Medical Director in the Physical Medicine and Rehabilitation and Sports Medicine Institute at St. Peter&#8217;s University Hospital
(since (December 2013), and an Assistant Fellowship Program Director in the Multidisciplinary Interventional Pain Medicine Fellowship
at JFK Johnson Rehabilitation Institute (since November 2013). Dr. Demesmin has been a member of the Board of Trustees of the New Jersey
Society of Interventional Pain Physicians, since September 2010, and the Middlesex County Medical Society of New Jersey, since January
2010, where he held the positions of President Elect, from June 2011 to June 2012, and President, from June 2012 to June 2014. Dr. Demesmin
received a BA in Psychology from Rutgers University in 1994, a Medical Degree from the University of Medicine and Dentistry of New Jersey
in 2000, and an MBA from the Kellogg School of Management of Northwestern University in 2018. Mr. Demesmin&#8217;s medical healthcare background
in the field of interventional pain management and business background have given him the expertise needed to serve as one of
our directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shanth
Thiyagalingam <i>Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Thiyagalingam has been a director of Milestone Scientific since 2025. He currently serves as Chief Executive Officer of PainTEQ, a manufacturer
of proprietary medical equipment focused on interventional pain therapy. From 2020 through 2025, he held successive leadership roles
at the company&#8212;from Chief Commercial Officer to Chief Operating Officer, and ultimately as CEO. During his tenure, he led the company&#8217;s
transformation from early-stage startup to hyper-growth innovator in the interventional pain space. He also led M&amp;A initiatives and
was instrumental in securing a Category 1 CPT code for the LinQ procedure&#8212;a new therapy in the interventional pain market. Under
his leadership, PainTEQ was recognized three years in a row by the INC 5000 and named a &#8220;Best Place to Work&#8221; by the Tampa
Bay Business Journal. He holds a Bachelor of Medical Science from the University of Sydney, a Master&#8217;s in Marketing Management,
and an MBA from Macquarie Graduate School of Management (MGSM). He is also a certified Gallup Strengths Coach and is passionate about
fostering high-performance cultures and mentoring emerging leaders in the medtech industry. Mr. Thiyagalingam&#8217;s medical, marketing
/ commercialization background in the area of medical devices and business background have given him the expertise needed to serve
as one of our directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Eric
Hines, <i>President, Chief Executive Officer and Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Hines has been President, Chief Executive Officer and a director of Milestone Scientific since July 31, 2025. He most recently served
as President of North America at Ex Libris Group (September 2014 - June 2021), a global provider of cloud-based solutions for higher
education and libraries. From June 2021 to July 2025, Mr. Hines was involved in providing consulting services for Alethea, a technology
start-up company, and also invested in commercial and personal real estate ventures. Prior to his role at Ex Libris Group, Mr. Hines
held various roles at NICE Systems (October 2004-June 2014), a multinational company that designs and manufactures smart home security
and automation products. Mr. Hines served as Senior Director of Sales at NICE Systems from October 2004 to November 2005 and subsequently
served as Vice President of several North American divisions of NICE Systems from November 2005 through June 2014. Prior thereto, Mr.
Hines served as Regional Director of Sales at AMDOCS Clarify CRM (October 2003- October 2004), a provider of customer relationship management
(CRM) solutions to the communications industry. Mr. Hines received a Bachelor of Science in Chemistry from Wake Forest University in
1989 and an MBA in International Business from Xavier University in 1996.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dawood
Sayed, M.D., <i>Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Sayed is a Professor of Anesthesiology and Pain Medicine at the University of Kansas Medical Center and currently serves as Division
Chief of Pain Medicine, Director of Interventional Spine Services, and Director of the Center for Neuromodulation. With a robust clinical,
academic, and policy background, he brings over a decade of leadership in pioneering minimally invasive pain therapies, neuromodulation,
and health system innovation. Dr. Sayed also serves as Vice Chairman and Co-Founder of the American Society of Pain and Neuroscience
(ASPN), where he works closely with key stakeholders, including commercial payers, regulators, and medical device manufacturers to advance
access to innovative pain relief technologies. His leadership has earned him multiple honors, including the 2025 Presidential Award from
the North American Neuromodulation Society (NANS). Dr. Sayed has authored over 100 peer-reviewed publications, contributed to national
guidelines in pain medicine, and currently leads multiple clinical trials evaluating neuromodulation and spinal therapies. He also serves
as a medical advisor to several leading medtech innovators and participates on national AMA CPT&#174; and NANS advocacy committees. Dr.
Sayed&#8217; s medical healthcare background has given him the expertise needed to serve as one of our directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CORPORATE
GOVERNANCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Leadership Structure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board believes that the segregation of the roles of Board Chairman and the Chief Executive Officer ensures better overall governance
of the Company and provides meaningful checks and balances regarding its overall performance. This structure allows our Chief Executive
Officer to focus on developing and implementing the Company&#8217;s business plans and supervising the Company&#8217;s day-to-day business
operations and allows our Chairman to lead the Board in its oversight and advisory roles. Because of the many responsibilities
of the Board and the significant time and effort required by each of the Chairman and the Chief Executive Officer to perform their
respective duties, the Company believes that having separate persons in these roles enhances the ability of each to discharge those duties
effectively and enhances the Company&#8217;s prospects for success. The Company also believes that having separate positions provides
a clear delineation of responsibilities for each position and fosters greater accountability of management. For the foregoing reasons,
the Board has determined that its leadership structure is appropriate and in the best interest of stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Board</b>&#8217;<b>s Oversight of Risk Management</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board recognizes that companies face a variety of risks, including China operation risk, liquidity/capital accessibility risk, medical
product acceptance risk, and operational risk. The Board believes an effective risk management system will (1) timely identify the material
risks that we face; (2) communicate necessary information with respect to material risks to senior executives and, as appropriate, to
the Board or relevant Board committee; (3) implement appropriate and responsive risk management strategies consistent with the Company&#8217;s
risk profile; and (4) integrate risk management into the Company&#8217;s decision-making. The Board encourages, and management promotes,
a corporate culture that incorporates risk management into the Company&#8217;s corporate strategy and day-to-day business operations.
The Board also continually works, with the input of management and executive officers, to assess and analyze the most likely areas of
future risk for the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Composition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board may establish the authorized number of directors from time to time by resolution. Our Board currently consists of six (6) authorized
members. During the year ended December 31, 2024, our Board met six (6) times. All&#160; of our Board members attended at least 75% of
the aggregate of all Board meetings and all meetings of the Board committees upon which they served while they were on the Board during
fiscal 2024. Our Board does not have a policy regarding Board members&#8217; attendance at meetings of our stockholders and five members
of our Board attended our prior year&#8217;s annual meeting of stockholders. The Board also acted by unanimous consent six (6) times
during fiscal 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
under the listing requirements and rules of the NYSE American, independent directors must comprise a majority of a listed company&#8217;s
board of directors. Our Board regularly undertakes a review of its composition, the composition of its committees and the independence
of each director. Our Board has determined that, none of our current directors or director nominees, other than Mr. Hines and Dr.
Demesmin have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities
of a director and that each is &#8220;independent&#8221; as that term is defined under the applicable rules and regulations of the SEC
and the listing requirements and rules of the NYSE American. In making this determination, our Board considered the current and prior
relationships that each nonemployee director nominee has with our Company and all other facts and circumstances our Board deemed relevant
in determining their independence, including the beneficial ownership of our capital stock by each nonemployee director nominee. Accordingly,
the majority of our directors are independent as of the date of this Proxy Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Committees
of the Board </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board has standing audit, compensation, and nominating and corporate governance committees (respectively, the &#8220;Audit Committee,&#8221;
the &#8220;Compensation Committee,&#8221; and the &#8220;Nominating Committee.&#8221;)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee reviews and recommends to the Board the compensation and benefits of all officers of the Company, reviews general
policy matters relating to compensation and benefits of employees of the Company and administers the issuance of stock options to the
Company&#8217;s officers, employees, directors, and consultants. It also provides recommendations to the Board with respect to non-employee
director compensation. The Compensation Committee may not delegate its authority to any other person, other than to a subcommittee. Chairman</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee meets with management and the Company&#8217;s independent accountants to determine the adequacy of internal controls
and other financial reporting matters. The Audit Committee&#8217;s purpose is to: (A) assist the Board in its oversight of: (i) the integrity
of our financial statements; (ii) our compliance with legal and regulatory requirements; (iii) our independent auditors&#8217; qualifications
and independence; (iv) the performance of our internal audit function and independent auditors to decide whether to appoint, retain or
terminate our independent auditors; and (v) the preparation of our Annual Report on Form 10-K for the fiscal year ended December 31,
2024 (the &#8220;Annual Report&#8221;); and (B) to pre-approve all audit, audit-related and other services, if any, to be provided by
the independent auditors. Chairman</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Committee Financial Expert</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board has determined that Benedetta Casamento is an &#8220;audit committee financial expert,&#8221; as that term is defined in Item 407(d)(5)
of Regulation S-K, and &#8220;independent&#8221; for purposes of the listing standards of the NYSE American and Section 10A(m)(3) of
the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nominating
Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nominating Committee identifies potential director nominees and evaluates their suitability to serve on the Board. Based on its evaluation,
it recommends to the Board the director nominees for Board membership. In addition, the Nominating Committee also evaluates each existing
Board member&#8217;s suitability for continued service as a director. Chairman</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nominating Committee believes that the minimum qualifications for service as a director of the Company are that a nominee possess an
ability, as demonstrated by recognized success in his or her field, to make meaningful contributions to the Board&#8217;s oversight of
the business and affairs of the Company and an impeccable reputation of integrity and competence in his or her personal or professional
activities. The Nominating Committee&#8217;s criteria for evaluating potential candidates include the following: an understanding of
the Company&#8217;s business environment; and the possession of such knowledge, skills, expertise and diversity of experience so as to
enhance the Board&#8217;s ability to manage and direct the affairs and business of the Company including, when applicable, to enhance
the ability of committees of the Board to fulfill their duties and/or satisfy any independence requirements imposed by law, regulation
or listing requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nominating Committee considers director candidates recommended by stockholders. In considering candidates submitted by stockholders,
the Committee will take into consideration the needs of the Board and the qualifications of the candidate. The Nominating Committee may
also take into consideration the number of shares held by the recommending stockholder and the length of time that such shares have been
held. To have a candidate considered by the Nominating Committee, a stockholder must submit the recommendation in writing and must include
the following information: the name of the stockholder and evidence of the person&#8217;s ownership of Company stock, including the number
of shares owned and the length of time of ownership; the name of the candidate, the candidate&#8217;s resume or a listing of his or her
qualifications to be a director of the Company; and, the person&#8217;s consent to be named as a director if selected by the Nominating
Committee and nominated by the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nominating Committee may also receive suggestions from current Board members, the Company&#8217;s executive officers or other sources,
which may be either unsolicited or in response to requests from the Nominating Committee for such candidates. The Nominating Committee
also, from time to time, may engage firms that specialize in identifying director candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
a person has been identified by the Nominating Committee as a potential candidate, it may collect and review publicly available information
regarding the person to assess whether the person should be considered further. If the Nominating Committee determines that the candidate
warrants further consideration, the Chairman or another member of the Nominating Committee may contact the person. Generally,
if the person expresses a willingness to be considered and to serve on the Board, the Nominating Committee may request information from
the candidate, review the person&#8217;s accomplishments and qualifications and may conduct one or more interviews with the candidate.
The Nominating Committee may consider all such information considering information regarding any other candidates that it might be evaluating
for membership on the Board. In certain instances, Nominating Committee members may contact one or more references provided by the candidate
or may contact other members of the business community or other persons that may have greater first-hand knowledge of the candidate&#8217;s
accomplishments. The Nominating Committee&#8217;s evaluation process does not vary based on whether a candidate is recommended by a stockholder,
although, as stated above, the Board may take into consideration the number of shares held by the recommending stockholder and the length
of time that such shares have been held.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board has determined that Benedetta Casamento, Neal Goldman,  Dr. Dawood Sayed, and Shanth Thiyagalingam (the &#8220;Independent Directors&#8221;)
are independent, as that term is defined in the listing standards of the NYSE American. In determining director independence, the Board
also considered all equity awards, if any, to the Independent Directors for the year ended December 31, 2024, disclosed in &#8220;Director
Compensation&#8221; below, and determined that such awards were compensation for services rendered to the Board and therefore did not
impact their ability to continue to serve as Independent Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholder
Communication with the Board </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board has established a process to receive communications from stockholders. Stockholders and other interested parties may contact any
member (or all members) of the Board, or the non-management directors as a group, any Board committee, or any chair of any such committee
by mail or electronically. To communicate with the Board, any individual director or any group or committee of directors, correspondence
should be addressed to the Board or any such individual directors or group or committee of directors by either name or title. All such
correspondence should be sent &#8220;c/o Corporate Secretary&#8221; at 425 Eagle Rock Ave., Suite 403, Roseland, New Jersey 07068. The
Corporate Secretary of the Company will open all communications received as set forth in the preceding paragraph for the sole purpose
of determining whether the contents represent a message to our directors. Any contents that are not in the nature of advertising, promotions
of a product or service, patently offensive material or matters deemed inappropriate for the Board will be forwarded promptly to the
addressee. In the case of communications to the Board or any group or committee of directors, the Company&#8217;s Corporate Secretary
will make sufficient copies of the contents to send to each director who is a member of the group or committee to which the envelope
is addressed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section
16(a) Beneficial Ownership Reporting Compliance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16(a) of the Exchange Act requires our officers and directors, and person who own more than ten percent of a registered class of our
equity securities, to file reports of ownership and changes in ownership with the SEC. Officers, directors and greater than ten-percent
stockholders are required by SEC regulation to furnish us with copies of all Section 16(a) forms they file. Based solely on review of
the copies of such forms furnish to us, or written representations that no Forms 5 were required, we believe that all Section 16(a) filing
requirements applicable to our officers and director were complied with during the fiscal year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Insider
Trading Arrangements and Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBQb2xpY2llcyBhbmQgUHJvY2VkdXJlcwA_" id="xdx_909_eecd--InsiderTrdPoliciesProcAdoptedFlag_dbT_c20240101__20241231_zVzFBQ1EZl6h"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000013" name="ecd:InsiderTrdPoliciesProcAdoptedFlag">adopted</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an insider trading compliance policy governing the purchase,
sale, and/or other dispositions of our securities by our directors, officers, and employees that we believe is reasonably designed to
promote compliance with insider trading laws, rules and regulations, and the exchange listing standards applicable to us. The insider
trading policy prohibits the use of material non-public information about the Company when making decisions to purchase, sell, give away
or otherwise trade in the Company&#8217;s securities or to provide such information to others outside the Company. We have established
blackout periods to which covered persons are subject with respect to the filing of our regular reports with the Securities and
Exchange Commission. The Company may impose additional blackout periods from time to time as other types of material non-public information
occur when non-public material events or disclosures are pending. Covered persons are permitted to trade in the Company&#8217;s securities
only when there is no blackout period in effect and such trade has been pre-cleared by the appointed Company officer, or when a qualified
10b5-1 plan has been established in accordance with federal securities laws. No covered person has adopted or terminated a Rule 10b5-1
trading plan during the last fiscal quarter of the fiscal year to which this report relates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Ethics</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milestone
Scientific has adopted a code of ethics that applies to its directors, principal executive officer, principal financial officer, and
other people performing similar functions. This code of ethics is posted on Milestone Scientific&#8217;s website at <span style="text-decoration: underline">www.milestonescientific.com</span>.
Milestone Scientific will also provide a copy of the Code of Ethics to any person without charge, upon written request addressed to the
Chairman of the Board, Neal Goldman, at the Company&#8217;s principal executive office, located at 425 Eagle Rock Avenue,
Roseland, NJ 07068.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clawback
Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eecd--ErrCompAnalysisTextBlock_c20240101__20241231__ecd--RestatementDateAxis__2021-12-31_zGD9Y8xnpRni" class="xdx_phnt_RGlzY2xvc3VyZSAtIFJlY292ZXJ5IG9mIEVycm9uZW91c2x5IEF3YXJkZWQgQ29tcGVuc2F0aW9uAA__"><ix:nonNumeric contextRef="From2024-01-012024-12-31_2021-12-31" escape="true" id="Fact000014" name="ecd:ErrCompAnalysisTextBlock">Our
Board has adopted a written policy to recover &#8220;excess&#8221; compensation that is granted, earned, or vested based wholly or in
part upon the attainment of a financial reporting measure. The compensation includes both cash-based and equity-based incentives. The
compensation covered includes incentive awards awarded to any individuals (including former employees) who served as an executive officer
during the three most recently completed fiscal years preceding the date on which the preparation of an accounting restatement is required,
provided that the executive officers were awarded more incentive awards than they would have received if the financial statements had
been prepared correctly. The recovery will include an executive incentive award even if the executive was not involved in preparing the
financial statements or did not commit misconduct that led to the restatement. Restatements attributable to an inadvertent error also
will subject executive officers to the recovery of previously received incentive awards.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employee,
Officer, and Director Hedging</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
policy against insider trading prohibits all employees and directors from engaging in any short sales of our securities, hold our securities
in a margin account, or pledge our securities as collateral for a loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eecd--AwardTmgMnpiDiscTextBlock_c20240101__20241231_zDvvtwvVb7J" class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000015" name="ecd:AwardTmgMnpiDiscTextBlock">The
Compensation Committee approves all equity award grants to our named executive officers (NEO) on or before the grant date. The committee&#8217;s
general practice is to complete its annual executive compensation review and determine performance goals and target compensation for
our NEOs, and then equity awards are granted to NEOs and become effective. Annual equity awards are typically granted to our NEOs in
March. On occasion, the compensation committee may grant equity awards outside of our annual grant cycle for new hires, promotions, recognition,
retention or other purposes. While the compensation committee has discretionary authority to approve equity awards to our NEOs outside
of the cycle described above, the compensation committee follows a practice of <span id="xdx_906_eecd--AwardTmgMnpiCnsdrdFlag_dbF_c20240101__20241231_zqG8UZ8s5md8" class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000016" name="ecd:AwardTmgMnpiCnsdrdFlag">not</ix:nonNumeric></span> granting equity awards when the company anticipates
releasing material nonpublic information and, in any event, we do <span id="xdx_90E_eecd--MnpiDiscTimedForCompValFlag_dbF_c20240101__20241231_zPjtMA4h4jaj" class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000017" name="ecd:MnpiDiscTimedForCompValFlag">not</ix:nonNumeric></span> time the release of material non-public information in coordination
with grants of equity awards in a manner that intentionally benefits our NEOs.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY
COMPENSATION TABLE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following Summary Compensation Table sets forth all compensation earned, in all capacities, during the fiscal years ended December 31,
2024 and 2023 by Milestone Scientific&#8217;s (i) chief executive officer during the last completed fiscal year and (ii) two most highly
compensated executive officers, other than the chief executive officer, who were serving as executive officers at the end of the last
completed fiscal year and whose salary as determined by Regulation S-K, Item 402, exceeded $100,000 (the individuals falling within categories
(i) and (ii) are collectively referred to as the &#8220;Named Executive Officers.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Name and Principal Position</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Year</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Salary</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Bonuses</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Option Awards</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Other Compensation</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Total</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Jan Adriaan (Arjan) Haverhals (1) (3)</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 41%; text-align: left">Chief Executive Officer - Wand Dental Inc</td><td style="width: 2%">&#160;</td>
    <td style="width: 6%; text-align: center">2024</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">350,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">478,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">53,422</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">881,422</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">President of Milestone Scientific Inc.</td><td>&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">350,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">281,853</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">48,412</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">680,265</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Peter Milligan (2)</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Chief Financial Officer</td><td>&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;&#160;&#160;&#160;-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">170,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    2024 Mr. Haverhals was awarded $478,000 in a discretionary performance bonus for the year ended December 31, 2024. Other compensation
    represents payments made for health insurance coverage of approximately $39,000 and car allowance of approximately $14,000. Mr. Haverhals
    was awarded $281,000 in a discretionary performance bonus for the year ended December 31, 2023. Other compensation represents payments
    made for health insurance coverage of approximately $34,000 and car allowance of approximately $14,000.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    Milligan was appointed as the Chief Financial Officer of the Company February 1, 2023. He was awarded a $100,000 bonus for joining
    the company to be paid in shares of stock. On August 24, 2023 the Company announced that Peter Milligan resigned from the Company
    effective September 1, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Haverhals resigned as the Chief Executive Officer of the Company as of December 31, 2024.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Eric Hines became the Chief Executive Officer on July 31, 2025. From July 31, 2025 through December 31, 2025 (the &#8220;Initial Term&#8221;),
Mr. Hines will be entitled to base compensation at the rate of $15,000 per month. From January 1, 2026, subject to Mr. Hines&#8217;s
continued employment at the Company by mutual agreement (the &#8220;Extended Term&#8221;), Mr. Hines will be entitled to base compensation
at the rate of $25,000 per month. Mr. Hines was granted options (the &#8220;Signing Bonus Options&#8221;) for an aggregate of 2,000,000
shares of Common Stock of the Company. The exercise price of the Signing Bonus Options is $0.50. Ten percent (10%) of the Signing Bonus
Options will vest on the date of grant and the remaining ninety percent (90%) will vest in three (3) equal annual installments of 600,000
shares each. Mr. Hines will receive an annual incentive bonus, comprised of (i) separate performance-based bonuses; and (ii) a discretionary
bonus, each as determined by the Company&#8217;s Compensation Committee, in its sole discretion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pay
versus Performance Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(v) of Regulation S-K, we are providing the following information about the relationship between executive compensation actually paid (as defined by SEC rules) and certain financial performance metrics of the Company. For further information concerning the Company&#8217;s compensation philosophy and how the Company aligns executive compensation with the Company&#8217;s performance, refer to &#8220;&#8212;Compensation Philosophy and Objectives&#8221; and &#8220;&#8212;Compensation Elements&#8221;.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000019" name="ecd:PvpTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88F_eecd--PvpTableTextBlock_zq6prL7svOmc" summary="xdx: Disclosure - Pay vs Performance Disclosure" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td>&#160;</td><td style="font-style: italic">&#160;</td>
    <td colspan="2" id="xdx_48E_eecd--PeoTotalCompAmt_hecd--IndividualAxis__ecd--PeoMember_zkiSFXM1Flya" style="border-bottom: Black 1pt solid; font-style: italic"><span id="xdx_F50_zlT3owQFUjRj" style="font-family: Times New Roman, Times, Serif">(a)</span></td><td style="font-style: italic">&#160;</td><td style="font-style: italic">&#160;</td>
    <td colspan="2" id="xdx_485_eecd--PeoActuallyPaidCompAmt_zdTBalimNL8c" style="border-bottom: Black 1pt solid; font-style: italic"><span id="xdx_F58_zDJd37nhkgP6" style="font-family: Times New Roman, Times, Serif">(b)</span></td><td style="font-style: italic">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-style: italic"><span style="font-family: Times New Roman, Times, Serif">(c)</span></td><td style="font-style: italic">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-style: italic"><span style="font-family: Times New Roman, Times, Serif">(d)</span></td><td style="font-style: italic">&#160;</td>
    <td colspan="2" id="xdx_48A_eecd--TotalShareholderRtnAmt_pp2d_zcNlbKvZm00f" style="border-bottom: Black 1pt solid; font-style: italic"><span id="xdx_F50_zSSBzlw9pNv9" style="font-family: Times New Roman, Times, Serif">(e)</span></td><td style="font-style: italic">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_485_eus-gaap--NetIncomeLoss_zMCRN15epKe1" style="border-bottom: Black 1pt solid">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Value of Initial Fixed $100 Investment Based on:</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center; font-weight: bold">Year</td><td style="text-align: left; font-weight: bold">&#160;</td><td style="text-align: left; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Summary Compensation Table Total for PEO<br/>
($)</td><td style="text-align: left; font-weight: bold">&#160;</td><td style="text-align: left; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Compensation Actually Paid to PEO<br/>
($)</td><td style="text-align: left; font-weight: bold">&#160;</td><td style="text-align: left; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Average Summary Compensation Table Total for Non-PEO NEO&#8217;s<br/>
($)</td><td style="text-align: left; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Average Compensation Actually Paid to Non-PEO NEO&#8217;s<br/>
($)</td><td style="text-align: left; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Total Shareholder Return <br/>
($)</td><td style="text-align: left; font-weight: bold">&#160;</td><td style="text-align: left; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Net Income<br/>
 ($)</td><td style="text-align: left; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_414_20240101__20241231_zfb9bxFdPee4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; width: 9%; text-align: center">2024</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2024-01-012024-12-31_ecd_PeoMember" id="Fact000020" format="ixt:numdotdecimal" decimals="0" unitRef="USD">881,422</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000021" format="ixt:numdotdecimal" decimals="0" unitRef="USD">881,422</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="text-align: right; width: 14%"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eecd--NonPeoNeoAvgTotalCompAmt_c20240101__20241231_fKGMp_zBlJIf9XSpFe" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0024">-</span></span></span>n/a</td><td style="width: 2%">&#160;</td>
    <td style="text-align: right; width: 12%"><span id="xdx_906_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20240101__20241231_fKGQp_zQ7SrlQOh5s7" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0025">-</span></span>n/a</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><ix:nonFraction name="ecd:TotalShareholderRtnAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000022" format="ixt:numdotdecimal" decimals="2" unitRef="USD">137.14</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000023" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,713,597</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_415_20230101__20231231_zWkOoQBUHpvk" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: bottom; text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2023-01-012023-12-31_ecd_PeoMember" id="Fact000026" format="ixt:numdotdecimal" decimals="0" unitRef="USD">680,265</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2023-01-012023-12-31" id="Fact000027" format="ixt:numdotdecimal" decimals="0" unitRef="USD">680,265</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eecd--NonPeoNeoAvgTotalCompAmt_c20230101__20231231_fKGMp_zMMPUIshnIJ9" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0030">-</span></span>n/a</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20230101__20231231_fKGQp_zrxU16swoBTi" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0031">-</span></span>n/a</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ecd:TotalShareholderRtnAmt" contextRef="From2023-01-012023-12-31" id="Fact000028" format="ixt:numdotdecimal" decimals="2" unitRef="USD">150.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000029" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,929,104</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; display: none; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0B_z2AP2ADOexH9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_ztvD86PHUWd9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000032" xml:lang="en-US">The
    amounts reported in this column are the amounts of total compensation reported for <span id="xdx_90E_eecd--PeoName_c20230101__20231231_zqRdsMtPhZr6"><span id="xdx_907_eecd--PeoName_c20240101__20241231_zmayI0bM3Y88"><ix:nonNumeric contextRef="From2023-01-012023-12-31" id="Fact000033" name="ecd:PeoName"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000034" name="ecd:PeoName">Mr. Haverhals</ix:nonNumeric></ix:nonNumeric></span></span>, Chief Executive Officer, for each
    corresponding year in the &#8220;Total&#8221; column of the Summary Compensation Table (&#8220;SCT&#8217;) on page 12 of this proxy
    statement.</ix:footnote></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F07_zov9weRot5l8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1E_zTnv2lIE7oM1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000035" xml:lang="en-US">The
    amounts reported in this column represent the amount of compensation actually paid (&#8220;CAP&#8221;) Mr. Haverhals as computed
    in accordance with Item 402(v) of Regulation S-K, but do not reflect the actual amount of compensation earned by or paid to Mr. Haverhals
    during the applicable year. The determination of CAP begins with the total compensation reported in the SCT, which is then adjusted
    by equity-based and other compensation as set forth in the following table. For equity-based awards made during the year, the recorded
    grant date value is replaced with the estimated year-end value. For equity-based awards made in prior years that remain unvested
    at year-end, the estimated change in value from the beginning to the end of the year is included. For equity-based awards made in
    prior years, but vested during the year, the estimated change in value from the beginning of the year to the date of vesting is included:</ix:footnote></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0D_zNCI6ef3Inxk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zyyLbhWfMmF4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000036" xml:lang="en-US">The
    amounts reported in this column represent the average of the amounts reported for the Company&#8217;s Non-CEO named executive officer&#8217;s
    (&#8220;NEOs&#8221;) as a group in the &#8220;Total&#8221; column of the SCT in each applicable year. There were no NEO&#8217;s at
    the company during 2024 and 2023, respectively.</ix:footnote></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0C_zNY53xTgdw3h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zdUN7XDbOYs9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000037" xml:lang="en-US">The
    amounts reported in this column represent the average amount of CAP to the Non-CEO NEOs as a group, as computed in accordance with
    Item 402(v) of Regulation S-K. Since there were no adjustments to be made for these NEO&#8217;s, the amounts actually paid are equal
    to the SCT amounts calculated in the previous column.</ix:footnote></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F01_zgwpVZFf0hff" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_zHlVXctfPb9i" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000038" xml:lang="en-US">This
    represents the year-end value of an initial $100 investment made at the beginning of the period.</ix:footnote></span></td></tr>
</table>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000040" name="ecd:AdjToPeoCompFnTextBlock"><p id="xdx_891_eecd--AdjToPeoCompFnTextBlock_dU_znX9qEJHLhTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Calculation of Compensation Actually Paid to PEO (column b)</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20241231_zoMRZbjr2hLi" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_zXTWDsneJER" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eecd--PeoTotalCompAmt_zQ91A81q8oVk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Total Summary Compensation Paid Table (SCT) - column (a)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000042" format="ixt:numdotdecimal" decimals="0" unitRef="USD">881,422</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2023-01-012023-12-31" id="Fact000043" format="ixt:numdotdecimal" decimals="0" unitRef="USD">680,265</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eecd--AdjToCompAmt_hecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ValueReportedUnderStockAwardsInSCTMember_ziuhK0SIt8h4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: value reported under stock awards in the SCT</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0045">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0046">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eecd--AdjToCompAmt_hecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--FVOfUnvestedEquityAwardsAtYearEndMember_z9e9k8vSD4i1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Add: FV of unvested equity awards at year-end 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0048">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0049">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eecd--AdjToCompAmt_hecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--FVOfVestedAwardsAsOfVestingDateMember_zgFNlA89vAC5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Add: FV of vested awards as of the vesting date.</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0051">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0052">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eecd--AdjToCompAmt_hecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--FVOfVestedAwardsAsOfVestingDateMember_zt9JzYYPyTQ2" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Adjustment to Compensation Amount</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0054">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0055">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eecd--PeoActuallyPaidCompAmt_zfE4bxfcjOe3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Compensation actually paid</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">881,422</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2023-01-012023-12-31" id="Fact000058" format="ixt:numdotdecimal" decimals="0" unitRef="USD">680,265</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zwS2MRXQp43d" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000060" name="ecd:NamedExecutiveOfficersFnTextBlock"><p id="xdx_896_eecd--NamedExecutiveOfficersFnTextBlock_dU_zil8ZrYNAs6h" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amounts reported in this column are the amounts of total compensation reported for <span id="xdx_907_eecd--PeoName_c20230101__20231231_zjT7BL49fKR8"><span id="xdx_906_eecd--PeoName_c20240101__20241231_zsfrw315eH67"><ix:nonNumeric contextRef="From2023-01-012023-12-31" id="Fact000061" name="ecd:PeoName"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000062" name="ecd:PeoName">Mr. Haverhals</ix:nonNumeric></ix:nonNumeric></span></span>, Chief Executive Officer, for each
    corresponding year in the &#8220;Total&#8221; column of the Summary Compensation Table (&#8220;SCT&#8217;) on page 12 of this proxy
    statement.</span></td></tr>

</table>

</ix:nonNumeric><p id="xdx_8AA_zdOzA9dRImw1" style="margin: 0; display: none">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000064" name="ecd:Additional402vDisclosureTextBlock"><p id="xdx_891_eecd--Additional402vDisclosureTextBlock_dU_zARRJIaWXtJ2" style="margin: 0; display: none">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amounts reported in this column represent the amount of compensation actually paid (&#8220;CAP&#8221;) Mr. Haverhals as computed
    in accordance with Item 402(v) of Regulation S-K, but do not reflect the actual amount of compensation earned by or paid to Mr. Haverhals
    during the applicable year. The determination of CAP begins with the total compensation reported in the SCT, which is then adjusted
    by equity-based and other compensation as set forth in the following table. For equity-based awards made during the year, the recorded
    grant date value is replaced with the estimated year-end value. For equity-based awards made in prior years that remain unvested
    at year-end, the estimated change in value from the beginning to the end of the year is included. For equity-based awards made in
    prior years, but vested during the year, the estimated change in value from the beginning of the year to the date of vesting is included:</span></td></tr>

</table>

</ix:nonNumeric><p id="xdx_8A0_zYz55lGOQO17" style="margin: 0; display: none">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amounts reported in this column represent the average of the amounts reported for the Company&#8217;s Non-CEO named executive officer&#8217;s
    (&#8220;NEOs&#8221;) as a group in the &#8220;Total&#8221; column of the SCT in each applicable year. There were no NEO&#8217;s at
    the company during 2024 and 2023, respectively.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amounts reported in this column represent the average amount of CAP to the Non-CEO NEOs as a group, as computed in accordance with
    Item 402(v) of Regulation S-K. Since there were no adjustments to be made for these NEO&#8217;s, the amounts actually paid are equal
    to the SCT amounts calculated in the previous column.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    represents the year-end value of an initial $100 investment made at the beginning of the period.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
and Consulting Contracts</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 2, 2021, the Company entered into a Royalty Sharing Agreement with Leonard Osser, pursuant to which Mr. Osser sold, transferred
and assigned to the Company all of his rights in and to a certain patent application as to which he is a co-inventor with Mark Hochman,
a consultant to the Company, and the Company agreed to pay to Mr. Osser, beginning May 9, 2027, half of the royalty (2.5%) on net sales
that would otherwise be payable to Mark and Claudia Hochman under their existing Technology Sale Agreement, dated January 1, 2005 and
amended from time to time, with the Company. In connection with the Royalty Sharing Agreement, the Hochman&#8217;s agreed with the Company,
pursuant to an addendum to such Technology Sale Agreement dated February 25, 2021, to reduce from 5% to 2.5% the payments due to them
under their Technology Sale Agreement beginning on May 9, 2027, and thereafter with respect to dental products embodying the invention.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the Succession Plan of the Company, Mr. Osser agreed, pursuant to an agreement dated April 6, 2021 (the &#8220;Succession Agreement&#8221;),
to restructure certain of his existing agreements with the Company, which provide for additional and broader executive support, and at
such time as he elects to step down as Interim Chief Executive Officer of the Company, to become the Vice Chairman of the Board
of the Company. With respect to Mr. Osser&#8217;s July 2017 Employment Agreement and July 2017 Consulting Agreement (each as previously
disclosed), the compensation under the Employment Agreement was modified to reduce the overall compensation by $100,000 to $200,000,
split equally between a cash amount and an amount in shares, and the compensation under the Consulting Agreement was increased by $100,000
to $200,000, equally split between a cash amount and an amount in shares, which shares were formerly payable under the Employment Agreement.
If the Company terminates Mr. Osser&#8217;s employment &#8220;Without Cause,&#8221; other than due to his death or disability, or if
Mr. Osser terminates his employment for &#8220;Good Reason&#8221; (both as defined in the agreement), Mr. Osser is entitled to be paid
in one lump sum payment as soon as practicable following such termination: an amount equal to the aggregate present value (as determined
in accordance with Section 280G(d)(4) of the Code) of all compensation pursuant to this agreement from the effective date of termination
hereunder through the remainder of the Employment Term. In connection with his acceptance of the Vice Chairman position and in
consideration of his services as a member of the Board and agreement to provide certain additional general consulting services, Mr. Osser
was granted options to purchase 2,000,000 shares of common stock, exercisable at the fair market value of the common stock on the date
of grant, vesting over the five-year period after he steps down as Interim Chief Executive Officer of the Company or ten years from the
date of grant, whichever shall end first. On May 19, 2021, Mr. Osser resigned as Interim Chief Executive Officer of the Company and assumed
the role of Vice Chairman of the Board. On November 7, 2025 Mr. Osser resigned as Vice Chairman and Director.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
under the Employment Agreement and the Consulting Agreement is payable for 9.5 years from May 19, 2021. The Company recorded expenses
of $200,000 related to the Employment Agreement for each of the years ended December 31, 2024 and 2023, respectively. The Company
recorded expenses of $200,000 and $200,000 related to the Consulting Agreement for each of the years ended December 31, 2024 and 2023,
respectively. Mr. Osser also owns 2,717,765 of the Company&#8217;s stock, and 2,481,048 shares to be issued at the termination of his
employment agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Arjan Haverhals retired as the Chief Executive Officer and other officer positions with the Company on December 31, 2024. The Company
entered into a consulting agreement with Mr. Arjan Haverhals that commenced on January 1, 2025, and continues for an indefinite period,
subject to the Company having the right to terminate the Consulting Agreement on 30 days advance notice in the event of his disability
to provide services and either party having the right to terminate the Consulting Agreement on 90 days&#8217; advance notice. Mr. Haverhals
will be paid an annual fee at the rate of $350,000, at the rate of $150,000 in respect of the first calendar quarter of 2025, and at
the rate of $66,666, in respect of each subsequent calendar quarter of 2025, payable monthly in arrears, in each case in equal monthly
installments on the last day of each month of such quarter. The Company will reimburse Mr. Haverhals for reasonable expenses in providing
the services. Mr. Haverhals will be an independent contractor and will not be provided with health and accident insurance, life insurance,
paid sick leave and/or paid vacation time. In connection with the Consulting Agreement, he has also entered into a Company-standard form
of non-disclosure, non-solicitation, non-competition and invention agreement. Mr. Haverhals will be issued 895,012 shares of the
Company&#8217;s stock ninety days after the termination of his consulting relationship.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Objective
of Executive Compensation Program</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary objective of the executive compensation program is to attract and retain qualified, energetic managers who are enthusiastic about
the mission and culture of Milestone Scientific. A further objective of the compensation program is to provide incentives and reward
each manager for their contribution. In addition, Milestone Scientific strives to promote an ownership mentality among key leadership
and the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee reviews and approves, or in some cases recommends for the approval of the full Board, the annual compensation
procedures for the Named Executive Officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation program is designed to reward teamwork, as well as each manager&#8217;s individual contribution. In measuring the Named
Executive Officers&#8217; contribution, the Compensation Committee considers numerous factors including the growth strategic business
relationships and financial performance. Regarding most compensation matters, including executive and director compensation, management
provides recommendations to the Compensation Committee; however, the Compensation Committee does not delegate any of its functions to
others in setting compensation. Milestone Scientific does not currently engage any consultant to advise on executive and/or director
compensation matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
price performance has not been a factor in determining annual compensation because the price of Milestone Scientific&#8217;s common stock
is subject to a variety of factors outside of Milestone Scientific&#8217;s control. Milestone Scientific does not have an exact formula
for allocating between cash and non-cash compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
CEO compensation consists of a base salary component, a bonus component (payable in a mix of cash and stock) and periodic stock option
grants. The Compensation Committee intends to set totals for the CEO for cash compensation sufficiently high enough to attract and retain
a strong motivated leadership team, but not so high that it creates a negative perception with the other stakeholders. The CEO receives
stock option grants under the stock option plan. The number of stock options granted to the executive officer is made on a discretionary
rather than a formula basis by the Compensation Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CEO&#8217;s current and prior compensation is considered in setting future compensation. To some extent, the compensation plan is based
on the market and the companies that compete for executive management. The elements of the plan (e.g., base salary, bonus, and stock
options) are like the elements used by many companies. The exact base pay, stock option grant, and bonus amounts are chosen to balance
the competing objectives of fairness to all stakeholders and attracting and retaining executive managers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards on December 31, 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Name</td><td style="padding-bottom: 1pt; text-align: left; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Number of Securities Underlying Unexercised Options (#) Exercisable<br/>
 (1)</td><td style="padding-bottom: 1pt; text-align: left; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Number of Securities Underlying Unexercised Options (#) Unexercisable<br/>
 (1)</td><td style="padding-bottom: 1pt; text-align: left; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Option Exercise Price<br/>
 ($)</td><td style="padding-bottom: 1pt; text-align: left; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Option Expiration Date</td><td style="padding-bottom: 1pt; text-align: left; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Number of Shares or Units of Stock that have not vested <br/>
(#) (2)</td><td style="padding-bottom: 1pt; text-align: left; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Market Value of Number of Shares or Units of Stock that have not vested<br/>
 (#) (3)</td><td style="padding-bottom: 1pt; text-align: left; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 13%">Jan Adriaan (Arjan ) Haverhals</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">167,739</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">48,557</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1.52</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 12%">3/30/2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">638,024</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">612,503</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">167,739</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">48,557</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">638,024</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">612,503</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leonard Osser</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">703,518</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/22/2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,481,046</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,381,804</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,200,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.47</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">4/23/2031</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">32,175</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3.11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2/9/2026</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,935,693</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">800,000</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,481,046</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,381,804</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,103,432</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">848,557</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,119,070</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,994,307</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table includes certain information with respect to all unexercised stock options and unvested shares of common stock of Milestone
Scientific outstanding owned by the Named Executive Officers on December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    stock option grants at fair market value on the date of grant.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of the shares of common stock have been deferred until the termination of employment with Milestone Scientific in accordance with
    the terms of respective employment arrangements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on the closing price per share of $0.96 as reported on the NYSE American on December 31, 2024</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Compensation for Fiscal Year Ended December 31, 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fees Earned paid in cash<br/>
$</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Stock Awards<br/>
 $</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options Award<br/>
 $</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Non-Equity Incentive Plan Compensation<br/>
 $</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Change in pension value and nonqualified deferred compensation earnings<br/>
 $</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">All other Compensation</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fees Earned paid in cash<br/>
$</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total<br/>
 $</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Neal Goldman</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">120,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">120,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Benedetta Casamento</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">120,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">120,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leonard Osser</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dr. Didier Demesmin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Michael McGeehan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gian Domenico Trombetta (1)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Resigned as of January 12, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Security
Ownership of Certain Beneficial Owners and Management and Related Stockholders Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table, together with the accompanying footnotes, sets forth information, as of November 4, 2025, regarding stock ownership
of all persons known by Milestone Scientific to own beneficially more than 5% of Milestone Scientific&#8217;s outstanding common stock,
Named Executives, all directors, and all directors and executive officers of Milestone Scientific as a group</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">Name of Beneficial Owner (1)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares of Common Stock Beneficially Owned (2)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Percentage</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-bottom: 1pt">Benedetta Casamento (3)</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 16%; text-align: right">404,490</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 12%; text-align: right">0.51</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Neal Goldman (4)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">2,325,856</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">2.96</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Eric Hines (5)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">325,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Jan Adriaan (Arjan) Haverhals (8)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">895,012</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">1.14</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Michael McGeehan (6)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">575,273</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Dr. Didier Demesmin</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">112,356</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Shanth Thiyagalingam</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Dawood Sayed, M.D</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Leonard Osser (7)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">5,198,813</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">6.61</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">All directors &amp; executive officers as a group (9 persons)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">9,836,801</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">12.51</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">BP4 SpA (9)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">8,896,765</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">11.31</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">* Less than 1%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    addresses of the persons named in this table are as follows: Eric Hines, Leonard Osser, Neal Goldman, Michael McGeehan, Benedetta
    Casamento, Arjan Haverhals, Shanth Thiyagalingam, Dawood Sayed, M.D. and Dr. Didier Demesmin are at 425 Eagle Rock Avenue, Roseland,
    New Jersey 07068. </span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    person is deemed to be a beneficial owner of securities that can be acquired by such person within 60 days from October 31, 2025,
    as applicable, upon the exercise of options and warrants or conversion of convertible securities. Each beneficial owner&#8217;s percentage
    ownership is determined by assuming that options, warrants, and convertible securities that are held by such person (but not held
    by any other person) and that are exercisable or convertible within 60 days from October 31, 2025, have been exercised or converted.
    Except as otherwise indicated, and subject to applicable community property and similar laws, each of the persons named has sole
    voting and investment power with respect to the shares shown as beneficially owned. The percentages for each beneficial owner are
    determined based on dividing the number of shares of common stock beneficially owned by the sum of the outstanding shares of common
    stock on May 28, 2024, and the number of shares underlying options exercisable and convertible securities convertible within 60 days
    from October 31, 2025, held by the beneficial owner.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    404,490 shares held by Mrs. Casamento.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    2,325,856 shares held by Mr. Goldman.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    325,000 shares held by Mr. Hines</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    575,273 shares held by Mr. McGeehan </span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    2,717,765 shares held by Mr. Osser or his family, 2,481,048 shares to be issued at the termination of his employment agreement, and
    1,279,975 vested stock options to purchase common stock of the Company.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    895,012 shares to be issued at the termination of Mr. Haverhals&#8217; consulting agreement on December 31, 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,896,765
    shares held directly by BP4 U.R.L. (&#8220;BP4&#8221;) of which 5,982,906 shares were issued upon the conversion of $7 million of
    preferred stock at $1.17 per share, as adjusted to date. Innovest S.p.A. (&#8220;Innovest&#8221;) is the controlling shareholder
    of BP4 and Dr. Pedro Palau, Liquidator is a controlling shareholder </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Authorized for Issuance under Equity Compensation Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity
Compensation Plan Information (as of December 31, 2024)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">Equity compensation plan approved by stockholders</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Securities to be issued upon exercise of outstanding options and warrants</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted-average exercise price of outstanding options and warrants</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of securities remaining available for future issuance under equity compensation plan</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Grants under our 2020 Stock Option Plan (1)</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">3,051,985</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">2.12</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">7,579,778</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">3,051,985</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">7,579,778</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    2020 plan, as amended and restated in 2021 and amended during 2024, provides for awards of restricted common stock and options to
    purchase up to a maximum of 11,500,000 shares of common stock and expires in December 2030. Options may be granted to employees,
    directors, and consultants of Milestone Scientific for the purchase of shares of common stock at a price not less than the fair market
    value of common stock on the date of grant. In general, options become exercisable over a three-year period from the grant date and
    expire five years after the date of grant. During the year ended December 31, 2024, 7,579,778 options and shares were issued.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>United
Systems</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milestone
Scientific has a supply agreement with United Systems the principal supplier of its handpieces, pursuant to which it procures manufactured
products under specific purchase orders, but without minimum purchase commitments. Purchases from this supplier were approximately $1.7
million and $2.3 million for the twelve months ended December 31, 2024, and 2023, respectively. As December 31, 2024, and December 31,
2023, Milestone Scientific owed this supplier approximately $664,000 and $402,000, respectively, which is included in accounts payable
and accrued expenses related party on the consolidated balance sheets. In June 2021, the Company signed a ten-year agreement with United
Systems for supplier of the handpieces</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2023, the Company had approximately $270,000 sales to Milestone China or agents of Milestone China, an entity
in which the Company formerly had an ownership interest terminating in 2021. The Company reported no sales to Milestone China or agents
of Milestone China during the year ended December 31,2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">K.
Tucker Andersen, a significant stockholder of Milestone Scientific, has an agreement with Milestone Scientific to provide financial and
business strategic services. Expenses recognized on this agreement were $100,000 for year ended December 31, 2023. The agreement was
not renewed for the year ending December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
of Clinical Affairs (Mark Hochman)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Director of Clinical Affairs&#8217; royalty fee was approximately $442,000 and $485,000 for the years ended December 31, 2024 and 2023,
respectively. Additionally, Milestone Scientific expensed consulting fees to the Director of Clinical Affairs of $156,000 for the year
ended December 31, 2024 and 2023, respectively. As of December 31, 2024, and 2023, Milestone Scientific owed the Director Clinical Affairs
for royalties of approximately $110,000 and $114,000, respectively, which is included in accounts payable, related party and accrued
expense, related party, in the consolidated balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
and Consulting Contracts</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 2, 2021, the Company entered into a Royalty Sharing Agreement with Leonard Osser, pursuant to which Mr. Osser sold, transferred
and assigned to the Company all of his rights in and to a certain patent application as to which he is a co-inventor with Mark Hochman,
a consultant to the Company, and the Company agreed to pay to Mr. Osser, beginning May 9, 2027, half of the royalty (2.5%) on net sales
that would otherwise be payable to Mark and Claudia Hochman under their existing Technology Sale Agreement, dated January 1, 2005 and
amended from time to time, with the Company. In connection with the Royalty Sharing Agreement, the Hochman&#8217;s agreed with the Company,
pursuant to an addendum to such Technology Sale Agreement dated February 25, 2021, to reduce from 5% to 2.5% the payments due to them
under their Technology Sale Agreement beginning on May 9, 2027, and thereafter with respect to dental products embodying the invention.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the Succession Plan of the Company, Mr. Osser agreed, pursuant to an agreement dated April 6, 2021 (the &#8220;Succession Agreement&#8221;),
to restructure certain of his existing agreements with the Company, which provide for additional and broader executive support, and at
such time as he elects to step down as Interim Chief Executive Officer of the Company, to become the Vice Chairman of the Board
of the Company. With respect to Mr. Osser&#8217;s July 2017 Employment Agreement and July 2017 Consulting Agreement (each as previously
disclosed), the compensation under the Employment Agreement was modified to reduce the overall compensation by $100,000 to $200,000,
split equally between a cash amount and an amount in shares, and the compensation under the Consulting Agreement was increased by $100,000
to $200,000, equally split between a cash amount and an amount in shares, which shares were formerly payable under the Employment Agreement.
If the Company terminates Mr. Osser&#8217;s employment &#8220;Without Cause,&#8221; other than due to his death or disability, or if
Mr. Osser terminates his employment for &#8220;Good Reason&#8221; (both as defined in the agreement), Mr. Osser is entitled to be paid
in one lump sum payment as soon as practicable following such termination: an amount equal to the aggregate present value (as determined
in accordance with Section 280G(d)(4) of the Code) of all compensation pursuant to this agreement from the effective date of termination
hereunder through the remainder of the Employment Term. In connection with his acceptance of the Vice Chairman position and in
consideration of his services as a member of the Board and agreement to provide certain additional general consulting services, Mr. Osser
was granted options to purchase 2,000,000 shares of common stock, exercisable at the fair market value of the common stock on the date
of grant, vesting over the five-year period after he steps down as Interim Chief Executive Officer of the Company or ten years from the
date of grant, whichever shall end first.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 19, 2021, Mr. Osser resigned as Interim Chief Executive Officer of the Company and assumed the role of Vice Chairman of the
Board. Mr. Osser resigned as Vice Chairman of the Board, and on November 7, 2025, Mr. Osser resigned from the Board of Directors.
Compensation under the Employment Agreement and the Consulting Agreement is payable for 9.5 years from May 19, 2021. The Company recorded
expenses of $200,000 related to the Employment Agreement for each of the years ended December 31, 2024 and 2023, respectively. The Company
recorded expenses of $200,000 related to the Consulting Agreement for each of the years ended December 31, 2024 and 2023, respectively.
Mr. Osser also owns 2,717,765 of the Company&#8217;s stock, and 2,481,048 shares to be issued at the termination of his employment agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of February 2024, the University Pain Medicine Center (STEMMEE), of which Dr. D. Demesmin, a Company board member is the CEO agreed to
purchases products from the Company under the same terms and conditions applying to other medical pain clinics in the United States.
STEMMEE purchased medical products in the amount of $21,000 for the year ended December 31, 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mr. Arjan Haverhals retired as the Chief Executive
Officer and other officer positions with the Company on December 31, 2024. The Company entered into a consulting agreement with Mr. Arjan
Haverhals that commenced on January 1, 2025, and continues for an indefinite period, subject to the Company having the right to terminate
the Consulting Agreement on 30 days advance notice in the event of his disability to provide services and either party having the right
to terminate the Consulting Agreement on 90 days&#8217; advance notice. Mr. Haverhals will be paid an annual fee at the rate of $350,000,
at the rate of $150,000 in respect of the first calendar quarter of 2025, and at the rate of $66,666, in respect of each subsequent calendar
quarter of 2025, payable monthly in arrears, in each case in equal monthly installments on the last day of each month of such quarter.
The Company will reimburse Mr. Haverhals for reasonable expenses in providing the services. Mr. Haverhals will be an independent contractor
and will not be provided with health and accident insurance, life insurance, paid sick leave and/or paid vacation time. In connection
with the Consulting Agreement, he has also entered into a Company-standard form of non-disclosure, non-solicitation, non-competition
and invention agreement. Mr. Haverhals will be issued&#160;895,012 shares&#160;of the Company&#8217;s stock ninety days after the termination
of his consulting relationship.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into a consulting agreement with Mr. Arjan Haverhals, which commenced on January 1, 2025, and continues for an indefinite
period, subject to the Company having the right to terminate the Consulting Agreement on 30 days advance notice in the event of his disability
to provide services and either party having the right to terminate the Consulting Agreement on 90 days&#8217; advance notice. Mr. Haverhals
will be paid an annual fee at the rate of $350,000, at the at the rate of $150,000 in respect of the first calendar quarter of 2025,
and at the rate of $66,666, in respect of each subsequent calendar quarter of 2025, payable monthly in arrears, in each case in equal
monthly installments on the last day of each month of such quarter. The Company will reimburse Mr. Haverhals for reasonable expenses
in providing the services. Mr. Haverhals will be an independent contractor and will not be provided with health and accident insurance,
life insurance, paid sick leave and/or paid vacation time. In connection with the Consulting Agreement, he has also entered into a Company-standard
form of non-disclosure, non-solicitation, non-competition and invention agreement. Mr. Haverhals will be issued 638,023 shares of the
Company&#8217;s stock ninety days after the termination of his consulting relationship.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsequent
Events</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>April
2025 Financing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2025, the Company issued a series of promissory notes in the aggregate amount of $800,000 to Mr. Neal Goldman, Ms. Benedetta
Casamento, and Dr. Didier Demesmin, each of whom is a director of the Company. The notes are due April 9, 2028, and bear interest at
the annual rate of prime less 2.50% payable annually. All principal and interest shall be payable in cash and/or shares of common
stock at the sole discretion of the Company. The notes are convertible into shares of common stock by the holder at any time and by the
Company at maturity. If the Company sells equity securities for gross proceeds in excess of $4,000,000, the holders may request repayment
of their note in either cash, shares of common stock or a combination of cash and shares; provided, that the holders would then be entitled
to receive only so much cash as the net proceeds to the Company in such sale of equity securities, after payment of other indebtedness
and other uses (other than working capital) specified as a use of the proceeds in the relevant offering or disclosure documentation,
shall be in excess of $4,000,000. Upon a liquidation event of the Company, as defined in the notes which includes a sale of the Company
or assets, a merger, reorganization or combination transaction where the shareholders before the transaction own less than 50% of the
Company after the transaction and a liquidation, dissolution or winding-up of the Company, the notes will be repaid in cash or its portion
of any non-cash consideration. The conversion rate for any issuance of shares of common stock will be at the then fair value of a share
of common stock, with the fair value being determined with reference to the public market price of a share of common stock, but not less
than $0.50. The notes are unsecured and have typical default terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
or effective November 7, 2025, Mr. Osser resigned from the Board of Directors in response to being advised that he was
not re-nominated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPOSAL
NO. 2</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VOTE
TO APPROVE AN AMENDMENT TO THE RESTATED CERTIFICATE OF</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INCORPORATION
TO INCREASE THE AUTHORIZED NUMBER OF SHARES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OF
COMMON STOCK FROM 100,000,000 TO 125,000,000</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(ITEM
2 ON THE PROXY CARD)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors is proposing for stockholder approval an amendment to the Company&#8217;s Restated Certificate of Incorporation, as
amended (the &#8220;Charter&#8221;), to increase the number of authorized shares of common stock, par value $0.001 per share, from 100,000,000
shares to 125,000,000 shares, subject to the Board of Directors&#8217; authority to abandon such amendment. The Board of Directors approved
this amendment, subject to stockholder approval, and directed that this amendment be submitted to a vote of the Company&#8217;s stockholders
at the Annual Meeting. The Charter also authorizes the issuance of up to 5,000,000 shares of preferred stock, par value $0.001 per share,
of which no shares are currently outstanding. The proposed amendment will not increase or otherwise affect the Company&#8217;s authorized
shares of preferred stock. The Board believes that it is in the best interests of the Company and its stockholders to increase the number
of authorized shares of common stock in order to give the Company greater flexibility in considering and planning for future potential
business needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purpose
of the Amendment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Charter currently authorizes the issuance of up to 100,000,000 shares of common stock. As of the close of business on October 31, 2025,
there were 78,628,913 shares of common stock issued and outstanding. In addition, as of the close of business on October 31, 2025 there
were no shares of common stock issuable upon exercise of outstanding warrants; shares of common stock issuable upon exercise of
outstanding stock options; 6,735,693 shares of common stock available for issuance pursuant to future grants which can be made under
the Company&#8217;s equity award plans; 3,708,663 shares of common stock issuable as deferred compensation to the Company&#8217;s executive
officers and employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therefore,
the purpose of this amendment to increase the number of authorized shares of common stock to 125,000,000 is to allow the Company to meet
is current contractual requirements to issue shares of its common stock and to issue additional shares of common stock for any proper
corporate purposes, including but not limited to, public or private financings, stock splits, stock dividends, potential strategic transactions,
including mergers, acquisitions, strategic partnerships, joint ventures and other business combinations, as well as for other general
corporate transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as described above, the Company has no current plan, commitment, arrangement, understanding or agreement regarding the issuance
of the additional shares of common stock resulting from the proposed increase in the number of authorized shares of common stock. The
additional shares of common stock will be available for issuance from time to time as determined by the Board of Directors for any proper
corporate purposes. Having these additional shares of authorized common stock available for future use will allow the Company to issue
additional shares of common stock without the expense and delay of arranging a special meeting of stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.2in 0 0.1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Possible
Effects of the Amendment and Anti-takeover Considerations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the amendment to the Charter is approved, the additional authorized shares would be available for issuance at the discretion of the Board
and without further stockholder approval. It is not the present intention of the Board of Directors to seek stockholder approval prior
to any issuance of shares of common stock that would become authorized by the amendment unless otherwise required by law or regulation.
Frequently, opportunities arise that require prompt action, and it is the belief of the Board of Directors that the delay necessitated
for stockholder approval of a specific issuance could be to the detriment of the Company and its stockholders. The additional shares
of authorized common stock would have the same rights and privileges as the shares of common stock currently issued and outstanding.
The adoption of the amendment would not have any immediate dilutive effect on the proportionate voting power or other rights of existing
stockholders. Shares of common stock issued in the future (including for the purposes described above in the section entitled &#8220;Purpose
of Amendment&#8221;), other than for a stock split, may decrease existing stockholders&#8217; percentage equity ownership and, depending
on the price at which they are issued, could have a financially dilutive effect on previously issued shares of common stock and have
a negative effect on the market price of the common stock. The Company cannot provide assurances that any such transactions will be consummated
on favorable terms or at all, that they will enhance stockholder value or that they will not adversely affect the Company&#8217;s business
or the trading price of our stock. Current stockholders have no preemptive or similar rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not proposed the increase in the number of authorized shares of common stock with the intention of using the additional authorized
shares for anti-takeover purposes, but the Company would be able to use the additional shares to oppose a hostile takeover attempt or
delay or prevent changes in control or management of the Company. For example, without further stockholder approval, the Board could
sell shares of common stock or preferred stock, including preferred stock convertible into shares of common stock, in a private transaction
to purchasers who would oppose a takeover or favor the current Board. Although this proposal to increase the authorized number of shares
of common stock has been prompted by business and financial considerations, and not by the threat of any known or threatened hostile
takeover attempt, stockholders should be aware that approval of this proposal could facilitate future efforts by the Company to oppose
changes in control of the Company and perpetuate the Company&#8217;s management, including transactions in which the stockholders might
otherwise receive a premium for their shares over then current market prices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effective
Date</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company&#8217;s stockholders approve the increase in the number of authorized shares of common stock to 125,000,000 shares, we must
file a Certificate of Amendment to the Charter with the Delaware Secretary of State in order for the amendment to become effective. If
we obtain stockholder approval of this proposal, we intend to file the Certificate of Amendment as soon as practicable. Our Board of
Directors reserves the right, notwithstanding stockholder approval of the amendment and without further action by our stockholders, not
to proceed with the amendment at any time before the filing of the Certificate of Amendment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
the authorized capital structure of the Company, the first sentence of Article FOURTH of the Charter currently reads as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;The total number of shares which this corporation shall have authority to issue is 105,000,000 shares, consisting of (i) 100,000,000 shares of common stock, $.001 par value per share (the &#8220;Common Stock&#8221;) and (ii) 5,000,000 shares of preferred stock, $.001 par value per share (the &#8220;Preferred Stock&#8221;).&#8221;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Board of Directors has approved the following amendment to Article Fourth, subject to approval of such amendment by the
stockholders of the Company at the Annual Meeting, as specified below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The first sentence of Article Fourth is to be deleted in its entirety and be replaced by the following sentence:</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;The total number of shares which this corporation shall have authority to issue is 130,000,000 shares, consisting of (i) 125,000,000 shares of common stock, $.001 par value per share (the &#8220;Common Stock&#8221;) and (ii) 5,000,000 shares</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of preferred stock, $.001 par value per share (the &#8220;Preferred Stock&#8221;).&#8221;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dissenters&#8217;
Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
Delaware law, nor the Company&#8217;s Charter, nor the Company&#8217;s Bylaws provides for appraisal or other similar rights for dissenting
stockholders in connection with this proposal. Accordingly, the Company&#8217;s stockholders will have no right to dissent and obtain
payment for their shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Vote
Required and Recommendation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
this matter, the affirmative vote of the holders of a majority of the Company&#8217;s outstanding shares of common stock is required
to approve this Proposal No. 2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.2in 0 4.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>The
Board recommends that stockholders vote &#8220;<span style="text-decoration: underline">FOR</span>&#8221; the resolution </b></span><b>above, approving AN amendment TO the RESTATED
Certificate of Incorporation to increase THE AUTHORIZED NUMBER OF SHARES OF COMMON STOCK FROM 100,000,000 TO125,000,000</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPOSAL
3</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RATIFICATION
OF THE APPOINTMENT OF INDEPENDENT AUDITORS </b></span><b><br/>
(ITEM 3 ON THE PROXY CARD)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
independent registered public accounting firm of CBIZ CPAs P.C. (&#8220;CBIZ&#8221;) has been our independent registered public accounting
firm since April 25, 2025. The registered public accounting firm of Marcum LLP had been our auditing firm from October 2022 until April
25, 2025, when it combined with CBIZ. The Audit Committee has appointed CBIZ as our independent registered public accounting firm for
the year ending December 31, 2025, and our Board has directed that management submit the appointment of CBIZ as our independent registered
public accounting firm for ratification by the stockholders at the Annual Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CBIZ&#8217;s
audit report appears in the Annual Report. A representative of CBIZ will be at the Annual Meeting and will have an opportunity to make
a statement, if he or she desires to do so, and will be available to respond to appropriate questions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selection of the independent accountants is not required to be submitted to a vote of our stockholders for ratification. In addition,
the Sarbanes-Oxley Act of 2002 requires the Audit Committee to be directly responsible for the appointment, compensation, and oversight
of the audit work of the independent auditors. However, the Board is submitting this matter to Milestone Scientific&#8217;s stockholders
as a matter of good corporate practice. If the stockholders fail to vote on an advisory basis in favor of the selection, the Audit Committee
will consider that when deciding whether to retain CBIZ and may retain that firm or another without resubmitting the matter to the stockholders.
Even if stockholders vote on an advisory basis in favor of the appointment, the Audit Committee may, in its discretion, direct the appointment
of different independent auditors at any time during the year if it determines that such a change would be in the best interests of Milestone
Scientific and the stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Vote
Required and Recommendation of the Board</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
affirmative vote of at least a majority of the votes present and entitled to vote at the Annual Meeting is required to approve this Proposal
No. 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS </b></span><b>VOTE &#8220;<span style="text-decoration: underline">FOR</span>&#8221; RATIFICATION OF THE APPOINTMENT OF THE
INDEPENDENT AUDITORS.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>********</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Fees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.85pt 0 1pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milestone
Scientific incurred an aggregate audit and financial statement review fees of approximately $220,000 from CBIZ (as the predecessor Marcum
LLP) for 2024. Milestone Scientific incurred aggregate audit and financial statement review fees of approximately $295,200 from CBIZ
(as the predecessor Friedman LLP) for 2023 These fees include fees for professional services rendered for the audit of our annual financial
statements and the review of financial statements included in our report on Form 10-Q&#8217;s or services that are normally provided
in connection with statutory and regulatory filings and fees related to registration statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tax
Fees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milestone
Scientific incurred aggregate tax fees of approximately $33,000 from CBIZ (as the predecessor Marcum LLP)for 2024. Milestone Scientific
incurred tax fees of approximately $42,000 from CBIZ (as the predecessor Friedman LLP) for 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Related Fees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milestone
Scientific did not incur audit-related fees from CBIZ in either 2024 or 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All
Other Fees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milestone
Scientific did not incur other accounting fees from CBIZ in either 2024 or 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Committee Administration of the Engagement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
engagements with CBIZ as the Company&#8217;s principal accountants and tax compliance services were approved in advance by the Board
and the Audit Committee. The Audit Committee approved no non-audit or non-audit-related services in either 2024 or 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Committee Pre-Approval Policies and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee charter provides that the Audit Committee will pre-approve audit services and non-audit services to be provided by the
independent auditors before the accountant is engaged to render these services. The Audit Committee may consult with management in the
decision-making process but may not delegate this authority to management. The Audit Committee may delegate its authority to preapprove
services to one or more committee members, provided that the designers present the pre-approvals to the full committee at the next committee
meeting. All audit and non-audit services performed by the independent accountants have been pre-approved by the Audit Committee to ensure
that such services do not impair the auditors&#8217; independence from us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AUDIT
COMMITTEE REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee&#8217;s purpose is to assist the Board in its oversight of (i) the integrity of our financial statements, (ii) our compliance
with legal and regulatory requirements, (iii) our independent auditors&#8217; qualifications and independence, and (iv) the performance
of our internal audit function and independent auditors to decide whether to appoint, retain or terminate our independent auditors, and
to pre-approve all audit, audit-related and other services, if any, to be provided by the independent auditors; and to prepare this Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is responsible for the preparation, presentation and integrity of our financial statements, accounting and financial reporting principles
and the establishment and effectiveness of internal controls and procedures designed to assure compliance with accounting standards and
applicable laws and regulations. The independent auditors are responsible for performing an independent audit of the financial statements
in accordance with generally accepted auditing standards. The independent auditors have free access to the Audit Committee to discuss
any matters they deem appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee reviewed our audited financial statements for the year ended December 31, 2024 and met with management to discuss such
audited financial statements. The Audit Committee has discussed with our independent accountants, CBIZ CPAs P.C., the matters required
to be discussed by the Statement on Auditing Standards No. 16, as adopted by the Public Company Accounting Oversight Board. The Audit
Committee has received the written disclosures and the letter from CBIZ CPAs P.C. required by the Independence Standards Board Standard
No. 1, as may be modified or supplemented. The Audit Committee has discussed with CBIZ CPAs P.C. its independence from Milestone Scientific
and its management. CBIZ CPAs P.C. had full and free access to the Audit Committee. Based on its review and discussions, the Audit Committee
recommended to the Board that the audited financial statements be included in the Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Submitted
by the Audit Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benedetta
Casamento</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neal
Goldman</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
McGeehan</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OTHER
BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Proxy Statement, we know of no other business that will be presented for consideration at the Annual Meeting other
than the items referred to above. If any other matter is properly brought before the Annual Meeting for action by stockholders, the persons
designated as proxies will vote all shares in accordance with the recommendation of the Board or, in the absence of such a recommendation,
in accordance with their best judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ADDITIONAL
INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Householding</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC&#8217;s rules permit companies and intermediaries such as brokers to satisfy delivery requirements for proxy statements and annual
reports with respect to two or more stockholders sharing the same address by delivering a single proxy statement and annual report addressed
to those stockholders. This process, which is commonly referred to as &#8220;householding,&#8221; potentially provides extra convenience
for stockholders and cost savings for companies. Some brokers household proxy materials and annual reports, delivering a single proxy
statement and annual report to multiple stockholders sharing an address, although each stockholder will receive a separate proxy card.
Once you have received notice from your broker that they will be householding materials to your address, householding will continue until
you are notified otherwise or until you revoke your consent. If at any time you no longer wish to participate in householding and would
prefer to receive a separate proxy statement and annual report, please notify your broker. If you would like to receive a separate copy
of this year&#8217;s Proxy Statement or Annual Report, please address your request for delivery of the Proxy Statement and/or Annual
Report to Corporate Secretary, Milestone Scientific Inc., 425 Eagle Rock Avenue, Suite 403 Roseland, New Jersey 07068.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Requirements,
Including Deadlines, for Submission of Proxy Proposals, Nomination of Directors, and Other Business of Stockholders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
interested in presenting a proposal or nominating a person for election as a director for consideration at the annual meeting of stockholders
in 2026 (the &#8220;2026 Meeting&#8221;) must follow the procedures found in Rule 14a-8 under the Exchange Act. To be eligible for inclusion
in the Company&#8217;s proxy materials for the 2026 Meeting, the stockholder must give the Company written notice of the proposal and/or
director nominee, which must be received by our Corporate Secretary no later than January 1, 2026 A stockholder who wishes to propose
the next annual meeting of stockholders without including the proposal in our proxy statement must notify us not less than thirty (30)
days and not more than sixty (60) days prior to the scheduled annual meeting, regardless of any postponements, deferrals or adjournments
of that meeting to a later date; provided, however, that if less than forty (40) days&#8217; notice or prior public disclosure of the
date of the scheduled annual meeting is given or made, notice by the stockholder, to be timely, must be so delivered or received not
later than the close of business on the tenth (10th) day following the earlier of the day on which such notice of the date of the scheduled
annual meeting was mailed or the day on which such public disclosure was made. If a stockholder fails to give notice by this date, then
the persons named as proxies in the proxies solicited by us for the next annual meeting of stockholders will have discretionary authority
to vote on the proposal. Stockholder proposals should be addressed to the Corporate Secretary, Milestone Scientific Inc., 425 Eagle Rock
Avenue, Suite 403 Roseland, New Jersey 07068.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EVERY
STOCKHOLDER, WHETHER OR NOT HE OR SHE EXPECTS TO ATTEND THE ANNUAL MEETING IN PERSON, IS URGED TO EXECUTE THE PROXY AND RETURN IT PROMPTLY
IN THE ENCLOSED BUSINESS REPLY ENVELOPE.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Electronic
Availability of Proxy Statement and Annual Report </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
required by SEC rules, we are making this Proxy Statement and our Annual Report available to stockholders electronically via the Internet
at www.proxyvote.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suppose
you received a paper copy of this Proxy Statement by mail and you wish to receive a notice of availability of next year&#8217;s proxy
statement either in paper form or electronically via e-mail. In that case, you can elect to receive a paper notice of availability by
mail or an e-mail message that will provide a link to these documents on <span style="text-decoration: underline">www.proxyvote.com</span>. By opting to receive the notice of
availability and accessing your proxy materials online, you will save the Company the cost of producing and mailing documents to you
reduce the amount of mail you receive and help preserve environmental resources. Registered stockholders may elect to receive electronic
proxy and annual report access or a paper notice of availability for future annual meetings by registering online at <span style="text-decoration: underline">www.proxyvote.com</span>.
If you received electronic or paper notice of availability of these proxy materials and wish to receive paper delivery of a full set
of future proxy materials, you may do so at the same location. Beneficial or &#8220;street name&#8221; stockholders who wish to elect
one of these options may also do so at <span style="text-decoration: underline">www.proxyvote.com</span>. Please enter your 12-digit control number located on the proxy card
or notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Annual Report accompanies the proxy materials being provided to all stockholders. We will provide without charge each person being solicited
by this Proxy Statement, on the written request of any such person, additional copies of the Annual Report including the financial statements
and financial statement schedules included therein. All such requests should be directed to Corporate Secretary, Milestone Scientific
Inc., 425 Eagle Rock Avenue, Suite 403 Roseland, New Jersey 07068.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>By
    order of the Board of Directors</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neal
    Goldman</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    of the Board</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Roseland,
    New Jersey</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    12, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">Page <b><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> </b>of <b>31</b></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><img src="formdef14a_001.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="formdef14a_002.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%">&#160;</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="formdef14a_003.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 33; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%">&#160;</td><td style="width: 33%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJyl0t1OwjAUB/An4B1Odo2wNcGL3eEchAhKBiwa40VhZ9iwtbPt+Hgk39KuBTWKF+rSZGl7fuf8k83z2t5QDFiBEu6vkjHMsawKqhESzFEiX6GpiEY3IZh3gmumtKRc2+0JRsIYNOayQ5bm3FZumcIshCDoBn6X9MDvhYTAdOK1mvtI8JxlyDWjBVCewVSKSjLUVB5chzndCy7Kg52UolRMcNOu47vrVyB+QOBWbOlOyI2C8TjyWm37tLyhFHVlquK9Rt5IiAsszTjl9MeyaVa10qIMU1rUmGAlpMZswTOUMy1Wm/6OykyN+CyaT7BcojTC9wkJ/H4TxiqQRwZ140A1EKiVwDjoZwTj4dF1ePqH+5p6kN7lC75FZbrELzXTBxe4rx+Qyphn50IPUhA5nBg4Bw4C1dDQCzTfhfgk+Dz9z/Bc7NQ2OcZVbs/4+tr8fz+Hduh9pDqdGQiN/J72N8LGfAOAEPkY -->
<!-- Field: Set; Name: xdx; ID: xdx_088_labels -->
<!-- eJwdzLEOgkAMgOHdxHdobjaU6Mams8MNbMShd1eVWCkpFw7fXmD//t9dU+pzrwMJ3CmwTO7k3jmPDWIppVqCSaX2wnNdX9BUGGVj7nhwHFPj57GlINzykm+i8bPmnn4wT+DZnmpfGiJDtyPYFOzssQ7+OCopiQ== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>formdef14a_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 formdef14a_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *) G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNO$7Q<T-=&O/L]X^D?:;.X7IN4R.HSZ'&/QH ]HDOK.*[CM)+J!+F4$QPM(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-=#X>M]6M=-,.L7 N+A9&VS;PQ=,\9PB@'VP?K67)H_B2>:\<ZG!;F:&/RS
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M^7I4<7AWQ4D$?FZXLTQL6MY29'53)DXD4 <'!&33YM"\53N6.MQP!H40I S
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M!= M]8@M)?[:NEGN&E)3:5*JG8#")^H/UK6HHH **** "BBB@ HHHH ****
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M,,P)9/NJ=JDLH*X)&1QUJ33+/PCXCBN!90-,HF6:0.LT1W\X(W8./O<#CK0
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M69FDBPC*<?=8$YQGZ>F: .FHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN9IG,BSA$FPI7&-I,?.?4X'H32VOBS7I-;TNQG\)W2V]UO%S>(S>7;D9Q]Y
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MO):-N+- SA_EV] X ZGKG%16'AZXM="O=,N-2:[%RC('F5GV[EP<[G8D=\9
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M4DRY*;4V[5[ \G)]^/I4M !1110 4444 %%%% !1110 4444 %%%% !1110
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M3:KXG225"^V!V:'SB3QA?-P<>A#=>U5M5MHM4\0R7L/BFPM;-[8P(J7;EC*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFS@@@@@8/M0!%_PGGAK_ *"7_D"3_P")J_J'B+2M*B@DO;KRDG7=&?+=MP_
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M)KH["]CU&RCN8U= V04D&&1@<%2/4$$4 4]3\2:3H\D27]UY+2KO0>6[9'X
MU%8>+-$U2\2TL[WS9WR57RG7..>I %1S^)TM]4N+%],OLP_*LW[O9(Y0N%7Y
M\@D \L ..2*K2^-8%MM/N(-'U2Z2]''D1QGRV!P4;+CY@0>!GI0!9N?&>@6=
MU);3W^R6-BKKY,AP?J%JS9^(])O[.XN[:Z\R"V&96\MQM[]",G\*R;?QS#=0
MW<D&BZG)]FF6!E7R22[-MV_ZS .2.#@X(KH=/ODU&QCNHXY(PQ96CD&&1E)5
ME.,C(((X)'I0!C?\)YX:_P"@E_Y D_\ B:O7/B32;/3[>_GN]EM<?ZI_+<[O
MP R/QK5HH P(/&OAZYGC@BU#=)(P51Y$@R3]5K@/%.D6<&LZF+F;21<74RRA
M)X9&\I.#N4B)AN;!!SGZ]J]&\3:I)H^C_:HKJSMF\V./S;Q28U#, 2<$>OK7
M%1?$#5;E;]DO_#\ M23^^5SE!_$,29()(QD+U'6@#+T_0H=;?4[?3TT$R3P)
M@)'*!"JA5.W=%R,C/.[MP.:U-6NO"L^@:?I*RV=XUDZK_I\,I"J""^-L?4XQ
MT''I5I?B!*DLUG<:CI"7&56.[\J46RD!?,RQ;YL%L  C'>K_ (?\7W6I^('T
M^XET]X560B6VZ/MV_=.\GN<Y4=L$T <U%H\(TR\U4?V+=Z?).K W,4A$)$K-
MM4"+=C#CKGG/-7M#UC1=.UG6KV:_LPE^!L6.&5B2-WWCY8XYZ?-]:E_X6).^
MZ."?3I9?-D"_N9%W1<[)%4MEU!4AMO7(QT(K7\.^*+K5+*^>>\TN1X(/-,EL
MK!(&^8;9 6/3;GJ./SH Y.;0;7PY8V$=U-IOFSQEB)5D*1<CYH1'&,$C@Y ;
M!QDU'H.DZ//=Z=8(=(OV$_FL)8959 4PZQXC51R P)P>.3WK1L?B#K%U/8V\
MTFD6MQ<1ERDZD9SMV=)3@-NXQNZ'I5M/&&L"U,LNJ^',R.8[9DBEPY5@'_Y:
M<X&3QZ@T 9-XNG65Q/:7,>@12K<NS0K#/MB+$?O%Q'@R <>GOUK3\-VMF?#V
MN+!<V%QNM$A;]U(%4!7P'++EAR<<' &*33?'FL77V:.XCTY)IC'\@1MZAF7G
M:';Y64G#9X(Y]*U?$WB;4]%U22&"ZT<1BV:X2WG#^<X! Z[@.23@?[/7T .)
M,.AQ:;':V\^D>8UMY<D[V\P:-]I!V!8@,-QG@?0UTAM;+3_AR]G-=6KV\[;K
M*9D< .?FSA8QM*L#C"CH">2:DMO'-Y,C.]]HR.+>>0VK@B560D $^85^O/XC
MJ+TGBN]'@"#74>R%U(X3YD_=G]X5X'F 9_X'CW(H Y6$Z/)<QQ0'17?">6S0
M3[I'!4B)OW>!'D'GZ''6KEE96'@_Q8;N[N=/LY&Y:WMH'V['!).1'G(;@ G&
M!G -6K[QSK5L#$!I27^]8S8G+RHV0.?WBJ=V<@9&,=6ZT\>-=3>VO+C^T_#T
M*P0Q2LCK(6B+\;6^<9(/';&: ,&VT&WUK4[@:9-I%T\UTUY+;30NB*H9L 9A
MP<AQG.3QP?1TDFEQ/*DRZ#/*IVR&6*X_TC!Z2?NSG;_#UZ"N@N_'-[;7#+'<
MZ/<;7VF"/=YN 0,CYL?/G*CVQDYR-*_\3W=EH&E7CW&FQ2W:;VEF5UB8[=P1
M!G(+=!DG'H>E ''P:#%_8][JJ2Z/>VKW&9A<Q2"/APP.!'N9CD@YW8['DBKO
MA[4]'TGQ%<ZA/JEL8I81&"D,K.2,<9,8( Z#);@#I5RR\?W,MS:&^OM&M+9B
MGG,RN=X(<G8V['\('(.#D<XKH?#.N7>M7.H+-+8O%:R"(&VSEB>=QRQP,$#!
M&<@T =!%(DT22QG*.H93CJ#3Z** "BJ-[)*]U!:Q2&/S S,XZX'84?V:W_/_
M '?_ 'V/\* +U%4?[-;_ )_[O_OL?X4?V:W_ #_W?_?8_P * +U%4?[-;_G_
M +O_ +['^%']FM_S_P!W_P!]C_"@"]15'^S6_P"?^[_[['^%']FM_P _]W_W
MV/\ "@"]15'^S6_Y_P"[_P"^Q_A1_9K?\_\ =_\ ?8_PH O451_LUO\ G_N_
M^^Q_A1_9K?\ /_=_]]C_  H O451_LUO^?\ N_\ OL?X4?V:W_/_ '?_ 'V/
M\* +U%4?[-;_ )_[O_OL?X4?V:W_ #_W?_?8_P * +U%4?[-;_G_ +O_ +['
M^%']FM_S_P!W_P!]C_"@"]15'^S6_P"?^[_[['^%']FM_P _]W_WV/\ "@!N
MKZ2FL6T<$EU=6XCE64-;N%)*G(!R#QFJ3>%X3?->#4=124R2R#;*N%+J%./E
M[ <?UJ__ &:W_/\ W?\ WV/\*/[-;_G_ +O_ +['^% &4O@ZW%I;6K:KJKPP
MY#(\ZD3*6W;7&W!'TP<=ZZ,# P.E4?[-;_G_ +O_ +['^%']FM_S_P!W_P!]
MC_"@#%3P%HZV7V1C-+$UX+N7S!&3,W/RO\OS+R>O/O4Y\(6N JZAJ2((]H5;
MC^+&T2=,[P. ?89R:T_[-;_G_N_^^Q_A1_9K?\_]W_WV/\* ,E?!=G%8?8K?
M4-2@@%Q'<*L<R_*R8QC*\ D!CZGFNDJC_9K?\_\ =_\ ?8_PH_LUO^?^[_[[
M'^% &7<>#[6X6:%M1U$6<K[S9^8C0CYMQ 5E/!/4$D<FH;;P)IMK<QW*75Z9
MH55;=RZ9MU#$[4(484Y((Z8-;7]FM_S_ -W_ -]C_"C^S6_Y_P"[_P"^Q_A0
M!6T7P_#H@;9=WETQ41JUU(&*(.BK@#BIM8T@:S;QPM?7EHJ2+)FU=5+%2",Y
M!X! -/\ [-;_ )_[O_OL?X4?V:W_ #_W?_?8_P * *]MH$-OJS:@UY>W#Y8Q
MQ3RADB+<,5&,C..F<5?O+2.^LYK64LJ2J5+(<,ON#V([&H/[-;_G_N_^^Q_A
M1_9K?\_]W_WV/\* ,NY\'6%S=0W)N;M)H$C2"163=%M/)4E206_B]:B3P5"F
MGW-E_;>LF*< '-PN5&22%^7 R6.>,]*V?[-;_G_N_P#OL?X4?V:W_/\ W?\
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MG_7.3^E7ZH3_ /(:M/\ KG)_2K] !1110 4444 %%%% !1110 4444 %%%%
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M'8167F/Y<2LKONP57*Y+[3D<]5'!S47A^[\2/XH*WT=\=*>W"HUQ$JD/R02
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MNK6[^R7MM&EPV83',@,2'=PK>6<\;3DC/I5Q8O%DJS W4%FS765)D6;]TV.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R?Q T6_UW1]/M].A
M$LL.J6UPX+A<1H^6/)[#M7644 %0WG_'E/\ ]<V_E4U0WG_'E/\ ]<V_E0 V
MQ_Y!]O\ ]<U_E5BJ]C_R#[?_ *YK_*K% %"?_D-6G_7.3^E7ZH3_ /(:M/\
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M(-X5_P"A?T[_ ,!UH_X0;PK_ -"_IW_@.M;]% &!_P (-X5_Z%_3O_ =:/\
MA!O"O_0OZ=_X#K6_10!@?\(-X5_Z%_3O_ =:/^$&\*_]"_IW_@.M;]% &!_P
M@WA7_H7]._\  =:/^$&\*_\ 0OZ=_P" ZUOT4 5[*QM--M$M+*WCM[=,[8HU
MVJN3DX'U-6*** "BBB@ HHHH **** "BBB@ HHHH **** "H;S_CRG_ZYM_*
MIJAO/^/*?_KFW\J &V/_ "#[?_KFO\JL57L?^0?;_P#7-?Y58H H3_\ (:M/
M^N<G]*OU0G_Y#5I_USD_I5^@ HHHH Y34_&7]E^*#I4MO$8%A,S2B0[\!22
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M** "BBB@ HHHH **** "BBB@ J&\_P"/*?\ ZYM_*IJAO/\ CRG_ .N;?RH
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MM_'GD]37544 <Z/!UF(VC_M#4RC;?E-SD#:NT8X]#70@8 &2<>M+10 4444
M%8U[X:M+XWOF3W:K=[/,1)?E 4YPH(X!/)]:V:* *]K:+:F<JQ;S93(<CID
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M*.RC('& 5/8=,FJFHZ1XHM[.65]1GF@BL0B6]I*Q=I@,9^[N(R1SN!XSCG%
M'>45Q-IX>\0)]AE%Y&HC#,$:ZG/D@_P@-_K/<ODCMTJ$^'?&>W2W.L6DTUO<
M&6Y,\DAW+\N%38$&,!LA@W44 =YG%%<7_P (SJUI:S6]DEBRB^6YA:XO+AL@
M,6^8'('I@<=^H%+=^&]>NKN\9KR)8;B12P2\G4LH.<8'"8'R_+UZGF@#LLC.
M,\^E*2 ,DX%<^VAW7]A78C:%=;N;00/="1\$@$+\WW@!D],'//7FG6&DZE'X
M+_LK4)[>YOS;R1/)\QC8G./O98C! YR>* -U65UW*P8>H.:6O.X/!7B33O[+
MATW4[.*UM9?-DC)==V=I( 0*O7<.5P1R1DFIXO"7B!K27[;=VMU.FH?:K9?M
M=PBJA!R&8')/(X^[QT% '>T5PDGA7Q%=R:P+ZZL98+F>.XM(H[BYCV%7)PS!
MLC(('RXY'2ED\,^*GU.\F_M.U^QSVRQI;B>=2I&WY=V>%X8;@ WS<DT =SD$
M9R,>M"LKC*L&'J#FL#3=#N[3P=_9$CP1SA'53$S,@!8D#)P3P<$UB1^%=?@O
MM*EL'TG3;2WE+7%G:-*J'+<E,8&2."&!'ICK0!W=(2 "20 .M<2GA?7Y8;6?
M4;^.\O;>[,J![N1(UC(Z QJI)'H00<4:GX6U75-,U2PN8-,DM[J[2=8S=3@.
MN?G5R.><=!P,GT% '; @]#FEKD#X>U>+^TH+,6-O:7$42PJEQ,K#8 NTD?<7
M&1\O/XDU43PQXDEU)OM5Y9?V;)8FU>)+BX:3)7@[B0#\W\6 V.] '=45P]OX
M:\30ZEHDR7]G#:6:E)[=9YY-PR?NLQ^;(/\ &#CMBMOQ!I>IZC<63V%RD21/
MN?=*Z%3D88!>&(&1M;Y>: -P,"2 1D=12!U9BH8%AU /2N=\,>&_[$O=7NY;
M:U2>^N#(9899)'=>=H8OTQGH.*I7WA>_N=2U.>"#3;9+QXLRP22132(I);>Z
M@$$@]CVH [&BN+;P]XD>0NU[;LS6PA+B[F7MRNT#&#C[_P!\9Z]JCN-%\36]
MM$6U&3[);VD@>WM)F>1Y/F*@%EW-CY1RP)Q^8!W%%<)IWA_Q"UIITK72Q!7\
MWRI+J?=!G:>_+D_-E7X&>/9MWX=\:3V(5-9M&NA>><#/))L6,<J%\L(0?4-N
M'% '>YXS17%S^&-66'58K9;)OM<RSHTUY<'YMVXY7D  YX7@\9%/O/#_ (BN
M[R[F^V0(MQ&JD)=3+W4E0!PN,-AAR<\T =C16/H\.K6@AL[M(&MHHF'G"9G<
MG<=B_,,G"8RQ.2:9J]AJ<^L6-W8+9E(5=9#/+(&PW!VJORYZ<GGC'<T ;=%<
M1'X8\0QV4$'VR&39,LK!KZ<$MM^9M_7[W(3[M0ZGX:\8WUG>)'KL*2O<AX5>
M1_+$?S?*=BHP(RO\1SCF@#O:*X.?PWXOEGU=AJ=@L=Y;I'#B6<-&XQ\QP<<X
M.=H7K5D:!XE6!$^T6#3'3?LLUSY\P=I .&7^Z,YY')SSG H [.BN#&BZW:ZW
MI$#R32VJS$LT=S.1%$,G:S$_.2<<MSV'%;WB'1KC4KG3;JT$32V<Q<K+<2Q*
M5(P?N=3TX(Q0!O @C(.117GEQX-\2II;6FF:E:6N9A+M,TY4G+9Q@@H/NX4<
M<'(KJM9TV_U+18;2.=5FWQF=A,\6Y1]X!D^89H V:3()(R,CK7&7&A>+)XHK
M9M3MFMB@$H\^1&S\N0K*N<#;D'.>3G-4[7PAXCMK[S4OK2,B(1K<K<3-)]TC
M+*>'^8_Q'@=,4 >@45PNE>'/&%K;:;;W6M0;(9W:Y-O*^9$)! 'F*Y./FZD=
M?RWO$VF:EJ=O;IIUPD3(Y9M\SQ\X^5LIR2#SM/![T ;>X;MN1GKBEKFM$\-M
MIWB;5M8GM[7SKS"K<)-(\A08^5@WRJ,C.%XYJK-HWBH^);^^M]0L8[*5%\B(
M-+ORI4@/G*@'# E0#AJ .N) &2<"EKB)?"^M3G[1</97%Y+:/;SM+<S!!RVW
M" ;6X89)7.1Q3[;PSKMJ=/B6]B,%I)\A-W,65<@G.?ODC*X;( Z<T =I17%P
M:#XG6"TDN[ZUO;R&\\_,\[[$3! "A47)Y_B!Z9J+5/#WC"^MM2CBUJV4S72R
MVJR.^U(QNRAV!6'53PQZ<\=0#N<C.,\TA( R3@>]<IIGA[5K?Q2FJWL]O,H@
M,;2>=(SG*KP%(VJ P)R.N>:B\0>&]<U;7)YH+NT&F2V1MS;S/)EF.<' ^4#)
M!SC/ Y[4 =C17#IX=\4P:IIDT%]8BTM&<-%)/<.[H<X!8G#$9!RP)R.M0OX8
M\9NFG.VOQ/-!<%YQ)(Y5DR,;=BKSC<,,&'- '?4=*Y[PUI6L:;=ZK)JEY#/%
M<W!DMUC>1BB\\'=WZ?=P/:LW4_"^L:A_;$;3V\D-ZNU$DNIP'&X'#!>$PN5^
M3KGF@#L@0PR""/44M4M'L(]*T>TL(H(H([>)8UBA)*)@= 3R1]:NT %0WG_'
ME/\ ]<V_E4U0WG_'E/\ ]<V_E0 VQ_Y!]O\ ]<U_E5BJ]C_R#[?_ *YK_*K%
M %"?_D-6G_7.3^E7ZH3_ /(:M/\ KG)_2K] !1110!BOXDABFN/-L;U;6(E5
MN5C#K,P(!5%4ER<_[/.#BH7\:Z''(4,\^=@?(M92,8W==N. 03Z9J>;PKH\\
MUQ,]M)ON#F3;<2*,^H ;"GW&*B?P7H#JJM8DA>G[^3T _O>BCZ_B: 'Q^+-(
ME$166;]ZK,,VT@VXSPWR_*3@X!P3VS5_3=3M=6M?M-HSM'N*_/&R'/T8 ]""
M/4$&L_\ X0_0O,,GV-@3NR!/)ALC!R-V"<=,].V,5H:?I=GI4;QV<1C5R"P,
MC-DA0H^\3V 'X4 8L'C?3YI'06>H96Z^R_NX/..[!.2(RQ48'< ^U7Y/$NF1
M-<*9)BT!"[4MW8R'.,1@#]Y@\';G!XIA\)Z,8IHS;2XFD$KM]IEW[AG&&W9
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M.>>?QR]2^(UAI,EQ]K@(BBOQ9>;'*'!8\\A<E3Z ]<&@#LZ*XZ7XA6,2R.T
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M<G(ZFG5Y9X6\(V'BB+5]0U.[U-K@:K=0CR[^6-0JN0  #CI32OJP;/41&@
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MOL:)!<^=N/F;\]!CO77WG_'E/_US;^535#>?\>4__7-OY4-W!*PVQ_Y!]O\
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MUL(03([2#&#CGC .>>IXS5#5O"6IZJU[%=S6EW9S74<JP7#R;2JMG! Z$#
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M)$0[2WS,!P.I^@H ?142W5NZAEGC(*;\AA]WU^GO0;F  DS1@!=YRPX7U^E
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MW\$BWU+2;M-2*)IIDVP0VL<:.K= 0!P1ZC&>]2^)O#MUJ1FNK2?<YMVB^R2
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MX\I_^N;?RJ:H;S_CRG_ZYM_*@!MC_P @^W_ZYK_*K%5['_D'V_\ US7^56*
M*$__ "&K3_KG)_2K]4)_^0U:?]<Y/Z5?H **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AO/\ CRG_ .N;
M?RJ:H;S_ (\I_P#KFW\J &V/_(/M_P#KFO\ *K%5['_D'V__ %S7^56* *$_
M_(:M/^N<G]*OU0G_ .0U:?\ 7.3^E7Z "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H;S_CRG_P"N;?RJ
M:H;S_CRG_P"N;?RH ;8_\@^W_P"N:_RJQ5>Q_P"0?;_]<U_E5B@"A/\ \AJT
M_P"N<G]*OU0G_P"0U:?]<Y/Z5?H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AO/^/*?_KFW\JFJ&\_X
M\I_^N;?RH ;8_P#(/M_^N:_RJQ5>Q_Y!]O\ ]<U_E5B@"A/_ ,AJT_ZYR?TJ
M_5"?_D-6G_7.3^E7Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "H;S_CRG_ZYM_*IJAO/^/*?_KFW\J
M&V/_ "#[?_KFO\JL57L?^0?;_P#7-?Y58H Q8+V.[UB*-9!)-:[X)RJD 2;4
M8X]L,#^-;58&F6P@GT^1G@EN;F$S7,\ PD\NQ%+@>A"C'MBM^@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ J&\_X\I_^N;?RJ:H;S_CRG_ZYM_*@!MC_ ,@^W_ZYK_*K%5['_D'V_P#U
MS7^56* ,T^8=3L/."B7R7WA#D X&<>U:59%L;<W&E&UE66W-L?*D4@AEP,$8
MXP16O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5#>?\>4__ %S;^535#>?\>4__ %S;^5 #;'_D'V__
M %S7^56*KV/_ "#[?_KFO\JL4 8.EAEBT,,MLK"R (M3F$':OW/]GT]L5O5@
M:2NRWT%=EN@%B!MMCF(?(O"'NOI[5OT %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0WG_'E/_P!<V_E4
MU07I L9R3@>6W\J $L?^0?;_ /7-?Y58JO8C%A;@_P#/-?Y58H I_P!EVBV4
M%I#$(8K= D(CX\M0, #VQ3/[/G_Z"-Q^G^%7Z* *']GS_P#01N/T_P */[/G
M_P"@C<?I_A5^B@"A_9\__01N/T_PH_L^?_H(W'Z?X5?HH H?V?/_ -!&X_3_
M  H_L^?_ *"-Q^G^%7Z* *']GS_]!&X_3_"C^SY_^@C<?I_A5^B@"A_9\_\
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M  H_L^?_ *"-Q^G^%7Z* *']GS_]!&X_3_"C^SY_^@C<?I_A5^B@"A_9\_\
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7P)[N>5,Y*,0 ?RJ_10  8&!1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>formdef14a_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 formdef14a_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "( G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&B@#GO["UO\ Z&^__P# 2V_^-T?V%K?_ $-]_P#^ EM_\;KH:* .>_L+6_\
MH;[_ /\  2V_^-T?V%K?_0WW_P#X"6W_ ,;KH:* .>_L+6_^AOO_ /P$MO\
MXW1_86M_]#??_P#@);?_ !NNAHH Y[^PM;_Z&^__ / 2V_\ C=']A:W_ -#?
M?_\ @);?_&ZZ&B@#GO["UO\ Z&^__P# 2V_^-T?V%K?_ $-]_P#^ EM_\;KH
M:* .>_L+6_\ H;[_ /\  2V_^-UF:I:>(+&^TN!/%EZRW=P8G+6EMD#:3D?N
M_:NTKGO$7_(7\._]?Q_]%M0 ?V%K?_0WW_\ X"6W_P ;H_L+6_\ H;[_ /\
M 2V_^-UT-% '/?V%K?\ T-]__P" EM_\;H_L+6_^AOO_ /P$MO\ XW70T4 <
MSH\FIVOBV]TJ]U674(%L8;A&EAC1E9GD4CY%&1A1UKIJYR#_ )*1??\ 8)M_
M_1LU='0 4444 %%%% !1110 4444 %%%% !7'Z<FMZW=:M*OB.YLXK>_EMHX
M8;:!@JKC'+(23SZUV%<YX0_YCO\ V&+C_P!EH =_86M_]#??_P#@);?_ !NC
M^PM;_P"AOO\ _P !+;_XW70T4 <]_86M_P#0WW__ ("6W_QNC^PM;_Z&^_\
M_ 2V_P#C==#10!SW]A:W_P!#??\ _@);?_&Z/["UO_H;[_\ \!+;_P"-UT-%
M '/?V%K?_0WW_P#X"6W_ ,;H_L+6_P#H;[__ ,!+;_XW70T4 <]_86M_]#??
M_P#@);?_ !NC^PM;_P"AOO\ _P !+;_XW70T4 <]_86M_P#0WW__ ("6W_QN
MC^PM;_Z&^_\ _ 2V_P#C==#10!SW]A:W_P!#??\ _@);?_&Z/["UO_H;[_\
M\!+;_P"-UT-% '/?V%K?_0WW_P#X"6W_ ,;H_L+6_P#H;[__ ,!+;_XW70T4
M <]_86M_]#??_P#@);?_ !NC^PM;_P"AOO\ _P !+;_XW70T4 <7K]IK^D:/
M+>1>++UW1D #VEMCE@.T?O6G_86M_P#0WW__ ("6W_QNE\:_\BM<?[\7_H:U
MT% '/?V%K?\ T-]__P" EM_\;H_L+6_^AOO_ /P$MO\ XW70T4 <]_86M_\
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M$'_/:/\ [Z%>6Z#\-/!>J+$\_AG3Q'-;+.C6U]/(,DD%2<@<<=.^:W/^%.>
M/^A=C_\  B;_ .+H [;[1!_SVC_[Z%<_XAGA.K>'CYL>!?'^(?\ /-JR?^%.
M> /^A=C_ / B;_XNLCQ%\,/ ^E6,,MOX>TQ9)9UBW7U]-%&,@GE@QYXH ]+^
MUVW_ #\1?]]BC[7;?\_$7_?8KQ&/1?AI<B[CL_"=I/=6WE%X1JI7 9@K$DO\
MNTD=:U-(\(_"[6/$=QHD/AV 74$8=@+UVYP"1@/T&X<]#0!ZU]KMO^?B+_OL
M4?:[;_GXB_[[%<7_ ,*;^'__ $+D7_@1-_\ %T?\*;^'_P#T+D7_ ($3?_%T
M :MK(DGQ'OS&ZN/[)M^5.?\ EK-72UA>'?!OA_PF)_[#TR.S^T8\TJ[,6QG'
M+$^IK=H **** "BBB@ HHHH **** "BBB@ KF?"<L:'70TB*?[8N."P']VNF
MKROQ=X:\)3^- =1\.6-Q-=QF26:2\>)I'"DCHP4?=[XH ]0^T0?\]H_^^A1]
MH@_Y[1_]]"O%[GP[\-+6WMI1X6M[@2P+*S0ZD=JD@D@;I 3C!R>@Z4R30_AB
METMC_P (Q:_VBT,C?9#JAWK(H)"<2'.0.HXH ]K^T0?\]H_^^A1]H@_Y[1_]
M]"O(8/"OPM^SQ->^'8;:XD&?*6^:4?Q=&63!^X>G0D#O5:UT3X47FK:=81>&
MBC7_ /JC-<21D^A"E\L.#R.E 'L_VB#_ )[1_P#?0H^T0?\ /:/_ +Z%>9:G
M\-?A_8W$T/\ 8%C#Y=MYHENKV:./>Q*HI.[@$J<GZ8S6%#X7\ K:O]J\)V0N
M4A$A*:FXC)(#$?,X8 *P.2 "00* /:OM$'_/:/\ [Z%'VB#_ )[1_P#?0KQN
MY\*_#M#<K:^$K>Y,2@HZZH527[I;#&3C"N#DU<U'P!X%M]-L;FW\-::KW*[S
M]IU.18P ,E5=6(9NPQQUH ]8^T0?\]H_^^A1]H@_Y[1_]]"O%CHGPM?RUM_"
M4[NREY%EFDA\L $MDO(,D $X&?UID6E_".1[M?\ A'=WD3K !#<R2,Y)('RB
M3*\CH: /;/M$'_/:/_OH4?:(/^>T?_?0KQ^S\*?#;4+V\M;;PO%YEE/%'.K7
MDA=5<X!VAS@Y_A/O75?\*<\ ?]"['_X$3?\ Q= ';?:(/^>T?_?0H^T0?\]H
M_P#OH5Q/_"G/ '_0NQ_^!$W_ ,71_P *<\ ?]"['_P"!$W_Q= ';?:(/^>T?
M_?0H^T0?\]H_^^A7$_\ "G/ '_0NQ_\ @1-_\71_PISP!_T+L?\ X$3?_%T
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<@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>formdef14a_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 formdef14a_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *Z I # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ***IZGJEGH]G]KOYO)@\Q(MVTM\SL
M$48 )Y9@* +E%%% !115>*^M9[VXLXIE>XM@AF0=4W E<^Y SCZ>HH L4450
M?6M.CM-1NC=*8=-+"[=06\HJ@=AP.2%(/&?3KQ0!?HK+T[Q%I.K2P1V%XL[7
M%HM[%M5L-"QP&R1@<\8ZCTJY<W]K:3VL-Q,L<MU(8H%/61@I8@?@I/X4 6**
MBM;A+NUCN(UE5)%W*)8FC<#W5@&!]B :EH **P+/QIH5]>PVL%Q<[IYWMX9)
M+&>.*25-VY%E9 A(V/P#_":WZ "BBB@ HK/T[6[#5E5K&266-O,Q)Y$@3,<A
MC<;BH (8$8SDXR,CFM"@ HJO=WUK8B$W,RQ^=*L$6>KNQX4>_P#@3VIFFZE:
M:O8K>6,OFV[,Z!]I7)5BK<$ \%2/PH MT45E:#XDTCQ-:RW.CW@NH8I/*=@C
M+AL!NC $@A@01P<\&@#5HHK/_MJQ&HPV#R2I<SO(D220.N\Q@%B"5P0 1ST/
M8F@#0HJG=:I9V=_8V5Q-LN+YW2V3:3O94+L,@8&%4GG%1WVMV&FS)%=R2Q%Y
M(8D8P2%&>5]B*&"[22W!&>,@G (- &A15*WU:RN;J.U21UN9(WE6&2)XWV*P
M0L58 @9(QGKU&15V@ HJCJNL6.BVT<]])(B2RK#&(X7E9W;HH5 6)X/050U;
MQCHFB7LMI?3W"RPP"XF\JRFE6*(E@'=D0JH^5N21T- &[12(ZR(KHP96&0P.
M01ZTM !117.77CWPS9+K#7.J+&-&:-+_ ##(3$7.%XV_-D_W<T ='14,%U#<
MV<=W%(#!)&)5<\ J1D'GIQ265[;:C8P7MG*)K:=!)%(O1E(R"* )Z*BEN$AF
M@B992TS%5*1,R@@$_,P&%&!U8@$X'4@5#>ZE::?)9QW4WEO>3BW@&TG?(59L
M<#CA&.3QQ0!;HHJCI.L6.N69N]/DDEMP[1B1H7C#$=2NX#</]H9!]: +U%%9
MEEX@TK4KJ*WL[Q9I)8#<Q[%;#1AMA8-C&-W'7WZ4 :=%%94_B32+7Q#;:!->
M!=3N4\R*#8QW##'[V-H.$; )R=IH U:*** "BBLBX\3Z/:Z5J&J37FVSTZ5X
M;J3RG/ENI 88 R<$CH#0!KT5B6OB_0;W5[/2K;4%DO;RS6^@C6-_G@;H^[&!
MGT)!]JVZ "BJ7]KV1O)+1)6DGBE2&5(HF?RV9=Z[]H.T;<')P.1ZBKM !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#IMG'"D?E+&D"A0F<[0 ,8SSCUJ.[\/Z+?NKWFD:?<NLAE5IK9'(<XRPR.O
MY]A1=3:REC ]I86$MXV/.BEO7CC3CG:XB8MSZJOKQTJE]K\6_P#0$T3_ ,'$
MO_R-0!IMI>GN9BUA:L9E=)<PJ=ZOC>&XY#8&0>N!41T'1VU1]4;2;$Z@Z[7N
MS;IYK#;MP7QDC;QUZ<4FI3:S$\8TNPL+E"#O-U>O 5/; 6)\_I5:WNO$[7,:
MW.D:1' 6 D>/5)'95[D*;< GVR/K0!<LM%TK3;.2SL=,LK6UDSO@@@5$;/!R
MH&#FHK+PWH6FP7,%CHNG6L-TNRXC@M419EP1AP!\PPQX/J?6FW]QX@CNBNG:
M9IEQ;X&'N-1DA?/?Y5@<?K26-QX@DNE74-,TRWM\',EOJ,DS@]OE,"#]: '?
M\(UH)L8+$Z)IOV2WD\V&#[(GEQO_ 'E7& >3R/6G/X>T62[N+M]'T]KFY4I/
M,ULA>52,89L988XY[57N;GQ,MS(MKI&D2P!CY;RZI(C,.Q*BW8 ^V3]:LZ;-
MK4LCC5+"PMD ^0VMZ\Y)]PT28_,T 66L+-I?-:T@,GF^=O,8SYFSR]V?[VSY
M<]=O'2JMAX=T32B#IVC:?9E7\P?9[5(\-M*[OE YVL1GT)'>J9N_%N3C1-$(
M[9U>7_Y&J[:3:R]E.]Y86$-VH/DQ0WKR(YQQN<Q*5YXX5N.>>E $T&EZ?:R^
M;;V-K%)Y2P;XX54^6.B9 ^Z,G Z5!;>'=$L[Y;ZUT;3X+Q4$8N(K5%D"A0H7
M<!G 4 8] !5/[7XN_P"@)HG_ (.)?_D:KOG:S_97F?8+#^T<_P#'O]M?R<9_
MYZ>5GIS]SKQ[T *-"T==6;51I5B-2;K>"W3SCQC[^-W08ZTVX\/:)=VT5O<Z
M/I\T$,C2QQ26R,J.Q)9@", DDDD=235/[7XN_P"@)HG_ (.)?_D:KMU-K*6,
M#VEA82W; >=%+>O'&G'.UQ$Q;GCE5]>.E "MH.CO$\3:38M&ZE&0VZ$,I54(
M(QR-J(N/1%'857;PGX;>T6T;P_I36RL66$V490$@ D+C&<*O_?(]*A%WXMSS
MHFB8_P"PQ+_\C5=U*;68I(QI=A87*$?.;J]> @^P6)\_F* "^T#1M3C:._TB
MPNT:7SF6>V20&3:%WD$?>V@#/7 Q3KW0])U**"*_TNRNH[<YA2>W1Q%_N@CC
MH.E5+>Y\3-<QK=:1I$<!8>8\6J2.RCN0IMU!/MD?6I;^X\01W173],TRXM\#
M$EQJ,D+D]_E$#C]: +":59VZW)LH(K*>XC6-Y[:)%?Y5VH>00=HZ @@>F.*P
MXO!*VZ[8=;O8U\DP82SL0/+))*<6_P!W))QTY-:EA<>()+H+J&F:9;V^#F2W
MU&29P>WRF!!^M17-SXF6YD6UTC2)( Q\MY=4D1F'8E1;L ?;)^M;4Z]2DFH.
MU_3]4Q-)F?\ \(/'Y$T']M7ODS1I%+']BL=KH@PJL/L_( X /2G/X,+I*AU_
M40)9&EDVVUD"SE=I?(M\[BO&[KBM?39M9ED<:I86%L@'R&UO7G)/N&B3'YFJ
M'VSQA_T M#_\',W_ ,BUM]=Q'\WX+_(7*BC8^ H-,A2*RUF^@1'$@V6ED#O
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% &;XBU)]&\,ZKJD2+))96<UPJ-T8HA8 ^W%>=>&/ VL>)?#M
MEKNM^._$Z7FI1+=>5IU]Y$,:N-RJ%P1T(Z8'M7;^._\ DGGB7_L%77_HIJ/
MG_)//#7_ &"K7_T4M '/_P#"K/\ J??'/_@X_P#L*/\ A5G_ %/OCG_P<?\
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M %/OCG_P<?\ V%>@44 >?_\ "K/^I]\<_P#@X_\ L*/^%6?]3[XY_P#!Q_\
M85Z!10!Y_P#\*L_ZGWQS_P"#C_["C_A5G_4^^.?_  <?_85Z!10!Y_\ \*L_
MZGWQS_X./_L*/^%6?]3[XY_\''_V%>@5YGX]U[5-!\:6-Y9S7,EO;Z9*\EE&
MQ*S.\BQ1_+T)#NG)[9H N?\ "K/^I]\<_P#@X_\ L*/^%6?]3[XY_P#!Q_\
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M&./9;<QM-'DJHD&0!P3CIF@#K_\ A5G_ %/OCG_P<?\ V%'_  JS_J??'/\
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M_85Z!10!Y_\ \*L_ZGWQS_X./_L*/^%6?]3[XY_\''_V%>@44 >?_P#"K/\
MJ??'/_@X_P#L*/\ A5G_ %/OCG_P<?\ V%>@44 >?_\ "K/^I]\<_P#@X_\
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MN;5KB\N[J!3;F&0/'$^U55 6/.0&;=UZ8 +<OCF$>$]=\06]HMQ!IC.(U6;
MN%5%<,&V_+D-Z&LM_B9Y>DWMY]ETJ;[-=VUM]HM]6\RS/G$#)G\L;=G5AM.
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M%6O_ **6CQW_ ,D\\2_]@JZ_]%-1X$_Y)YX:_P"P5:_^BEH Z"BBB@ HHHH
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M%B,X"\#)X[.B@#RB+P[XFTN"[GM= BN[VUMQ;6GFR0LLLOVF247"AF'W5<,
MQ5MQ(_VJT=,\-W^G:GH1T_2=1M&ACA2ZO9M07;)"@EW1S0)(4+;GRNT, 7SN
M7&*]&HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *\\^*O\ K/!/_8T67\VKT.O//BK_ *SP3_V-%E_-J .C\=_\
MD\\2_P#8*NO_ $4U'@3_ ))YX:_[!5K_ .BEH\=_\D\\2_\ 8*NO_134>!/^
M2>>&O^P5:_\ HI: .@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG)!\Q3TSG<Q82ZOH7C^^MKL6VJVZRF[\RV634&2-(OGP#Y-NCY&5X+L"1SD
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M &E GF$ A,YX;D?*>?:K/]L:9YUQ#_:-IYMM&99T\]=T2 D%F&?E ((R?0T
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M^X?WA.X, " < &_I_@^#3_$LVMKJNJ322J0;::5# K,!N95"@J20"<'!..,
M :FL:3%K-A]EDE>%@ZR1S1JC/&RG(*[U9?4<@\$CO7%WOQ5LK#1(M1E337$E
MR(08-3$T0!7< 9$0[9.VT@+P3OP-U-U+XF/:W6V)-&CMA<")9;G4@H<%G4!O
ME'E8V,Q/SD!0 K;LJ ;%EX!M;&U%NFK:@RJA0%DMA@;857@1 ':((\ C!QAM
MPXJ)_AW;2SVT[Z]K7FPSM,Q1X8UG+/YA$BK$%(WY;H#DYSD#$,/Q+T^3Q%IV
MDR1P1->6XF#&XY.0QRAV['C^7&_>,]0" 2-SPOXGM?%>G/?64$D<"OL#//!)
MN.,D?NI' (R.#@\]* ,&[^%NE74=Z!J5_;27EP9Y)[6*UAFR=VY?,6$,5.\@
M@DY'&<$YV[[PY+=3W]S_ &O?.US L:6S>0L2%"60@^46X8D_-N')RI&!7.ZU
MX]DTVQOS:ZKHMU=6NI_9B$VX1#&7"L#,,/N5ESNR=K80D;:[N.[MI;J:UCN(
MGN( K2Q*X+QAL[2PZC.#C/7!H Y.V\#O<Z1!#JNI70N@LWF& PL,RW(G8[O)
M7))502%48&=H/-);_#FVMM,ELEU[69?-+!Y[AH)I"C)L9/GB(VD #ID 8! X
MJ[>>)/L_CJRT-+^P;SH&E>RV_P"D8"L=P8R '.  @0G 9L@5AW/CN:W\++J3
MZWH(F:\$"/Y9\J3,:MY0S, K*6PSEL#:<KG@ ':7.F?:=(6P-Y<(RB/;<H$\
MP,A!#\J5SE0?NX]JH1^&@-3M[Z75KZ=HMK.DB0 3.JE0[%8PP.&Z(57KQRV:
MWAGQ!<ZOK&N6D]SIT\=G<;;<V+!ML9+ "4B1L2?+R,+QCKDA<^Y^(-N=>U[0
M[%K"74-.M'GC1YY%+,J@E7!C '7^!GX!SMH VO$_AE?$]G%:OJ^JZ=&C%F.G
M7 B,H(QM?*G<OMTH7PXXM[J ZWJ1CF<2Q@K!^XD#^9O3]UR2W.&W#VQ5O0]4
M36=)BO4FL)2Q(9K"[^TP@@XP)-JY[9X&#Q7/^'/&,M_I%Q>:@MNX2^2TCEMI
M(%C??M PWGNK8+8X;<>@3/% ":K\.X-8N_M-QXAUM9&@\F94>#9-\I4NR&(K
MN*DKD <$X R<W+KP9%<YQK&HQ9F:5MB6[;LR^<%^:(X"N21C!]2<#%+5?%D]
MGJ^I6BZGI%LENJ#%RA+6P+1#S9?W@^0^8V!\OW1R><;,^O)8^#?[>O)+=0ED
M+EV)98\E0>H#,%)/8,?8T :&HV0U&Q>V\^6W)*LLT.W>C*P8$;@5X('4$5S\
MG@>*XCN1<ZWJLTER)!+,1 CDNL2@Y2)<%?)0CZ<Y'%7/#?BS3?$6B6&HQ7=H
MIO'>*-$FSOD7.57<%8\*6P5!QR0*H:%XXM]3>Z-]_9]G###YXE34%E4H I9F
M)50H DCYYY)!Q@9 -71] &BZ"VEP:GJ$S'>1>7#)).&;^+.W:2"<Y93D]<\U
MDQ?#^TAM/LBZSJ[6_)"2R12D.8# 6#/&6!VL3C.T'@ +\M=/%>6L]S+;17,,
MD\*JTL22 L@;.TL.H!P<9ZX-<GJ/B>^@\=G0;;4M&13;+(D-PH\UI&W (")M
MQ.0K<1$;2<D'&0"_+X.M[B6[DN-1O96NA*)-Z0<ETB4'B/JODH5/J.<C %/3
M_A^FGZM;ZA'XFUY_(>1UMFD@6W+.7+,8EB"Y)D8YQGGK5GPUXA:]T^2[U'6]
M$NH6NS:P367[I6?>5"'=(^6;Y2 #D[AQW.EXDU<:%H%WJ)FLXC"N0UW-Y<><
M^O<^B\;C@9&<@ DT;2I-(M9('U.\O]\K2[[I8@REB6('EH@QDD\COZ5SUQ\.
MK.XMS'_;6LPR% //@EBCD# C#AEC&&VJ%XXQSC<2QN:3XQM-7U^33X)+"2##
M_9[BWOEE\XH(V.% Z;9D/4\AN, %FW?C?3[/QY:>%I)K47%Q%O ,KB0,0Q V
M^7L((7^_NR?NXYH BL_ -G9:MI^H1:OJY-G&B>0TR>3*5! 9U"?>P<97;QTZ
MG-N/PM/$;(+XDU?RK.3?#$4M=H&W:$)\G)7:2.N>3SG!%K5O$ TF\@MFTV\N
M&N !"86B D?< 8QO=3N"DOTQM5CG@BLB7Q_IEG9ZS<W-W83G3[L0&&SO8BP5
MMH4L9'10<DY!(P0RC=MR0!]SX0F@M)Y-.U*[>^)\R,RM!&OF>;)(6)\A@#F9
MQRC#H<;OFK4MM""^$;30YYF'DVD5N98PI(**!N *[3R,X*X/0C'%8EQXZ^QW
ML4EU#80:=-9+=QK+J,8NG!WEBB#,<@ 4$[9. <\Y J&Y^*6A17>CQQ7=DT>H
MW$D&7N<LNV3RPRF-7C()^;YG3Y<=3P #;B\,M"UBZ:WJ.^UG>>0[+<?:6<Y;
M>!%@#!(^0+U)^]S4OB3PY;^)M.2RN;B6&-9/,S'##(<@$ CS8W (SP0 1ZTW
M0M>M]5O=5M$U/3KR:SNBFVT8;DC*J0'&YN02RD\ E3P.E4O$/B\:#JT-HT-F
M\+1K+-)+>B)XU.\DA-IW#;&^#D#.!QU !=NO#@NI;L_VI?1P72@/;J(F0. H
M#Y:,L3A%X)*G'*G)JL?!Z;8"-8OQ*C.TTIBMF-QN<.=RF$JO('W N>IR>:Y2
M[^-&F6LMW&T%LK6]UY!$ERZ8^]P_[KY9/EX'*<G+C:V.DC\7D:GJMM<3:'!'
M;P>?;";4_+E=/+1@TB%/DCRQRX)QC&#C- "1^ ;2+3TL(]6U,6J;RL;&%\.\
M31,^YHRV2'8XS@$X "_+4UUX-6Y>X;^W-3B$Z.I$:6WRE]H<@F$DE@N""2!G
M@#:NW.E^(EG!9:9=)+IUY#<6RSW$L-ZH,8WI&VU.<G?(H W=F!.0 VQX6\2?
M\)+;74ZI8[+>80[[*^%U&S;5<X8*!P'4'WW#H 2 177@Z.]N89KC6-1?85:5
M=EN/.<(4W,?*W*2K$?(5')P 22<O_A6&G-I2Z?<ZOJ=Y&MR+G??+;7+;@NT#
M]Y"PP <#C(&!G  J-/&]ZEYKTL]UX;:QL;A+6&--0*M$Q)!:YE(VQJ<' "D[
M@5Y(Y??_ !+LK4V=O#:1RWMW!#,BR:C;11 2-M&6+[R.^Y48$8(X- &WH'A2
MV\/7^HW=O?7LXOF4F"=D\J  LP6)55=HR[''<G/4DE=1\,IJ&HM>#4[VV+ $
MQPK"5WA657!>-F! ;@!MO7(.6SSG_"U--BGT:"Z:P@FU";RWC^UNQC!V%""(
MMI^612P9DQSC=UKH?#VORZK>:C9W;:6ES:3.GDVEZ9954.P!D0JI3("D<G.<
M\=* -33+%M-TV"R:[GN_)7:)IP@=AVSL55X&!P!TYR>:P%\#PQP3QQ:UJD;3
MVYMY9%%ON<$C)YB(!VJ%X &.<;B6-?5O'T&F:M>6#?V4K0$(OVK54@96^4[I
M5*DQQX;A_FR<#'S+E8O'T$E];1-#;>3-#'(62]5Y TD<CHBH!\V?*?!!Y!0K
MG<=H!=N/"+7BWBW?B'5YUNK9;=P?LZ;=O*NI2($,"2>N,GIC %./X>VR1Z4A
MU[6W.G7!N%=YHRUPQ=7(E;R\NI9%)'&2,G) -4+3XFV<=EJ%[J<FG-!#-LC.
MGW\,R#]R) K2,Z@NQ$@' &5(YP&:P_C[[19ZC/I_]BO]DECYEU9<+&9=C-,%
M4F$XYY#  \G(*T :4OA#S;!+0Z[J>V+<D3&.V8QQ%=IC :$J5QW(+=1NP2"E
MUX)M;HW>[4M107(D#>6T0*[EB48;9NRODQX))/'S;AQ6-J/Q1L-/U6VT]A82
M//:"<2)?'RV)!.4<IM:($8,A((Y.TA3C?\,>()-=\/S:@39W,T<\T>S3IUE1
MMK':JN2 25V\G;G.2%S@ %O0=#30-(&GQW][=X9F^T7;J\I+'))(4 G/.2,G
MOFLBV\!6EGIQM+;5+V$FX:?S8X+48W)L91'Y/E $=3LW')YP2*;<>.[5-/BO
M76'3K8W<-N\VI7,48.['F*FUSN=#\K E0I#'+;"#+IOCG3=2\;7WAF&>T>>V
MC\Q3',Y=L!<@J4"_Q<;7?@'..E ":KX)&KO,9?$.M0*Z1JBVKP1>3LSM*,L6
MX'YF[G[Q]!B>P\'P:?<6DT>J7[M:K"J;Q#RL:RJ%)$8.#YSDXQVQ@<%-7\46
MVDZ[]AFU;1XBUC).EM=W A?S%((+.6.$(+?P$C8QYZ5%;^-;:73],GAMY-1-
M]"ICEL9(3')-D!HEW2 [AEF([*C<_*: )X_"T\1L@OB35_*LY-\,12UV@;=H
M0GR<E=I(ZYY/.<$22>&I)+35;<Z]J8347W,0MOF$'@JG[KH1@?-N. ,$')-/
MPMXWM/%&JZK80I&DM@^TJLC,X&2,.I5=K<=!N'.-V00*5S\3M&LO%6H:+<S6
MH%GMWR+<;6CR5!\P2*B  N!\KOZD+S0!N+X<(U*WOGU:]D>)4$B216Y$[(&
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MVH Z/QW_ ,D\\2_]@JZ_]%-1X$_Y)YX:_P"P5:_^BEH\=_\ )//$O_8*NO\
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M>LIC.PAA]GV&-R6(.\MQQ@8!#4Y;+Q[-IOE_;;.&Z^TJYDAO$'[H1A2H+6C
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M.[VPV_V5(GOIWC,6" K(SE6X)Z@_H* $A\7Z+</;(EQ.'N)/*C5[292#\O+
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MJ#GH#5*\\">'M1LIK.\M+BXMYUQ(DM[.V[]XTF<E\YW._/7!(Z<5);>#-%M
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M*47UG$(89FNYF(0= V7P_P#P+/0>@P ;,^I6-K.L%Q>VT,S;=L<DJJQW-M7
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MSPU_V"K7_P!%+1X[_P"2>>)?^P5=?^BFH\"?\D\\-?\ 8*M?_12T =!1110
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M/+D0J"6\V1AM#M@A4"\D,"V$+5Z+10!R-UXYCDNM7T[3+/S;_3[5ISYUQ"J
MA V&17,H^\ <IUXXZU7TCQV+_7H;)[G09[>;RT\VPU,3>5,XE(CS@>9D0YSA
M"-P #<FNVHH QO$>OP>'[6TN+B[L+:*6ZCB=[RX$0"$_,5S]Y@.V1@9;G;@U
MM.\5PW_B6XT@?8]J&1(I8[Q9&D=!&S#9CC"RKW)R&&, %NBHH R?$FIW&CZ+
M)?6R6;-')&'-Y.88E0N%9F<*VT '.<<=>V*Y>#XCQHFI2W$FDW-O;Q22036%
M]YBR%$B9UX!RJ^<,N.<*Q*+P#WU% &+X5\16_BK0(-5MO*V2%E/E2%TR#C@E
M5.._*@^H!KG+;QY<6D6MW^I_9+G3+&Z-M'+:/!$=_F%-A+W!!."I.[R\=@P/
M'>T4 <1%\2;%C=RS001P06QN/+&HP-<!1MY= VQ%;<-K[R&R.FY<Z$'CBSNK
M:&>WT^_E2>9[>$#R@SRJX7RRID!5\;GVMM(5&W8(Q73U3N-+M;K4;2_E\XSV
MA8P@3R*@+*5)*!MK'#$9()&>* ,/QWXCN/#.B1WEK<6$,K2[<WA3:1M8\!I8
M\G('1B<9PK5!=^-5TR]UR/4)-'MXK" SP*]\XN'78C O$(RP7+$%EW$8QM)K
MKZ* .#@^(T5U8:1JD#:1_9UXLHE>2_9&\Q'4;(@T8+L020C!">/NU5L?BM%J
MFG1W%A;:;-*TS1%&U(HHY0 @M$&/,@!&W@#(W#!/HU% 'G3?%FPDUMM+LXK)
MYG,2VZSWIA:0R;0N04(VG>#E6<[03C[H;9T_QC]OUG3H-^D1V6H6<=Q 6U']
M^[L'W+&FW$F"H!PPQUYSBNLHH AM;NVOK<7%I<17$)+*)(7#J2"5(R..""#[
M@UQ-]\3+&V\4WGA^!M-FO87CBCCDO7A9Y'9%VMNBV\,X/R,YVJQQD!3W$$$5
MM!'!!$D4,2A(XXU"JB@8  '  ':I* .(3Q_%=:OH5M;2Z7'!J'EF3S;U3,V^
M-F CCXW*&"KOR?FRNWJ5WO$>OP>'[6TN+B[L+:*6ZCB=[RX$0"$_,5S]Y@.V
M1@9;G;@[-% '.^'/%46OW=U !9J8AOB,%X)_-0221EN ,#=&V.O!7.#E0W4?
M$<MAXF.ESSZ-:6TEJ)8IKN]*2EOGSMB*@.!M7.'7 .<\\=)10!YK;_%JV2;2
MK34(;&*[O#&'$=Z6&'2-U*80@MB0$JQ4#& SY&=N7Q_IEG9ZS<W-W83G3[L0
M&&SO8BP5MH4L9'10<DY!(P0RC=MR>OHH R9==2/PP=;\C9&8!,J2S1A0#T+2
M(S(%Y!+ D <]JYW2O'T%TNE_;-2T",W=[<6[>3?JX^4GRQ'S\^?ERW'5?D&_
M"]Q10!P\7Q(LYWU^.-;$/I-PD!>2^V1?.[(&ED*;8Q\N>-_W@/O?*!?B;ITD
M-^8K7S9+&T^TS/#>VTL0&U3G*2-)LRP!?R\=Z[BB@#AK#X@KJ4.BWD3:-%87
MYDCDEN-1:/YU=0!$6C&\D,2%8(3T.W!I;SXBV5F;Y/M>B2SVUXT)0ZHD2)&%
M!&YV'^L/("8'(89PA:NXHH YS3/%D6H>(YM**6T87S%C870:1W01LRF/ *D+
M*N><@A@1@ L[Q)XNL_#31172J)KE<6WFW$<22/N5=N6;/&]2<*3MR0&(Q70U
M'<0)<VTL$F_RY4*-L<HV",'# @@^X.10!PR_$RV?2!?!-* ,@ =M7C$&W;NV
MF7&!-CCRO7G=M^:MK3/%D6H>(YM**6T87S%C870:1W01LRF/ *D+*N><@A@1
M@ G<L[2*QLX;6#S/*B4(GF2M(V!ZLQ)/XFIZ .8U+QG;Z=XVLO#1BCEN+NW:
M9%6?$I(5VVA"-O1.K,O+#&<,11E^).E2:6U[82V+JMP(&:[U&*",$QB3[X+
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M_P#)//$O_8*NO_134>!/^2>>&O\ L%6O_HI: .@HHHH **** "BBB@ HHHH
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M[!5K_P"BEH Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY)YX:_[!5K_Z*6@#H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\\^*O\ K/!/_8T67\VKT.O//BK_ *SP3_V-%E_-J '7
MZ(OPR\6/_P (]%I$C:9=C=% L0N$"2!'VCYER.=K#*[L<UT/@3_DGGAK_L%6
MO_HI:YN_N+N?P!X[CGMKFV@MK*X@AAGF:3'^B[V*ET#8R^WJP^7C Z])X$_Y
M)YX:_P"P5:_^BEH Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O//BK_ *SP3_V-
M%E_-J]#KSSXJ_P"L\$_]C19?S:@"E/;RV/@SQQ8W-S+)<P:&=Z%@RD&*;$C,
M"=TKX.\X7[J?+C!/8>!/^2>>&O\ L%6O_HI:Y&Y22U\%^.+)[=]/6/1I)%TV
M2<SM%NBF_>>82<A]N, G'EGUKKO G_)//#7_ &"K7_T4M '04444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_A+/B1_T3-/_  >P?X5Z%10!Y[_PEGQ(_P"B9I_X/8/\*/\ A+/B1_T3-/\
MP>P?X5Z%10!Y[_PEGQ(_Z)FG_@]@_P */^$L^)'_ $3-/_![!_A7H5% 'GO_
M  EGQ(_Z)FG_ (/8/\*/^$L^)'_1,T_\'L'^%>A44 >>_P#"6?$C_HF:?^#V
M#_"L]=)\9^-O&&BW?B;18M#T71YOMB6R7JSO/.,;"2IQ@'GH.-PYSQZE10!_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>mlss-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaWPSbP9z5Z8SekhvWB/bdlaXycl845PQCwfKJmG4ZUO -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:MLSS="http://milestonescientific.com/20241231" elementFormDefault="qualified" targetNamespace="http://milestonescientific.com/20241231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://milestonescientific.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="mlss-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="mlss-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="mlss-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="MLSS_ValueReportedUnderStockAwardsInSCTMember" name="ValueReportedUnderStockAwardsInSCTMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MLSS_FVOfUnvestedEquityAwardsAtYearEndMember" name="FVOfUnvestedEquityAwardsAtYearEndMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MLSS_FVOfVestedAwardsAsOfVestingDateMember" name="FVOfVestedAwardsAsOfVestingDateMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>mlss-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="mlss-20241231.xsd#Cover" roleURI="http://milestonescientific.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://milestonescientific.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:loc xlink:type="locator" xlink:href="mlss-20241231.xsd#MLSS_ValueReportedUnderStockAwardsInSCTMember" xlink:label="loc_MLSSValueReportedUnderStockAwardsInSCTMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_MLSSValueReportedUnderStockAwardsInSCTMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="mlss-20241231.xsd#MLSS_FVOfUnvestedEquityAwardsAtYearEndMember" xlink:label="loc_MLSSFVOfUnvestedEquityAwardsAtYearEndMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_MLSSFVOfUnvestedEquityAwardsAtYearEndMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="mlss-20241231.xsd#MLSS_FVOfVestedAwardsAsOfVestingDateMember" xlink:label="loc_MLSSFVOfVestedAwardsAsOfVestingDateMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_MLSSFVOfVestedAwardsAsOfVestingDateMember" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember" xlink:label="loc_ecdPeoMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_ecdPeoMember" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>mlss-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember" xlink:label="ecd_PeoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoMember" xlink:to="ecd_PeoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoMember_lbl" xml:lang="en-US">PEO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mlss-20241231.xsd#MLSS_ValueReportedUnderStockAwardsInSCTMember" xlink:label="MLSS_ValueReportedUnderStockAwardsInSCTMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MLSS_ValueReportedUnderStockAwardsInSCTMember" xlink:to="MLSS_ValueReportedUnderStockAwardsInSCTMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MLSS_ValueReportedUnderStockAwardsInSCTMember_lbl" xml:lang="en-US">Value reported under stock awards in the SCT [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mlss-20241231.xsd#MLSS_FVOfUnvestedEquityAwardsAtYearEndMember" xlink:label="MLSS_FVOfUnvestedEquityAwardsAtYearEndMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MLSS_FVOfUnvestedEquityAwardsAtYearEndMember" xlink:to="MLSS_FVOfUnvestedEquityAwardsAtYearEndMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MLSS_FVOfUnvestedEquityAwardsAtYearEndMember_lbl" xml:lang="en-US">FV of Unvested Equity Awards at Year-end 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mlss-20241231.xsd#MLSS_FVOfVestedAwardsAsOfVestingDateMember" xlink:label="MLSS_FVOfVestedAwardsAsOfVestingDateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MLSS_FVOfVestedAwardsAsOfVestingDateMember" xlink:to="MLSS_FVOfVestedAwardsAsOfVestingDateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MLSS_FVOfVestedAwardsAsOfVestingDateMember_lbl" xml:lang="en-US">FV of Vested Awards as of Vesting Date [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">Total Summary Compensation Paid Table (SCT) - column (a)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">Compensation actually paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="ecd_AwardTmgDiscLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgDiscLineItems" xlink:to="ecd_AwardTmgDiscLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgDiscLineItems_lbl" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrByIndTable" xlink:to="ecd_TradingArrByIndTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrByIndTable_lbl" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="ecd_TradingArrAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrAxis" xlink:to="ecd_TradingArrAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrAxis_lbl" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xml:lang="en-US">Aggregate Available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MLSS_ValueReportedUnderStockAwardsInSCTMember" xlink:to="MLSS_ValueReportedUnderStockAwardsInSCTMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MLSS_ValueReportedUnderStockAwardsInSCTMember_doc" xml:lang="en-US">Value reported under stock awards in the SCT [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MLSS_FVOfUnvestedEquityAwardsAtYearEndMember" xlink:to="MLSS_FVOfUnvestedEquityAwardsAtYearEndMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MLSS_FVOfUnvestedEquityAwardsAtYearEndMember_doc" xml:lang="en-US">FV of Unvested Equity Awards at Year-end 2021 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MLSS_FVOfVestedAwardsAsOfVestingDateMember" xlink:to="MLSS_FVOfVestedAwardsAsOfVestingDateMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MLSS_FVOfVestedAwardsAsOfVestingDateMember_doc" xml:lang="en-US">FV of Vested Awards as of Vesting Date [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>mlss-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="mlss-20241231.xsd#Cover" roleURI="http://milestonescientific.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:presentationLink xlink:type="extended" xlink:role="http://milestonescientific.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember" xlink:label="loc_ecdPeoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_ecdPeoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mlss-20241231.xsd#MLSS_ValueReportedUnderStockAwardsInSCTMember" xlink:label="loc_MLSSValueReportedUnderStockAwardsInSCTMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_MLSSValueReportedUnderStockAwardsInSCTMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mlss-20241231.xsd#MLSS_FVOfUnvestedEquityAwardsAtYearEndMember" xlink:label="loc_MLSSFVOfUnvestedEquityAwardsAtYearEndMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_MLSSFVOfUnvestedEquityAwardsAtYearEndMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mlss-20241231.xsd#MLSS_FVOfVestedAwardsAsOfVestingDateMember" xlink:label="loc_MLSSFVOfVestedAwardsAsOfVestingDateMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_MLSSFVOfVestedAwardsAsOfVestingDateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="loc_ecdEqtyAwrdsAdjFnTextBlock" />
      <link:presentationArc order="2290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdEqtyAwrdsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="loc_ecdTradingArrByIndTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTradingArrByIndTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="loc_ecdTradingArrAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdTradingArrAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember" xlink:label="loc_ecdAllTradingArrangementsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrAxis" xlink:to="loc_ecdAllTradingArrangementsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="loc_ecdTrdArrSecuritiesAggAvailAmt" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrSecuritiesAggAvailAmt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">DEF 14A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Milestone
Scientific Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000855683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTableTextBlock', window );">Pay vs Performance [Table Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88F_eecd--PvpTableTextBlock_zq6prL7svOmc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Pay vs Performance Disclosure">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td>&#160;</td><td style="font-style: italic">&#160;</td>
    <td colspan="2" id="xdx_48E_eecd--PeoTotalCompAmt_hecd--IndividualAxis__ecd--PeoMember_zkiSFXM1Flya" style="border-bottom: Black 1pt solid; font-style: italic"><span id="xdx_F50_zlT3owQFUjRj" style="font-family: Times New Roman, Times, Serif">(a)</span></td><td style="font-style: italic">&#160;</td><td style="font-style: italic">&#160;</td>
    <td colspan="2" id="xdx_485_eecd--PeoActuallyPaidCompAmt_zdTBalimNL8c" style="border-bottom: Black 1pt solid; font-style: italic"><span id="xdx_F58_zDJd37nhkgP6" style="font-family: Times New Roman, Times, Serif">(b)</span></td><td style="font-style: italic">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-style: italic"><span style="font-family: Times New Roman, Times, Serif">(c)</span></td><td style="font-style: italic">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-style: italic"><span style="font-family: Times New Roman, Times, Serif">(d)</span></td><td style="font-style: italic">&#160;</td>
    <td colspan="2" id="xdx_48A_eecd--TotalShareholderRtnAmt_pp2d_zcNlbKvZm00f" style="border-bottom: Black 1pt solid; font-style: italic"><span id="xdx_F50_zSSBzlw9pNv9" style="font-family: Times New Roman, Times, Serif">(e)</span></td><td style="font-style: italic">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_485_eus-gaap--NetIncomeLoss_zMCRN15epKe1" style="border-bottom: Black 1pt solid">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Value of Initial Fixed $100 Investment Based on:</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center; font-weight: bold">Year</td><td style="text-align: left; font-weight: bold">&#160;</td><td style="text-align: left; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Summary Compensation Table Total for PEO<br/>
($)</td><td style="text-align: left; font-weight: bold">&#160;</td><td style="text-align: left; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Compensation Actually Paid to PEO<br/>
($)</td><td style="text-align: left; font-weight: bold">&#160;</td><td style="text-align: left; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Average Summary Compensation Table Total for Non-PEO NEO&#8217;s<br/>
($)</td><td style="text-align: left; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Average Compensation Actually Paid to Non-PEO NEO&#8217;s<br/>
($)</td><td style="text-align: left; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Total Shareholder Return <br/>
($)</td><td style="text-align: left; font-weight: bold">&#160;</td><td style="text-align: left; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Net Income<br/>
 ($)</td><td style="text-align: left; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_414_20240101__20241231_zfb9bxFdPee4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; width: 9%; text-align: center">2024</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">881,422</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">881,422</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="text-align: right; width: 14%"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eecd--NonPeoNeoAvgTotalCompAmt_c20240101__20241231_fKGMp_zBlJIf9XSpFe" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0024">-</span></span></span>n/a</td><td style="width: 2%">&#160;</td>
    <td style="text-align: right; width: 12%"><span id="xdx_906_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20240101__20241231_fKGQp_zQ7SrlQOh5s7" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0025">-</span></span>n/a</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">137.14</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">(4,713,597</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_415_20230101__20231231_zWkOoQBUHpvk" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: bottom; text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">680,265</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">680,265</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eecd--NonPeoNeoAvgTotalCompAmt_c20230101__20231231_fKGMp_zMMPUIshnIJ9" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0030">-</span></span>n/a</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20230101__20231231_fKGQp_zrxU16swoBTi" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0031">-</span></span>n/a</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">150.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,929,104</td><td style="text-align: left">)</td></tr>
  </table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NamedExecutiveOfficersFnTextBlock', window );">Named Executive Officers, Footnote [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p id="xdx_896_eecd--NamedExecutiveOfficersFnTextBlock_dU_zil8ZrYNAs6h" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amounts reported in this column are the amounts of total compensation reported for <span id="xdx_907_eecd--PeoName_c20230101__20231231_zjT7BL49fKR8"><span id="xdx_906_eecd--PeoName_c20240101__20241231_zsfrw315eH67">Mr. Haverhals</span></span>, Chief Executive Officer, for each
    corresponding year in the &#8220;Total&#8221; column of the Summary Compensation Table (&#8220;SCT&#8217;) on page 12 of this proxy
    statement.</span></td></tr>

</table>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoTotalCompAmt', window );">Total Summary Compensation Paid Table (SCT) - column (a)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 881,422<span></span>
</td>
<td class="nump">$ 680,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoActuallyPaidCompAmt', window );">Compensation actually paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 881,422<span></span>
</td>
<td class="nump">680,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToPeoCompFnTextBlock', window );">Adjustment To PEO Compensation, Footnote [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p id="xdx_891_eecd--AdjToPeoCompFnTextBlock_dU_znX9qEJHLhTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Calculation of Compensation Actually Paid to PEO (column b)</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20241231_zoMRZbjr2hLi" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_zXTWDsneJER" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eecd--PeoTotalCompAmt_zQ91A81q8oVk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Total Summary Compensation Paid Table (SCT) - column (a)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">881,422</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">680,265</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eecd--AdjToCompAmt_hecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ValueReportedUnderStockAwardsInSCTMember_ziuhK0SIt8h4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: value reported under stock awards in the SCT</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0045">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0046">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eecd--AdjToCompAmt_hecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--FVOfUnvestedEquityAwardsAtYearEndMember_z9e9k8vSD4i1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Add: FV of unvested equity awards at year-end 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0048">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0049">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eecd--AdjToCompAmt_hecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--FVOfVestedAwardsAsOfVestingDateMember_zgFNlA89vAC5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Add: FV of vested awards as of the vesting date.</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0051">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0052">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eecd--AdjToCompAmt_hecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--FVOfVestedAwardsAsOfVestingDateMember_zt9JzYYPyTQ2" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Adjustment to Compensation Amount</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0054">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0055">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eecd--PeoActuallyPaidCompAmt_zfE4bxfcjOe3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Compensation actually paid</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">881,422</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">680,265</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgTotalCompAmt', window );">Non-PEO NEO Average Total Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt', window );">Non-PEO NEO Average Compensation Actually Paid Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TotalShareholderRtnAmt', window );">Total Shareholder Return Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">137.14<span></span>
</td>
<td class="nump">150.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (4,713,597)<span></span>
</td>
<td class="num">$ (6,929,104)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoName', window );">PEO Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Mr. Haverhals<span></span>
</td>
<td class="text">Mr. Haverhals<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Additional402vDisclosureTextBlock', window );">Additional 402(v) Disclosure [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p id="xdx_891_eecd--Additional402vDisclosureTextBlock_dU_zARRJIaWXtJ2" style="margin: 0; display: none">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amounts reported in this column represent the amount of compensation actually paid (&#8220;CAP&#8221;) Mr. Haverhals as computed
    in accordance with Item 402(v) of Regulation S-K, but do not reflect the actual amount of compensation earned by or paid to Mr. Haverhals
    during the applicable year. The determination of CAP begins with the total compensation reported in the SCT, which is then adjusted
    by equity-based and other compensation as set forth in the following table. For equity-based awards made during the year, the recorded
    grant date value is replaced with the estimated year-end value. For equity-based awards made in prior years that remain unvested
    at year-end, the estimated change in value from the beginning to the end of the year is included. For equity-based awards made in
    prior years, but vested during the year, the estimated change in value from the beginning of the year to the date of vesting is included:</span></td></tr>

</table>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ecd_PeoMember', window );">PEO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoTotalCompAmt', window );">Total Summary Compensation Paid Table (SCT) - column (a)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">$ 881,422<span></span>
</td>
<td class="nump">$ 680,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ecd_PeoMember', window );">PEO [Member] | Value reported under stock awards in the SCT [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ecd_PeoMember', window );">PEO [Member] | FV of Unvested Equity Awards at Year-end 2021 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ecd_PeoMember', window );">PEO [Member] | FV of Vested Awards as of Vesting Date [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The
    amounts reported in this column represent the amount of compensation actually paid (&#8220;CAP&#8221;) Mr. Haverhals as computed
    in accordance with Item 402(v) of Regulation S-K, but do not reflect the actual amount of compensation earned by or paid to Mr. Haverhals
    during the applicable year. The determination of CAP begins with the total compensation reported in the SCT, which is then adjusted
    by equity-based and other compensation as set forth in the following table. For equity-based awards made during the year, the recorded
    grant date value is replaced with the estimated year-end value. For equity-based awards made in prior years that remain unvested
    at year-end, the estimated change in value from the beginning to the end of the year is included. For equity-based awards made in
    prior years, but vested during the year, the estimated change in value from the beginning of the year to the date of vesting is included:</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The
    amounts reported in this column represent the average of the amounts reported for the Company&#8217;s Non-CEO named executive officer&#8217;s
    (&#8220;NEOs&#8221;) as a group in the &#8220;Total&#8221; column of the SCT in each applicable year. There were no NEO&#8217;s at
    the company during 2024 and 2023, respectively.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The
    amounts reported in this column represent the average amount of CAP to the Non-CEO NEOs as a group, as computed in accordance with
    Item 402(v) of Regulation S-K. Since there were no adjustments to be made for these NEO&#8217;s, the amounts actually paid are equal
    to the SCT amounts calculated in the previous column.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">This
    represents the year-end value of an initial $100 investment made at the beginning of the period.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">The
    amounts reported in this column are the amounts of total compensation reported for <span id="xdx_90E_eecd--PeoName_c20230101__20231231_zqRdsMtPhZr6"><span id="xdx_907_eecd--PeoName_c20240101__20241231_zmayI0bM3Y88">Mr. Haverhals</span></span>, Chief Executive Officer, for each
    corresponding year in the &#8220;Total&#8221; column of the Summary Compensation Table (&#8220;SCT&#8217;) on page 12 of this proxy
    statement.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Additional402vDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Additional402vDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToPeoCompFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToPeoCompFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NamedExecutiveOfficersFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NamedExecutiveOfficersFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgCompActuallyPaidAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoActuallyPaidCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoActuallyPaidCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TotalShareholderRtnAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iv<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TotalShareholderRtnAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=ecd_PeoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=ecd_PeoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=MLSS_ValueReportedUnderStockAwardsInSCTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=MLSS_ValueReportedUnderStockAwardsInSCTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=MLSS_FVOfUnvestedEquityAwardsAtYearEndMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=MLSS_FVOfUnvestedEquityAwardsAtYearEndMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=MLSS_FVOfVestedAwardsAsOfVestingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=MLSS_FVOfVestedAwardsAsOfVestingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recovery of Erroneously Awarded Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_RestatementDateAxis=2021-12-31', window );">Restatement Determination Date [Axis]: 2021-12-31</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ErrCompRecoveryTable', window );"><strong>Erroneously Awarded Compensation Recovery [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ErrCompAnalysisTextBlock', window );">Erroneous Compensation Analysis [Text Block]</a></td>
<td class="text">Our
Board has adopted a written policy to recover &#8220;excess&#8221; compensation that is granted, earned, or vested based wholly or in
part upon the attainment of a financial reporting measure. The compensation includes both cash-based and equity-based incentives. The
compensation covered includes incentive awards awarded to any individuals (including former employees) who served as an executive officer
during the three most recently completed fiscal years preceding the date on which the preparation of an accounting restatement is required,
provided that the executive officers were awarded more incentive awards than they would have received if the financial statements had
been prepared correctly. The recovery will include an executive incentive award even if the executive was not involved in preparing the
financial statements or did not commit misconduct that led to the restatement. Restatements attributable to an inadvertent error also
will subject executive officers to the recovery of previously received incentive awards.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_ErrCompAnalysisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br> -Paragraph 1<br> -Subparagraph i<br> -Sentence B<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 6<br> -Subsection F<br> -Paragraph 1<br> -Subparagraph i<br> -Sentence B<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Section 19<br> -Paragraph a<br> -Subparagraph 1<br> -Sentence ii<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-CSR<br> -Section 18<br> -Paragraph a<br> -Subparagraph 1<br> -Sentence ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_ErrCompAnalysisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_ErrCompRecoveryTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 6<br> -Subsection F<br> -Paragraph 1<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Section 19<br> -Paragraph a<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-CSR<br> -Section 18<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_ErrCompRecoveryTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_RestatementDateAxis=2021-12-31">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_RestatementDateAxis=2021-12-31</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Award Timing Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgDiscLineItems', window );"><strong>Award Timing Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiDiscTextBlock', window );">Award Timing MNPI Disclosure [Text Block]</a></td>
<td class="text">The
Compensation Committee approves all equity award grants to our named executive officers (NEO) on or before the grant date. The committee&#8217;s
general practice is to complete its annual executive compensation review and determine performance goals and target compensation for
our NEOs, and then equity awards are granted to NEOs and become effective. Annual equity awards are typically granted to our NEOs in
March. On occasion, the compensation committee may grant equity awards outside of our annual grant cycle for new hires, promotions, recognition,
retention or other purposes. While the compensation committee has discretionary authority to approve equity awards to our NEOs outside
of the cycle described above, the compensation committee follows a practice of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_906_eecd--AwardTmgMnpiCnsdrdFlag_dbF_c20240101__20241231_zqG8UZ8s5md8">not</span> granting equity awards when the company anticipates
releasing material nonpublic information and, in any event, we do <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90E_eecd--MnpiDiscTimedForCompValFlag_dbF_c20240101__20241231_zPjtMA4h4jaj">not</span> time the release of material non-public information in coordination
with grants of equity awards in a manner that intentionally benefits our NEOs.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiCnsdrdFlag', window );">Award Timing MNPI Considered [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MnpiDiscTimedForCompValFlag', window );">MNPI Disclosure Timed for Compensation Value [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgDiscLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgDiscLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiCnsdrdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiCnsdrdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiDiscTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiDiscTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MnpiDiscTimedForCompValFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MnpiDiscTimedForCompValFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>11</ContextCount>
  <ElementCount>21</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>5</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="formdef14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://milestonescientific.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="formdef14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="formdef14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995440 - Disclosure - Recovery of Erroneously Awarded Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/ErrCompDisclosure</Role>
      <ShortName>Recovery of Erroneously Awarded Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="formdef14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995443 - Disclosure - Award Timing Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure</Role>
      <ShortName>Award Timing Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="formdef14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="DEF 14A" isProxy="true" isUsgaap="true" original="formdef14a.htm">formdef14a.htm</File>
    <File>mlss-20241231.xsd</File>
    <File>mlss-20241231_def.xml</File>
    <File>mlss-20241231_lab.xml</File>
    <File>mlss-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>formdef14a_001.jpg</File>
    <File>formdef14a_002.jpg</File>
    <File>formdef14a_003.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="35">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "formdef14a.htm": {
   "nsprefix": "MLSS",
   "nsuri": "http://milestonescientific.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "formdef14a.htm"
     ]
    },
    "schema": {
     "local": [
      "mlss-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "mlss-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "mlss-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mlss-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 21,
   "keyCustom": 0,
   "axisStandard": 3,
   "axisCustom": 0,
   "memberStandard": 2,
   "memberCustom": 3,
   "hidden": {
    "total": 15,
    "http://xbrl.sec.gov/dei/2024": 3,
    "http://xbrl.sec.gov/ecd/2024": 12
   },
   "contextCount": 11,
   "entityCount": 1,
   "segmentCount": 5,
   "elementCount": 96,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ecd/2024": 35,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://fasb.org/us-gaap/2024": 2
   },
   "report": {
    "R1": {
     "role": "http://milestonescientific.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formdef14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formdef14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "2",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:PvpTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formdef14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:PvpTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formdef14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
     "longName": "995440 - Disclosure - Recovery of Erroneously Awarded Compensation",
     "shortName": "Recovery of Erroneously Awarded Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "3",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_2021-12-31",
      "name": "ecd:ErrCompAnalysisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formdef14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_2021-12-31",
      "name": "ecd:ErrCompAnalysisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formdef14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
     "longName": "995443 - Disclosure - Award Timing Disclosure",
     "shortName": "Award Timing Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formdef14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formdef14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formdef14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formdef14a.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r41",
      "r51",
      "r61",
      "r86"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r44",
      "r54",
      "r64",
      "r89"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r45",
      "r55",
      "r65",
      "r82",
      "r90",
      "r94",
      "r102"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "auth_ref": [
      "r100"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://milestonescientific.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://milestonescientific.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://milestonescientific.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://milestonescientific.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://milestonescientific.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://milestonescientific.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r41",
      "r51",
      "r61",
      "r86"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r38",
      "r48",
      "r58",
      "r83"
     ]
    },
    "MLSS_FVOfUnvestedEquityAwardsAtYearEndMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://milestonescientific.com/20241231",
     "localname": "FVOfUnvestedEquityAwardsAtYearEndMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FV of Unvested Equity Awards at Year-end 2021 [Member]",
        "documentation": "FV of Unvested Equity Awards at Year-end 2021 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "MLSS_FVOfVestedAwardsAsOfVestingDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://milestonescientific.com/20241231",
     "localname": "FVOfVestedAwardsAsOfVestingDateMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FV of Vested Awards as of Vesting Date [Member]",
        "documentation": "FV of Vested Awards as of Vesting Date [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r55",
      "r65",
      "r90"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r55",
      "r65",
      "r90"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r55",
      "r65",
      "r90"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r55",
      "r65",
      "r90"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r55",
      "r65",
      "r90"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r55",
      "r65",
      "r82",
      "r90",
      "r94",
      "r102"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r100"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r37",
      "r106"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r37",
      "r106"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r37",
      "r106"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r107"
     ]
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r43",
      "r53",
      "r63",
      "r88"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r46",
      "r56",
      "r66",
      "r91"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r46",
      "r56",
      "r66",
      "r91"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r69"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation actually paid"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Summary Compensation Paid Table (SCT) - column (a)"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r38",
      "r48",
      "r58",
      "r83"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r39",
      "r49",
      "r59",
      "r84"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r40",
      "r50",
      "r60",
      "r85"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r47",
      "r57",
      "r67",
      "r92"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r42",
      "r52",
      "r62",
      "r87"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "MLSS_ValueReportedUnderStockAwardsInSCTMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://milestonescientific.com/20241231",
     "localname": "ValueReportedUnderStockAwardsInSCTMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value reported under stock awards in the SCT [Member]",
        "documentation": "Value reported under stock awards in the SCT [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0001493152-25-021913-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-021913-xbrl.zip
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M\ BR3I(ZOC\Z=3SWAZ!<?RHH[]W$50:/?BH';K7^L[=P"A@;LX2QY7Z["*?
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M$DZ,' E'"E*2%. Y)TWZ8033PT9P'R'X$..]@161-,8>P2@<(/FMU/E_]2R
MUVBNJT__!3BTN-8O[DA6Y^-:8ST2NIX&8Y29/*$7))3JAU?O[>'?]NYI*[9/
M:[LU#(>4"1A*5:%;[X&N, 2R@"^ANH%,E<1*?+CKQ7!.]D@XD0W/X)W7NL%J
M@W6#URAR_OJXL;BN+^Y(UN;CNIZGG3Y?4PJ3;*? .T4<XX4<."/;%SW']T?H
M]10VV^9-M8T5NF!D.^ZW,(T"O-W 62-[&,;), P$?X!#B[!;'F/SX\[-A9I^
MCYK^-G0B%ZGNGM),[#X<<->[%2QQ=?R0L^#T^8-8=!Q>,S%=8UI:450Z0FN.
M:[LH@B$Q=D6"27*!DKIBT[K5=Z[EYU;D]?J4LA20&9W$,A3Y0OLZA*&>U"+P
M"R"']+;-SM3OO6DE"7-.LBI_9E.<.H'?7GGSEIP^ES>T%5NNB#N1U^94$#R*
M(06RZY@K+?/(HZG8HS E:QO5,41C&VI0=)ITIX8.LD5OB%=4#GF=/UT,C<=!
M;H TVXYY9]&]):^X$ROQ;4H*42 /%>0%<B(<'"8BCB+75U@5?HJE[S!\QH)7
M@!TYP57%;D?AE8BJKG!\$=&0S*QB#S8<A+\PZCF!]YU$SII]@<)FI\.2I!PU
MMY>@(_JIB_L2)U%*%AQ:33^\P5TTMLZ26V=R._D442R",5,GRR18VE<[/\Z"
MM#T#T*:+Q7(4G<L=IW*$D _$]V)XAOT?@] 5-?M]>".N$>'4S>%1!("AWB0S
ML.9?@!UQVAYXB?U/BO5*$:_<-%+L3TV;:O-$\4K>B';L)6*!'\\ ]%>XNQ:=
MFP<D88#-$YP@J=E?^H*("U 9$%.(<@U]S!W2]'4"'>[ @$Y/&/(,W/X0/1TQ
MBL.Q)W%%!%B D[V#2$ L24!PE$@,X4=T=;L+<>CY@3Y4:&!QH <FBX'DK*[K
M(88@!"*Q6]<.,)ZVYWM8,:8KT\YT=KYB:_?X?0$7@(2\GQ1G4;,N^H":8REM
M.#)_N NP58CL(!^2LW$?$((!$\ )K1R&UT<9>\=^L-=U7HYO_D3PMR.+O'Q*
M>AA7U.9I-?.W_\<@4EKO /_AX7F">[?O>)$!\\P&MDQ$G*<=.0/U!-BT6['P
MG0] 7\5HGN!7JI35:*HPNT6(W4PCL9NO[9,A">4[.)4L,?C:INY9\/6_*E![
M_-P+60@4+XUU;HP=57OYVL9JG3MV*P(9J//:QG1\WN_C$'>QF8N\5F_A-Q19
M!B0&!L9V".TWB^CP^;MILXPU/CPZ/3F[:!U?[%C[@,4CTPY5L6^D+@8,*41#
M"ZA9MT.XMW%!&\L+VA74Z-)(JF+B5G321!A6-128(Y&D$59=P<\&PP24?K;1
M6("J:.IR,T,7*&7PM0BNA1\.10V6PZ8$>($,0#PJF0108\0D2O17HF9(\02@
M#.+C;"PB<U!Y7*BTD[DB!N'/ M#=$,@,6=V->3P$Z#KL2'&>OPJ';/OZ(NR;
M,$4[VQ# Z%#91'J@YTDKO(=^'=BY2(\YP,(-N)<TQ*\<W7T'<UA=\('9\X'5
M!1]X"6C_TJOY3&H*<'B\^P390L]1V?KLY*^OW ?@"!8S?VN84RPZ""/KN?.R
MGBT?:Z*=< YKB,^EM$H. RV#Q5R5E>L M$7?\;N3C7CV\DW?Z_3M&[3P=[&^
M>$BN51# 9(X.O3-5U@_(@]:>\)T;-.P:L:\3YI#CWXB*'%U]DL;%3P <_=&=
M&405M"Y;6#<9Y$]<!&7AW)?E5 J>,4G^?;T7;"57V8@7_32*76>DKX%5G@6T
M[\1HJ[<3.%/R&&.!JF!$]5(]F(>CA<TH)7HHBV)2,4L5;<T?IK#7,:",Z\6=
M-(Z5LU[9Z+-6!C7ZP),^G0Q3<,F8+T.5L^)""I_TFBOG$:R5Y?089?2AB$ %
M&?,-Y;=LD4-3R*&97:(,2W#C@84LM,/W9;49'@'O/+"CS$EF/^!/J4/M;C]:
M%O529.$RNL+$)SJ8.=@]>5=5TL-;R=@_>T[>Q8AIE,C8GRR5<AXW3T:4*R90
MN2\7%'-2?>(!8XK$7"P98S<1T)QKMZ+N$DH)RN*%-JT[BOC/Q6H!:PE0TUM-
MPD$#!!+$;Q*^D#LB/AO+6\03WP.T_-"C1 I,V)QQON87C)1C:VP(X'B^(185
M0Q=8@N[HT 7\+$/HHA 9D%C6#M,D"S;<U,&&X9@D9<0NFI&19GQQ06BR#V4<
M)-E-?>\*HR'[*,%WPN%(R?3WW\#"8JWL1F*8AF1EL"E%6S6N#P33;II@5)"Q
M%EL2;]AWW%+4-");R!]A30 T2+"^<&)!8JW32>PTQE6N 1W<=WJ^L,[0VMRZ
M%D$*4K!VD=K''^SZ9GT#:*84X&]$FVQI=,T&2O6(M>:!%PZFART7OACV42WA
MJ;8W5ZOKJ^O5YF9C<Q&B].01V^TW%^_WK<\G%X?'[ZAI)ORX;Y_M__GI\&Q_
M;V$)>)XS.","8V$/=R)A?Z9AE X6N_\\0&-G)FN"]BQ)_%3!ZKFZ*WRD-AZI
MMCP4P^OS62O(4JP)+.5$E9K7@U;8GL#1]IM;E8WF5F6[L0K$-XE!ER*-* LD
M[W!>,BVR@@'I]C4ZI^S_U.KU!E63I&=U 1C.8[9(35+@HPVDTY</%G*=T8!E
MK@SI.<E5]CG#8,:AMD>VP)&T&4)Z5(&/I &Z(J^$*[DZG(+PKH5+<?-PBI,B
M(57X-,Y)20:Q:H51LUOV/W2=]$,2DLE.TSPNW% :$IR5Y>/!4R<_6%\5F"];
MY2A#B9?IQ7$J7!E!F1U$.'9\A L%0%2!'%CKD/H0(']NCW@K%KSP>>('/I-O
MW9*V@V=H#;K8^TPU9;2/J:(/9L>0J9+LGD.C/QG>%1U48<1*D$QN7,9<['LL
MBZAD&5$QK$0-4+,_!72[*0_HQHN%57R<GC,T#D4?[IU:=C:EEW;L96]%$S$A
MR[UH(E(H]P)$9P#<1L06=M<J6(<SS> U#&J,ZL@R&#,J@6%4P+ >6 %CRNH7
M\E-:AK$.G%[E_9?D_%M9SO]Y/N>_S-,QXP(  .KU"HQE%=%!SD,F_4BP4X#*
M5(V*^="4KH$9T<5,Z(&1&S:6"3V6^#P?E_M%Q6VN+4)S9A^:L_:O#,WY%>_/
M[)*?NI9*9LNE V?J%09DH@]W()P@SB6_XDLJ'!*9'^?%(;D<RY/%N@-4-3!>
MM IZ,G_EK K[S;Q'T.S*U#P=C-L;F]OS44OG@OL8<1:K4D,KDR.CM<&]L5%U
MO9Y'95V3*/25F-@-TX#B+(R 8S35HP@84>,\$6GKQZQ:)KW@(CZS0]@%BJ*X
M'(5IKY]S=%?L7HC8]2!'=YDC$ ?!H@^^(*LL:VM1&'@= X]K]E=T]:CL_?B*
M[5^R[@3%_R.TA5L1FC4YZ#JX BL@1]H10^-&F?>>ECN W<1IE%4,5<M&8V=]
MVQ[6!K6*CE'"'<Q']FU6" RR4G+\4P<N9C*[+F6+*_<ON7)9K8D[L+>"E52&
M7.6+[D^%K"WLGZ4J3X4![LR@T9DRW%=,E70!G9TB!F'.M-.ODL*?>1/13A2!
M5(G%,XCWR*297(V6-D[O4QO*1G6K7J^N;VY7&QNKV]J)*X%B>9,,1@H(@Y&E
ML:F_%_VQ-\*P$14$5TK/(6O/HI39"PD]D%H+%1<JE.,QO2B(FX!)<,A2/S$U
M&5V*PU1G..)4>Y8 ]QQ9B*A"98FR,D32[%<A0 AW),7/8R]9U[BJT5W#&)6(
MQE 073$>/8QVR7Q1FSP>6U)(RSDHI.6QC U3Q"\;]+1--0-?3O%@N&5IDYI]
MRF$* 4L!L-MF3:B'')N'7A:7PX?'MB?SQ.1\15:N6 OGZ0GI^&HG#KPUY=$
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M&I,&LIIX[1S*&6(@KH&>ZCO7Z!^P1;<+:[6DRQT@3?U$45%\[S5>*RS+3P*
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M".PR(&\T1HBAX5THX4N9L;5O4R?QRHXK-*:@:$4K;P_3L2-*V-=AD2 V"!A
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MQ;)6"U+.+'^4F[IR+15*^3#[7*@*)$R:3(K..2NPK@1V@@JV1*J>I,V[!E3
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M5FKHUV- ZJVLY'_58,'X*3X>R4!&&0Z;<3FK@&1L9YHH*+SF]+.2#5 1LSR
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M&>2S/LB]) 5JA Z?E9T98"R1M=&NJ>*ZXZ\GHR%'.IL#J8E1!#]RHDZ_9I_
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MY"AA)I\='"C0N=$V-BH;\']A-")Q<'XQ.2[N&E,Q"A"LDCXH2"@&1A''H:D
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M\#:*KPEP?0LZ'O[7E!/:</!UF:U)@3$$TS#/D*(MMB:W6-GVYN,Y)JF"656
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MD\)*D6H*C%L4%$YRWV>%0/7!!D;5![%0(N5L[UR#P7G@OR?X!5@=;SJ?9>3
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M8^:6SUU-**!;)LHRB9I^20%1>TR4 @(4::L5RUK"LH/M*)TQY$$)0_2=(&I
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METM/>B>\DE"3]4%:?"!>Z-5.<DB2JOE83BD8Q7"\_!%6&C-"]&0>@IJ'$>[
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M,KTRY-?C$.G]'>_.>1XF3V%^##N0=7=^N[KFB]K[R+\ R_B"9UP'E*ZB.#;
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M[5,T'QEA;2XL]5W-W1%J66]5:FBFF%#&T?QQ0C]&;D O-6,"NA=KNJ$K-5_
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M,H0%UX>T9+)\W@'O0STK^US>Q\AP]4X%=1!XABU3XVD$YG-2';Q!*-9^"\5
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M3%@ETBZ,WY*%Q M)]J!.K! O7C[#69UH:E._4_,4]9/_]AY:I VK9/[&P7$
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M2Y)5:G@"MY-Q@C&KCZ"*.QC,>JYX9[KNN^_%F#[\J1\(XI7DZSU)94.I*NK
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M=RW+Q]RE>#9_=T)$;$D@6I#0IC]_$;U_1-=9J&;6>80]EQFB3&K8HJ@E[Z^
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MTKE6<8</^>TBXL@N=];?@_A<=UT!7D38N[<OQ%+<RHMWW=IX=F1?$8Y.*DT
M)*NO  S>=F ^;\EA.JJN[NK*LJ['M4V\H"@Q=4V3G6/][VUUGXPT'EP29EG
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M2_+GUD!<)M\QLMA! L\.)_%UTA.O1R68Q=#P:CVZ\U)F>X'":6B-0;?U"UY
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M@HGW91FW/X'4U+:N<>1;_:7B'N)Z&$\CJ@7Y3N1TFDZ9/$;QOB7P/(EM%@Q
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M:1(]TJQBHC0,10WC]3"'_:$;57W;?H'Y21A00_%RK[L-?XXB T8DQT.>=LU
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M,>E*6S'^BH7V+1-!SZL\B<WR=W$@];.GLF@X+9CW9"!=;L(\+5_E4:@M "K
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M+NF0/E(Q1/NCE;;9Q;)!2:/-*\ B0$7BT[+;+ET1%+S%F'/LB)O+OW$T1$J
MUMF> C.R[R.648HI1I (VFKZJL%HU/[S]M/AV"M@0^;N_4N L]^Z;OJ3&LE9
MSA/B*T"DH>V,R>"%SE\0Z.7GZ<?'77X;NJOO]PI 4FQ/OT).?@5 ;[\"-HL3
MS\N[_% \U(=DIJLC:$D;\5MRO$>ZZ@9-\7"IL:".L5%WGSS?L([NTKWJS+_0
M2D ;ORT2^S=Z[EXMO/QO,$D)]HWY%J?EVZ6MESC?@K_AI"NH'Z6H2E9>NO&2
M^Z7 QA4I._(M['L9)E$ R<FE[G'I&LC6YNJWACQXUW9>KH&)\H?I11B\8P=I
M0#SAMSX+P5'O11H@<O?-0_ TSKMY&3_\Y/Z1+BT.JT[6.<K^>R]S0@AG(L,+
MI<,Q9]22)U_D5\I:C_%J4=!)^275.-_&#VH0K!N6$CRY.W?8.G[%5(F]9G*.
M!<K8^VVNIU5-YLX38! (L8]3_[[98J2$]D?K: !LP@*^,)N8EIS/)@!@IZ\H
M:%V;Y<_3\D7UG#$GJ:<_4-,&$]N"6!3 :LATP;9<QWQ;?R\%:<K4M?K YYO.
M>+-YH25%T9U5<"D- T*'\3(AOB[_'U^F+$6(\>E"P/$C1ZASG!(RR9=#E?_N
M!D=A3+)'O;K0(WTM,'++5P2J"U,:+02;2)!56M79DDCE^#5R@<$7S"Y;BC"%
M;-8N6 J_#S4V=Q"9&4Y^>3K;C[A4C7^FC9LQY*GCR["X\3KZE+6\@N>ZB<3E
M&ROM4?<1ZMXU2X1DR4 %X#VF71?9#0Z/E.J-!G4X#0@'7-%^=0-+500GSF^!
ME9RLW2J;.?/E<SP,Y*;*D!)+;4V"!U.B!C,(U4N_WC+:J,[@Q<JTF%%JBFQA
M3!/E->]VM (F7,OA]O%3KQJ35W27&,!_IJF4-*]Y4 /T8WV0=?=O6:BX!]Y_
MW,V3_EA/@I[?C8Y^Y]LG'=WU\'G '*F3TE:DT($?8H^M;+?(*GC-Z $WPM&&
M<5<G5Q>_4<IH9_BN9(HCV/T3XO8/07GWN/X[;MG94E=Y/]79X]+2O.F\'[,$
MGLWMF>_M==%E#POE'$ =$EBJOSQ!R1L1Z-@>33U@JU@#WIHVS2P,?1G\HGM9
MQV!25ZK<B*Y9WP]WB1OS' /VGS3<;K^:)IW(B-NJ+76]/[#J=B-F'6^6*=?=
MUU9(];8NU&/L;)X+H=+]6,9:_: ZJ^T7?JU(8,G76I.GJ;FT?S::OG<KJ;(C
M B^?C=MCZR>(<KSE[JI]TSFG'&S<%&P6I>.@?N1E?LWY-;Q[O,< T0*9]J>E
MP]L:]SR>:J'PQ1C_R& R1:8R4K^>IKC[5YJL4"OL69%L)5. (9'YH]B?[Z8R
MSQNG[<7@.W?9M!WZ'Z4X,IF)^<'S8&.W XW)&IH,I $CFR2//QA &_*+&V*G
M^EZZW/)0#F_:[/C%3IJM: )<<W*\VUOA5"ME$;RY1K2$@I6(XB:.>%>1@/GT
MIA1(>:F$R484^N=IA4RSW"51CXE[29?/O IHB$_PV]K32G""<\$N_ ME>?53
M66"YTE9O3#]/4.)NC93K^AJ:@=3VRMY-5=[Z?!PWRE;*Y4G?9>D@#73P2T2^
ME;W=;>T/=IV4;AUAYOL>I= .??PZTHYL;8D?GR%#\MF>ZW5$=Z4'?V5<=25Q
M9HN,6XZ3B^Q()]O)LAZ("LP\>GN4&FH:BL242Q U35?_!\^TD_3XW7^H3G]$
M7?#;&SRE#[HK?P5\O(E]!1@U,3_CB1!MBWN^ HB_O'EV7"]JG'_[H0I8^IO+
M5SS_"N@76GMI*+\HQH+ZF\M7]/[M@M742\/ ,]WS?_@UZO\["O; D\B$_?4*
MB6+=5";F$%JAK<-ZO:YD=+Q 6E>-ZR\E**55O[Y?KX#KD;8X^;_1 *Z^%]&;
MOVB_.,VB&^$+]+I70)GU4U'/OQ,9PSIA'GES8"QLMQR=VVZ+)*?IV /9TWR"
M=8O<M=7BCK=+5[JA=JN-QX4VN=[/91:_$R6JIL>2J_F0,2 \ZL]F_TUD-JEZ
M%CE?][-Q#;>0,1] 9&PHL'T+0OSK,1W3\B:!77MP\CD+]],(YJ?1>4$LDV*7
M=>?^_%4/;]EIIJW&QFI,>0I].:X;/,7/0-"S5=L3V2K)I;;!4?_3;!U.K_Q(
MTQ#1!]XQXA8+:+5SU*;F@]JZ;C%CV)$FNKK?(K RAY&7^S*.FWI\BS(Q+^.?
M54H^J\ ;:K4@$$:>2:]CA#,),&:M4/P0C+\&<T1UQ-RK/F:7VVMKG+5&D,OJ
M]\C$S4K=+\4# =>0P@QD]\;4FJ EBNU;76ERD3"=V&5(Q@"0&B15JCYU7>5G
MY.W^G.IM$S\I'5Z'@)&'^"3+/IX&YSA9LK*OSMT[O[ST [4X]#M8<E(H-#TS
MIWJ2P:8DMZK.G[)Y>'B_/B7^<471"U!HOXFK#Z3<KK[A)_/,NSP/"TPAK 2C
MZYXIXEX7M&TP3\P/DJ7)/-5_6FL(3O>@!M  =^R-1FC.? ,+\5$%;$$? J22
MGL@Q-5U/8Q7\$/:8!:IJ4_&2-'%6MI>7%CE[H6QV(]&\QJ'3W\\7+;-+>!7"
M_""&6-W]_#/Z)?HWU$"?PM7.N=!/*@S*^9BG<[M.3L:*L:]7Q_<3U,%7EA%X
M#$$X"+B))*E!R&M3T;Y7"]]H,T>5AO+[J(8JO)(7PK3ZI/ $\ $+_XF$6.B\
M[-QYJYO-->6JD(-W'9V? _SM)!U\\RK?\ _<6?DS\H/["[#4?D($E^0LR$/C
M)?B9_Q4 -1M])]I,_PH0>TE]!?@?ZEPIP<$_D:YBOP(R_11> >VNV2_O[)%>
M >-M^7[K?+//6% !KP $[F"_/8.IMC,BBU? =X+.MBOF_;4[M)HV"8"A7R?J
MAL'#AZO3)WAMX?\S&,-ZTQ/(<TTP,I1"ZNH^'X=S+A;'Q@9<<QK_[XF'T62@
M??ERGG!C$(X6Q]@L"?M]>/('VA,LA7_]X50A$!O+[UT)U?3FU.3*]\G%FG;S
M)!;_J#5:_A8-/$+GI(.DR84M2^)5*G>]DAXH"J_W^\JHS(JX/<'ER-6^VQ[$
MJ7Q_F4;^/Z(6=N^M1LQNZCQR9: )66D O"87PJ0FT5XA79OJ005CN5U8^</3
M*I)AT B#F CP=PU?^C<;7:9LR&E4!A=D46@U?]D2!X'XTD?C7!XI,(*KZY1Q
MR5AQ"40/03PC -6SFQ;K37EB0=GA:,J%7T9=*(6DZR!TV>F"C4!ZC^]*GV(D
M6S"P:$C\"_^SF=[_=>6_=-[^6Z$-L8@+3WR'X2]JU.NE!-S+@2$.Y?A!X11H
MXNJ AO@E!1_@BJ4"C>8@V@?GCQ-.6_[Q4_"6JP21%@B0 :\LC4#ZS@E=C!;G
MDYN9ACJ=0SLAY% $[?^W)]E:&[9-9N+U=KA&_=?Y572150!!F0S8K!@M/7%:
ME/R?HOT<]/3FUL"@H*#Q<>@)>2V,(1A7XWP4J%'T%NA/9BAEN3J9\$'_!J.D
MDYC()KI(" 4D"4=Z^6=9B>BB@W/0_MN=OR=[P70<865KKC(=PK*^DHYI%H"L
MF$1E.7Y8Y>G8 .FR,BA)%(1^TMWPM_[^3VP _=>B"S6Y4MG5R8/910.6 :?'
M]Z9F_CQCPU(KQ+LME'F%EC[;SZD+WP,&,7/LD)8T+T\D %3EAHMET9Z&=5^T
M.;OE<=. H='D>%\.):/S:^.RM?:/73FG=,0J\'9Y/5E8&Z(+\^1*%D6+_,P'
MS60$VMB'+>8_P>>] IK2;7;*I3[*X0\0%&>CA'SY*37K3Z0[FKOQ.!11*K:Y
MP#%Y^7OXJ\?\5F!S Y'L\;WC%%5U:!B#T)Q@%5XVF%:=H9DA<P$$-RE)D ;)
MI;L+E?.^MP'O:WN82>NIO@^U^=FPGP),EP4D=2YJFC9YBA7$ZW5@;:$!J,\%
MYHC@@SB7M";E]"1'8?!CFCQ,-)#ZG?MP=U.<8Z[+!AEU%-/=X[R!MK\Z_3R$
M[@[:M&U7RZW-?&!S7JR:!S5Y?D1:P=\FXQKT^O-Z---O(I1Q]$9KA/#8YL3L
MR$\VV*Z[,*PVU?,"B%F5M#R8M0)US+P?5:LP=*4$FQ595W;0,B-,4RYD=L?#
M]Z>Z'PAV[8JM'#&2GPT?_4WK)N/M,??B)YI&BG0D"_&E>W* ;[K<Y86' RID
M%6=Z=J5U=)955RC%9@C/CDAIZY@49\MY0)B;R%I6C_C%#XXISOD&N6F-TL19
MP&:<%\9)=* OS^HJZ20!J6G(&\NBB@$V9?V#(2[ >PM#FP-*?X8ZTB;.4',&
MBS0, \3[)$@/3N]<[&\"Z>!Q%#O5#3@R=/+"U"&@.6R]XW:25)!PJU:"AW\S
M)ND_@L30BDW[Z[@QZX7<CL%0->+P![S4PB%T/-^(-BWB9]E+12F4M8=0 E9M
M1\? !&ZGCJ<7D<8MT!6GS?)Y^VO6W' .C-J<,?%PAG*IV9; G=T@4.H>$.^)
MOA"F'D/1CMA:&<B:]NVI]*+,W8%KW8[DK7_%U>'2-AOAE@(#&-!5#RDJ78Y$
M';\D%UAYH^YZ<0U? <I:;JNTDW9V)@'FIIYF'B:7Y&9H0X%B8-[U+:_+?1$"
M#G7#<[2?G9B<N,+?B++O6\\46Z+S4"FCPZY2)3=Q&9DQI=*8^0BA87Z $76O
M>WFO-OTY:4JL3]_O-]I>U2886(IC&6M1/O+_CI,!4K;W^>UJ&,W8F%OB\/\>
M[9'\.@I'B-E\M84$:) PERO?9V$X9LJTBX!2IF<_RVT]46Q!+K.\X)$VOTP>
MU<3]E%O+CA(UO\>Z?"Z"SZ'N,<<QW(U_0<G^>5R2<+TYW$'5O)R3T)=\(I=\
M:+ITB>$ P9<M(Y[$'^ZM/46S?,%Y^19UZMP8RSH59*91E6AHJ%H9T-EI[)S-
M,7!T>K(G1%4J7_1F>1:6-U1-8^>5X,G@@\O7O24OKJJE&7:_YS9+(+A30R'N
M!0D*>I;Z6$LEJ)VMW3A5RS&1WV\-(*D&Q8">'!6BNQ==TK\"CY'F,&38BML'
M!PN[<&#,_/";/ LZ3/):G@(U@K&$/D8VO?/!<O(:A\=S7'\%8(39;U;-V)"#
M+$HG5[E (G]^MZ]T_H$$19J4\Y;E2U>V5C>V6>=68BA^',"K4T=1&,=M]: .
MF,ROFCFRSPK>3%7+'9W/O:?H/T B%ET_#V\<QD F7$=)48+'L]W0,UZ]&F3B
MV(,\6J8@>ZQRT1\<H9^2%-S7=SRH:KR\GRTO+<F^Y.B7;P:_^Y.H3*YN\^2/
M,8I(>'6L<]-*-VF7)6694\M,UUWHBOQI>.36 1<-W42#Z;J4K7>AC*G\."O8
M,<$2#I[GY9L2/ GZ=P$9P@ 2U6KPLHY@O<IE:(=#^\G*/(IY>8M;DLU[[?WX
MV5NT<@[E(G9:"E8@WL#N9=&E1ZA4G7=P@G*=9&VD' N3D(0@XK,P'QA5?W17
M4D^;%K'*8CAS\*?;,]\X[ $]55]WH][#DJ<[''?#VK84&^Y"[:X[_!2V,41K
MBE$?.^UE!=\<$9<-_7=:T'D&\K2Z3TA#OE5"77R\!KU K2G#HVAG;-H;LD>7
M'?^'$44I]9.+5:L*QPUNH*5K^("DY8"N)-S,%W2H6E+-GZRGLKD?O\SP$-#0
M+6#TK3)1P*D;PCFA+$)X4Y6Q;$5,.N6**Y&HH^I*948YG1:,0(CQXJQZ7(WJ
M2U%W68/LF8<3*R[8#=J1'W;*=?0'M!^GM<[,3H@0/B51+J^B\8E70Z]GZ"9X
M8OC:G!DP./"9"VQ6;I[5EA-]K_VH Q-\;!C*6EW0DRV04H@+\WZ*\(5S\8TQ
MY6ZP@#*?51:CU0S^"0T.R@\_EX&H[HV&/<=([YVF')B/(;RD3I86_['/N/Y5
M,IM? =&TKX##9#^ZI+__ -A&/P4=O]%)KP"Z"K6COT45 9G"3R&EPH<IZ9/E
M,_\JJ.A/JV_Y<W5%1Y%\N-2N)[#W4?P\DN6$_]FJ-G;C41";+'P@]YT8Y3R8
MUTF@#\W79)2-![M4 F!RX$M0,Y.7)I<<T1(K9N2AKBOU<K-LXDZ=U&"2+Y'?
M@Z4DD*:J5$*/1VZ!O 9P%1S1S?)G.?G&;.],.94JKA*Y+%V)0=0!S9;/H\ #
MLYZNBV1RIS!SDI-B<" ]QC>JQL224<@ P'UL,'8\?0/=\.RVZWH?9TW!7(VV
M"7GWZEKN!3\C#>W@D?BA)JNO&='65!M 6KN-2C'57VFVZ4"X?N].I*RFLOQY
MSL^6/N'\L#&?3B27DJ ZK@-TP9P<IGLEO[Q#)1\&*0HK,<1((8Q,D<2QUYWO
MQD[/J4D G+,[9HVYHA_%O] L^7YQ_LE5-@$21'4A-80".Q[*_;^Q@"COC6(Y
MB/>.HENQ>]7PIX1M* 6'#!"40+KV0I8__>(B8V%*,<ZE&1LA*!%@<E5B\41B
M\CY!KNGLF%]AF+IWAU*1A^0(?;81GP:8.O6-P"BWM+++LZ ^8*@\U672C@+L
M_G[@4)WQ&R=LZ4Q-W](UHOZRT;>%6S@2;M0^88\7\<G:@@R4H6,<^L>$)+GB
M^MON"JQPO>(N.WCB!B(?>KK;3J2;#^^65H;8Y6'<'IESV"2Q%97@6.;?X)PK
MEA(\I=^Z!3&CZ-7C4+%W<GO03FJD,BP$(17+EH&%AW>G#!U!FW)E9M@KI "L
MN\S8_;O)&,CD !#\D!;X5W/A7S#DOE#=MDT;W.XXX$-(63O:(?E$0C7I'P*R
MDFA> =6<R+-@O#R/YHAX"22(!8IP6## >:K&=5H)%I5:NFZB5'MU8<?TZ\KC
MW+(4P%=7[>%-GI,IK!EL"2*+H1&NL0YH@# >"MV<S6FV0V/V,'\8*EMO#)_E
M,'D%9J-VDHE.P(O>(QR.E3!L8H^$4*#0.MFFMQF[646?*JV)L%4:<!9<QOC=
M-;HQ9!I;#V9O2JNILK?>TBIM2+(4@?$$U^[R7G,*8D$-+'\3GBK+"*&]9C1K
M3H0)>P78&7;AMD,*</OA\H7@)L!R/TKCO>620U>GEEK[B)R@^@ G'<2=C7\=
M&+2'L]R1<FEHC81@?$^'QKF7,86$\$O*6RSNG2U:I"\HCSE,V)A>ZEU2#\L(
M0-8FJRTRT%2$ 98_Y8TX-+3#O#&U*;@_DQMK5JP&;9-N@5)YBLZ^"?Q)ZYVW
M@NGSQ#IFE\GG%RN-[Q=C!_L#H%,"PH_V,E"BJ+MF%SF'JT2=/:D3\;O)D_2&
M\&DIU21Y@%0U>__.EY#^(R7D\D4@_Q509OM49/4O= %4[=_B5!H5KX"?/FW/
MS@;;ZC30_RI0I4K]=FDF_]DY]D'M 2 VB #CKRBBJ*W=-7/E'?'L+M4<Q3",
MX\0^.!FT V+A(C3T?ICM)G8,]ATGQX3L8( UA!8RX..5.N0 ?1EC5/$-QW(2
MS<WG7Q,*<MQ(S&I06U84%]E$ ?0F4)[[O7Y(B_XK!"8WP=\5X]LCP2T*O.2"
MK$F 1"U-,VGR^<FY),6-,4RM(>S&Y[CXDXTWH"W*KM,#C+FTIYUVR,'D)=WR
M6JR:>%(4P,_6TA^Q9)<V!LD5YBS?.;@?&PYFVXDL\HYQ0.UQN)2)>+CK<X->
M 4OHQ+:=R'&I2?+M:$C8%^?UY@X$80_G&.,"*HW;<6LW<:DC16*=F_PAL<Y5
MYG30&US0(G@J\_!)@*,.%"B8=][AV@-GVU$[J9D=)CY$*?9(]U:U9K6P1*P_
M$<H</+YHUU5:Z_ >0_Z?]MXZ**[H2Q=MM"'!71K7X.X0)%B0!D*P!@(T[NX$
M)T"@\<8;$IS@[H'@[@1W"9!&@Y/D)C,UKWZOIN;5NW=F[MQ;-7_LJOW/WOOL
M<];>:WWKK/4MQ3:_Q.SC,!7F- M-%8[@B,"23H"/D!Y^K.<:]-648G&2AQ/N
MDA<W=T\B#E[+Q9#XA.1VZT/"$]_B%^W)-$985<Z,[$LMN8F@:GI+ITW" ?PQ
M6[2N? )_T%=\AZUJXH%$H?L<3-]- G*UF*8='(I(Z<GAX6%J_X.JP4@A2"6U
M"F+B3!8G99B=0(,Y \]C]/F8IL=P/NYCW([4S%=T!.Z\1>R,F-$,;^W+"P7V
MCA8;QQ#,;7>W0<[<KOGJK5PZTUEA;AT3B%;8T?J^QAF7$ZM^2FY/#& S]&+3
M;29$0NO(H-2\Q8MR']YR_!G'7L!T8QR=RLQOF/&;*K,^41D3^_<">K<0W6L:
M ?OB@D+?C^L3AF^T$;:,M5CPZ^1:[PP<FY,3)F:/%EI!F)LLS1YIW[)O0!_V
M-:7BKCT33@_5D<=N^".]Z/VD^QU3\\N(6Y^! ,]FB?["6<@JI;/ZA8H/[VBD
M1B@F'S5#N!<)RKH-B3[Y'SM^HM+.0;@SV:#N_5YK9!4O#S4]OTL&*/0P=/!M
MOL[:K8MI6WN'=4>,>4N2&GI'KAJ[^  0._3BL=,?88M6-S0A.%GTC!XG)=3X
MP=;GS:*^A4BD5WNV'-H:-AUZB/SCAB]*RBQ0ZFH_U[SP2/N6]X%3"[&^_[@R
M3#Q\2;&8LW-J%=V#EH-@1_,R-/'AQ*3-WX=WG.!C^*9H_AI]IS'W?;NQ,7T\
M6<#$Q\:.'OU)IP^>/KJ[DFK9]EEZ--7,FZ:UY37-K'?+E>E('ZSR"%"4F3N8
M*:%]4$Z6!DGZ177K#:')<,73XT^49JT(R?<J!2VM">;Z;#@]=0)8=#SB-,\L
MSR9C\UYU9#]H?OWNL<)EY\R6^S*I>6\-01Y%'8)[Z:X!\!%'MV&B;>#DC/OT
M]^%JA-;P3F9[-I:(I @G".?5U<="R)AQ<HA[>H1CZ"*];GD;RASI5&>=N/>X
MW6QL9\I!S2S\H<EB#*&T&<>R-&L,]*BJ +S&OI+(JSOSQCSMS["+Z_7O(Z$G
MNRH+ A)H5&7,_@1R_51YD8TFK]3GN7C,9IF;V]I5%P2]Q/!:[^:'#G(\03AY
M?W970_]#O*A*]C9 __W#RZ?\4!<[-Q*U)T5]([UF3QN2;L@IZ7B?QPAK2_%O
MJWJQ/KS>2[]VA+/.;ZN]CTIA\96, 3QN](<LGLK2S)/VKMPZ]$T=&3$/!]O@
M%F6E(M9L$!J];"?U=-GTOP$48LC8E7/,]+(C43*PN7L2,[CUYN4WW5WS$%.*
MT*3&+E-;-%<^YA E96T5&L/8*(QW6O@O#P+YMSY_5ULS/8$XZ"+N-X>LH@R9
M?4R]HWAG*;^)E>NODW]NG6L4WPS7:%(;?"_0PYRDP?B,I;DM1([^6KH4K?9C
M2]/930RM/#+ >6SA"]'VB15R!(E&(?;P&Q!H4VT/VU$\%^YL4&RDE!EVL:,/
M"%#-W/63L<@G,QE/2'7OSGEK1M-/^L5NG>[\J9'=3.-,'^GC!H=:V8U<;LEG
M'O!XVEM,WVNGC7>!=M+1N@M.5-],_;HGF;/)^$<B+[X0!"DX@[2  0A!13>/
M6ZB>@9=!)7RXZZO 1+SP7L]=L[.XJ2S@('+S/ G<<?8;$%UURK/_8(G53%B>
MF/Z*UXM%%L3#MV@^_.?>7)PVN)>2:,R/FD#2.]A^-#_ SES-';1X[&7#CJL5
M9\W\M&CO<4PFZOW46H?4*W&2*[1FE:;\,X^_N]\.S3C :=KXQ5N*<QQO+;GK
M(<LE@9&>ZA+TIHW,YJN'U8B'1KR2K6J*#<-U9O_OSSA7WT6:*E_T!8N.>'/P
M,7$^*HOMAT@N<X;G];[EA0>91)68U:Y#"EVW#7N5=NCX>P;%Q)?)*PVI@#%Z
MZ. & Z%!C0>NKS*!/<NR8E:_ODWX@7(N<YX OG^KPK%M6ZMJ+I2]T. N'U,3
M\A%,(E%@<^!_+LX&:I9^1]JY34.UH],ZZUR)KL&=TS\RZL;U4C>.KG7NQV:<
M%N89?5QXDJ+?WF!XX,LLB)%=5EI1E3414E!3-Z?)+>P)?GLDR-6=LWS!<^6G
MFF+4C/B\]09E;L0DV1Z=+R8XPSI$Q$X FXF)J=(MG8K\/5LLI_4<,FLQGRA!
MYH7C8^N3D=;NE40/A.8?G!+(L"WI<"K,6\G$R$"U6MDWSK;&Q%7R[B[AG!:H
MK@7,US;F2=N:I#!:L6NZ,9JC9LA=WET9N4O"1D?9YTQ)R"ZC">8^);;+@I>X
M.&=Y?7DQM)<=.$DG=@=Y-DQ_V7 6,(6YOM7NK.2_#6^M).YU*O'-UEM@:VZ\
MK.;[Y)JB<D%"<6<@.E+ )&8J7EYON\XAP_*YJWF."UJ71CX4+=1^4:2"GU,*
MQ,'6PJ,*D=B6I61#A;?$!/)6:KZ==KW6)T]>ENY <H_U +F;L3 7MJ)4C7?=
MP$UG$^WVGK?P:R:,PCP&40^RUT-LX@^[<574]'@Y4T [13=76QDV V[F]J[&
MSHZHR\FQRZX^=0+42,7A@]O0PZSWNF<W<;R5C>S;"Y6IXYYURQ6P!QW^=G9O
M#/-Y,(Z_QZ 6W@&3V*101(B )K#3/<OF7:-#,$GQIP#ICA%Z_@:$9]P!1P<&
MDWU(=PZL=?_C.3#J:AQBC+#E06)F<B<UBUQ*95J+]W3?R0X#Q2;1$'-_1-U8
MPM>GG\\^RW+JC<%[-277:57IWO8/$R@6KGV6H!HVIDKY7Q3GV<4YR.J^2SE7
M4S=FV.L4)FIOCLOX7AP*#UF:*QI.Q-E"6H5=LW]%5M&N8+^'JV6SP;H2>\>9
MC\_AC:OT)]%79UVUI<&.2K,KP[A'R!?)1ZX@9R .><27O;>:K7\$GEX!)^R/
ML=RHIER3\'(:R<48QL[4' ,U^,#\T<P3_4)YH6KJ/_1WY%_?*T7UMHI%ULYX
M;2?$(.9UJT%OQ1@6AK9N.MOS[Y?AL9&/#A\&&12D[A;I&!=T^./7O'="Y&0R
MR_;/JA*DOA)+-V2?X%FNN#'&W8=0/PD:X& [,PTY*E]@CCQ\N),&_+KYF%"]
M;8MR?ENODOI"S_"S?T6OR QNRR3NQ6/AYB:(>$4X6&,.Z>7PIF%9L"$@]O&\
M#O23 FTJ3%H.L_XW8 M_JJ.7;7&1N)T>S$K-!&3RQAY4_X&,TXO**UHZU.[P
M=J.8'^+"B5MBD$_H )L!MV0I:GPWP%G*<C:E5LY=HP\M4COMZ+O1HZ04--TR
M\V_!1(=)PE\R6;E1GC9RK\6]$^LSPU\W._,^ ,::GR'B++($G7A8$U\BKS-]
M3B@'J+UE=\_PQ#]TL'W\O"QH_QMPB$Z)U9(("L]+W[_S.]CK!VC852^9'N%:
MD6?NAU"^58^2_]#L=J,\GI -"N/@_ T@["DYUKN'+KU1F2E08^ESI6-$!SQ.
M' #P)*V+FL[VTVP"TZ>,D&V**P>4H%IJ[Y"^O PS3_$#1,?L20.WQ,5O '*V
MEZ'E(DX2;J-=<T6!CO<K%<7 MUDA\<74FZ(^=R*I42\!QIV'L?S((XD=81O5
MA>]>I7L!K*G1&9PQYKY#S):NW;1INK[*+P@@O=>J4NVN+^R=K:2(<^BR]RF_
MX;DM5]DM\^052<5;H<07#5S\ 6\PH$X0.VK#_4V2D\>S61<J%1Z-EE!OEY20
ME?3]@;42J<2@<HBTO>3HI2-\MMQI-:7&!*8DRMXSH:3D#O@Q_N(7V?0>I#_
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M?+X>GLJUAJ"J3X>0^XWBD7\]E"6:5O>#QJ,-,Y;GX(ZYBA^^K&,2Q/!BP:-
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MGJ;H5\%XE.<>]S?Z7,VL[&=^WU:D*2APWA,L[7CG%/D4[WEM\F+->Y78I#L
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M[4CT9I^ZUDHR4PY5-&]Y--K.,W,\;Y+FQA'+T9\!: T2*$2B7L(T<KN;.CW
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M12^;9;F=5:IE2=5!M%A^2CD)U&A"9O2D+[%Q.4VTCL2X$_WQ15TI_>F%6B0
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MRK+UW9;3IJXLR"!5@(J77AS6JMT4>N>(NSSA86SQ8<S-F7HNA24KJ.'CA7O
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M@@NSR*NC*D\HR+3TV\G-5V$5IL?]^KFT:6/^'!('O'.M9/6.M-%#V[9%1=]
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MIELB&7D4 KL#SUO#^I5_MLNZBKDI 12])$CNX(63IASO_+$=:Z65?GW3EQA
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MMLWTFMQC&Z6SAE C8Z&2FE."_G$Z1NQH,,7AA W,^PZB/M;21C:;9L61/*Q
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MS7:H%-U#U^JY(DK+,;0.U?-B7/7*4DM]:M5D/(,O%F7J?LA9WR;,;D.'^O*
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MH!'7*+JSQSSO*^VS9S3)D,V7^0=(W_D/4$L#!!0    ( /N ;%L1$E0RF1$
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M>Y'9G;Y]^_9$W"VA'>1VCI/R&3^?E'0JS^QNK,'7F)#XC AZUR@,J*CUWL<
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MEA4OPW@A  VQMA!R*-ACQ<*=$T6<,SWB()FP;O;VWW"G+%<'9U<3"II-4;1
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MT3'KS!YS+)C%*_'EYBKIE(#/W!((4]O+K"7_FW0=<TK:-0HUUK9:E'3;BND
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MIZ;[^AJ0 NA'C<@Y&20.F[SM^J5K]A.[7%YB_YD'!+(K_P=02P,$%     @
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MGGXU+3SE#7A^$GJR%10*08 UJ*(G%:9TBU$*13=5Y,R0L&B$,0.S4 /<6MZ
MEKV:LR44CB-:O5V?"<],,Q1-&ZA#;DH_)&<:;!J%P.P7^=_$9TA\\S]02P$"
M% ,4    " #[@&Q;)!//W=RM  #O[00 #@              @ $     9F]R
M;61E9C$T82YH=&U02P$"% ,4    " #[@&Q;[E3]Q!:U  #!S0  $@
M        @ $(K@  9F]R;61E9C$T85\P,#$N:G!G4$L! A0#%     @ ^X!L
M6P%QZZF.'0  K"0  !(              ( !3F,! &9O<FUD968Q-&%?,# R
M+FIP9U!+ 0(4 Q0    ( /N ;%N"6O9#>8P  +FQ   2              "
M 0R! 0!F;W)M9&5F,31A7S P,RYJ<&=02P$"% ,4    " #[@&Q;_C2TW_P#
M  !F$   $0              @ &U#0( ;6QS<RTR,#(T,3(S,2YX<V102P$"
M% ,4    " #[@&Q;J@@$)3@$  !]'   %0              @ '@$0( ;6QS
M<RTR,#(T,3(S,5]D968N>&UL4$L! A0#%     @ ^X!L6Q$25#*9$0  M-L
M !4              ( !2Q8" &UL<W,M,C R-#$R,S%?;&%B+GAM;%!+ 0(4
M Q0    ( /N ;%N]LGP#3@P  #:;   5              "  1<H @!M;'-S
G+3(P,C0Q,C,Q7W!R92YX;6Q02P4&      @ "  $ @  F#0"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>formdef14a_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:MLSS="http://milestonescientific.com/20241231"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mlss-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:typedMember dimension="ecd:RestatementDateAxis">
                    <ecd:RestatementDateAxis.domain>2021-12-31</ecd:RestatementDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_ecd_PeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_ecd_PeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_ecd_PeoMember_custom_ValueReportedUnderStockAwardsInSCTMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">MLSS:ValueReportedUnderStockAwardsInSCTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_ecd_PeoMember_custom_ValueReportedUnderStockAwardsInSCTMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">MLSS:ValueReportedUnderStockAwardsInSCTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_ecd_PeoMember_custom_FVOfUnvestedEquityAwardsAtYearEndMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">MLSS:FVOfUnvestedEquityAwardsAtYearEndMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_ecd_PeoMember_custom_FVOfUnvestedEquityAwardsAtYearEndMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">MLSS:FVOfUnvestedEquityAwardsAtYearEndMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_ecd_PeoMember_custom_FVOfVestedAwardsAsOfVestingDateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">MLSS:FVOfVestedAwardsAsOfVestingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_ecd_PeoMember_custom_FVOfVestedAwardsAsOfVestingDateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">MLSS:FVOfVestedAwardsAsOfVestingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Ratio">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-12-31" id="Fact000004">0000855683</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0011">DEF 14A</dei:DocumentType>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0024"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0025"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0030"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0031"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_ecd_PeoMember_custom_ValueReportedUnderStockAwardsInSCTMember"
      id="xdx2ixbrl0045"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_ecd_PeoMember_custom_ValueReportedUnderStockAwardsInSCTMember"
      id="xdx2ixbrl0046"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_ecd_PeoMember_custom_FVOfUnvestedEquityAwardsAtYearEndMember"
      id="xdx2ixbrl0048"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_ecd_PeoMember_custom_FVOfUnvestedEquityAwardsAtYearEndMember"
      id="xdx2ixbrl0049"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_ecd_PeoMember_custom_FVOfVestedAwardsAsOfVestingDateMember"
      id="xdx2ixbrl0051"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_ecd_PeoMember_custom_FVOfVestedAwardsAsOfVestingDateMember"
      id="xdx2ixbrl0052"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_ecd_PeoMember_custom_FVOfVestedAwardsAsOfVestingDateMember"
      id="xdx2ixbrl0054"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_ecd_PeoMember_custom_FVOfVestedAwardsAsOfVestingDateMember"
      id="xdx2ixbrl0055"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-12-31" id="Fact000012">Milestone Scientific Inc.</dei:EntityRegistrantName>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000013">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <ecd:ErrCompAnalysisTextBlock
      contextRef="From2024-01-012024-12-31_2021-12-31"
      id="Fact000014">Our
Board has adopted a written policy to recover &#x201c;excess&#x201d; compensation that is granted, earned, or vested based wholly or in
part upon the attainment of a financial reporting measure. The compensation includes both cash-based and equity-based incentives. The
compensation covered includes incentive awards awarded to any individuals (including former employees) who served as an executive officer
during the three most recently completed fiscal years preceding the date on which the preparation of an accounting restatement is required,
provided that the executive officers were awarded more incentive awards than they would have received if the financial statements had
been prepared correctly. The recovery will include an executive incentive award even if the executive was not involved in preparing the
financial statements or did not commit misconduct that led to the restatement. Restatements attributable to an inadvertent error also
will subject executive officers to the recovery of previously received incentive awards.</ecd:ErrCompAnalysisTextBlock>
    <ecd:AwardTmgMnpiDiscTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000015">The
Compensation Committee approves all equity award grants to our named executive officers (NEO) on or before the grant date. The committee&#x2019;s
general practice is to complete its annual executive compensation review and determine performance goals and target compensation for
our NEOs, and then equity awards are granted to NEOs and become effective. Annual equity awards are typically granted to our NEOs in
March. On occasion, the compensation committee may grant equity awards outside of our annual grant cycle for new hires, promotions, recognition,
retention or other purposes. While the compensation committee has discretionary authority to approve equity awards to our NEOs outside
of the cycle described above, the compensation committee follows a practice of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_906_eecd--AwardTmgMnpiCnsdrdFlag_dbF_c20240101__20241231_zqG8UZ8s5md8"&gt;not&lt;/span&gt; granting equity awards when the company anticipates
releasing material nonpublic information and, in any event, we do &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90E_eecd--MnpiDiscTimedForCompValFlag_dbF_c20240101__20241231_zPjtMA4h4jaj"&gt;not&lt;/span&gt; time the release of material non-public information in coordination
with grants of equity awards in a manner that intentionally benefits our NEOs.</ecd:AwardTmgMnpiDiscTextBlock>
    <ecd:AwardTmgMnpiCnsdrdFlag contextRef="From2024-01-01to2024-12-31" id="Fact000016">false</ecd:AwardTmgMnpiCnsdrdFlag>
    <ecd:MnpiDiscTimedForCompValFlag contextRef="From2024-01-01to2024-12-31" id="Fact000017">false</ecd:MnpiDiscTimedForCompValFlag>
    <ecd:PvpTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000019">&lt;table cellpadding="0" cellspacing="0" id="xdx_88F_eecd--PvpTableTextBlock_zq6prL7svOmc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Pay vs Performance Disclosure"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48E_eecd--PeoTotalCompAmt_hecd--IndividualAxis__ecd--PeoMember_zkiSFXM1Flya" style="border-bottom: Black 1pt solid; font-style: italic"&gt;&lt;span id="xdx_F50_zlT3owQFUjRj" style="font-family: Times New Roman, Times, Serif"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_485_eecd--PeoActuallyPaidCompAmt_zdTBalimNL8c" style="border-bottom: Black 1pt solid; font-style: italic"&gt;&lt;span id="xdx_F58_zDJd37nhkgP6" style="font-family: Times New Roman, Times, Serif"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-style: italic"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-style: italic"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(d)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48A_eecd--TotalShareholderRtnAmt_pp2d_zcNlbKvZm00f" style="border-bottom: Black 1pt solid; font-style: italic"&gt;&lt;span id="xdx_F50_zSSBzlw9pNv9" style="font-family: Times New Roman, Times, Serif"&gt;(e)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_485_eus-gaap--NetIncomeLoss_zMCRN15epKe1" style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Value of Initial Fixed $100 Investment Based on:&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center; font-weight: bold"&gt;Year&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Summary Compensation Table Total for PEO&lt;br/&gt;
($)&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Compensation Actually Paid to PEO&lt;br/&gt;
($)&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Average Summary Compensation Table Total for Non-PEO NEO&#x2019;s&lt;br/&gt;
($)&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Average Compensation Actually Paid to Non-PEO NEO&#x2019;s&lt;br/&gt;
($)&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Total Shareholder Return &lt;br/&gt;
($)&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Net Income&lt;br/&gt;
 ($)&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_414_20240101__20241231_zfb9bxFdPee4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; width: 9%; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;881,422&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;881,422&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 14%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eecd--NonPeoNeoAvgTotalCompAmt_c20240101__20241231_fKGMp_zBlJIf9XSpFe" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0024"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;n/a&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 12%"&gt;&lt;span id="xdx_906_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20240101__20241231_fKGQp_zQ7SrlQOh5s7" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0025"&gt;-&lt;/span&gt;&lt;/span&gt;n/a&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 10%; text-align: right"&gt;137.14&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 10%; text-align: right"&gt;(4,713,597&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_415_20230101__20231231_zWkOoQBUHpvk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;680,265&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;680,265&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eecd--NonPeoNeoAvgTotalCompAmt_c20230101__20231231_fKGMp_zMMPUIshnIJ9" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0030"&gt;-&lt;/span&gt;&lt;/span&gt;n/a&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20230101__20231231_fKGQp_zrxU16swoBTi" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0031"&gt;-&lt;/span&gt;&lt;/span&gt;n/a&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;150.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(6,929,104&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ecd:PvpTableTextBlock>
    <ecd:PeoTotalCompAmt
      contextRef="From2024-01-012024-12-31_ecd_PeoMember"
      decimals="0"
      id="Fact000020"
      unitRef="USD">881422</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000021"
      unitRef="USD">881422</ecd:PeoActuallyPaidCompAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="2"
      id="Fact000022"
      unitRef="USD">137.14</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000023"
      unitRef="USD">-4713597</us-gaap:NetIncomeLoss>
    <ecd:PeoTotalCompAmt
      contextRef="From2023-01-012023-12-31_ecd_PeoMember"
      decimals="0"
      id="Fact000026"
      unitRef="USD">680265</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000027"
      unitRef="USD">680265</ecd:PeoActuallyPaidCompAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="From2023-01-012023-12-31"
      decimals="2"
      id="Fact000028"
      unitRef="USD">150.00</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000029"
      unitRef="USD">-6929104</us-gaap:NetIncomeLoss>
    <ecd:PeoName contextRef="From2023-01-012023-12-31" id="Fact000033">Mr. Haverhals</ecd:PeoName>
    <ecd:PeoName contextRef="From2024-01-01to2024-12-31" id="Fact000034">Mr. Haverhals</ecd:PeoName>
    <ecd:AdjToPeoCompFnTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000040">&lt;p id="xdx_891_eecd--AdjToPeoCompFnTextBlock_dU_znX9qEJHLhTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Calculation of Compensation Actually Paid to PEO (column b)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20241231_zoMRZbjr2hLi" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20231231_zXTWDsneJER" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eecd--PeoTotalCompAmt_zQ91A81q8oVk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Total Summary Compensation Paid Table (SCT) - column (a)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;881,422&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;680,265&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eecd--AdjToCompAmt_hecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--ValueReportedUnderStockAwardsInSCTMember_ziuhK0SIt8h4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: value reported under stock awards in the SCT&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0045"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0046"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eecd--AdjToCompAmt_hecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--FVOfUnvestedEquityAwardsAtYearEndMember_z9e9k8vSD4i1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Add: FV of unvested equity awards at year-end 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0048"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0049"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eecd--AdjToCompAmt_hecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--FVOfVestedAwardsAsOfVestingDateMember_zgFNlA89vAC5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Add: FV of vested awards as of the vesting date.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0051"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0052"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eecd--AdjToCompAmt_hecd--IndividualAxis__ecd--PeoMember__ecd--AdjToCompAxis__custom--FVOfVestedAwardsAsOfVestingDateMember_zt9JzYYPyTQ2" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Adjustment to Compensation Amount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0054"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0055"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eecd--PeoActuallyPaidCompAmt_zfE4bxfcjOe3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Compensation actually paid&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;881,422&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;680,265&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ecd:AdjToPeoCompFnTextBlock>
    <ecd:PeoTotalCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000042"
      unitRef="USD">881422</ecd:PeoTotalCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000043"
      unitRef="USD">680265</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000057"
      unitRef="USD">881422</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000058"
      unitRef="USD">680265</ecd:PeoActuallyPaidCompAmt>
    <ecd:NamedExecutiveOfficersFnTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000060">&lt;p id="xdx_896_eecd--NamedExecutiveOfficersFnTextBlock_dU_zil8ZrYNAs6h" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    amounts reported in this column are the amounts of total compensation reported for &lt;span id="xdx_907_eecd--PeoName_c20230101__20231231_zjT7BL49fKR8"&gt;&lt;span id="xdx_906_eecd--PeoName_c20240101__20241231_zsfrw315eH67"&gt;Mr. Haverhals&lt;/span&gt;&lt;/span&gt;, Chief Executive Officer, for each
    corresponding year in the &#x201c;Total&#x201d; column of the Summary Compensation Table (&#x201c;SCT&#x2019;) on page 12 of this proxy
    statement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;/table&gt;

</ecd:NamedExecutiveOfficersFnTextBlock>
    <ecd:PeoName contextRef="From2023-01-012023-12-31" id="Fact000061">Mr. Haverhals</ecd:PeoName>
    <ecd:PeoName contextRef="From2024-01-01to2024-12-31" id="Fact000062">Mr. Haverhals</ecd:PeoName>
    <ecd:Additional402vDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000064">&lt;p id="xdx_891_eecd--Additional402vDisclosureTextBlock_dU_zARRJIaWXtJ2" style="margin: 0; display: none"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    amounts reported in this column represent the amount of compensation actually paid (&#x201c;CAP&#x201d;) Mr. Haverhals as computed
    in accordance with Item 402(v) of Regulation S-K, but do not reflect the actual amount of compensation earned by or paid to Mr. Haverhals
    during the applicable year. The determination of CAP begins with the total compensation reported in the SCT, which is then adjusted
    by equity-based and other compensation as set forth in the following table. For equity-based awards made during the year, the recorded
    grant date value is replaced with the estimated year-end value. For equity-based awards made in prior years that remain unvested
    at year-end, the estimated change in value from the beginning to the end of the year is included. For equity-based awards made in
    prior years, but vested during the year, the estimated change in value from the beginning of the year to the date of vesting is included:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;/table&gt;

</ecd:Additional402vDisclosureTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000020"
          xlink:label="Fact000020"
          xlink:type="locator"/>
        <link:footnote id="Footnote000032" xlink:label="Footnote000032" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
    amounts reported in this column are the amounts of total compensation reported for <xhtml:span id="xdx_90E_eecd--PeoName_c20230101__20231231_zqRdsMtPhZr6"><xhtml:span id="xdx_907_eecd--PeoName_c20240101__20241231_zmayI0bM3Y88">Mr. Haverhals</xhtml:span></xhtml:span>, Chief Executive Officer, for each
    corresponding year in the &#x201c;Total&#x201d; column of the Summary Compensation Table (&#x201c;SCT&#x2019;) on page 12 of this proxy
    statement.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000020"
          xlink:to="Footnote000032"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000026"
          xlink:label="Fact000026"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000026"
          xlink:to="Footnote000032"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000021"
          xlink:label="Fact000021"
          xlink:type="locator"/>
        <link:footnote id="Footnote000035" xlink:label="Footnote000035" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
    amounts reported in this column represent the amount of compensation actually paid (&#x201c;CAP&#x201d;) Mr. Haverhals as computed
    in accordance with Item 402(v) of Regulation S-K, but do not reflect the actual amount of compensation earned by or paid to Mr. Haverhals
    during the applicable year. The determination of CAP begins with the total compensation reported in the SCT, which is then adjusted
    by equity-based and other compensation as set forth in the following table. For equity-based awards made during the year, the recorded
    grant date value is replaced with the estimated year-end value. For equity-based awards made in prior years that remain unvested
    at year-end, the estimated change in value from the beginning to the end of the year is included. For equity-based awards made in
    prior years, but vested during the year, the estimated change in value from the beginning of the year to the date of vesting is included:</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000021"
          xlink:to="Footnote000035"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000027"
          xlink:label="Fact000027"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000027"
          xlink:to="Footnote000035"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0024"
          xlink:label="xdx2ixbrl0024"
          xlink:type="locator"/>
        <link:footnote id="Footnote000036" xlink:label="Footnote000036" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
    amounts reported in this column represent the average of the amounts reported for the Company&#x2019;s Non-CEO named executive officer&#x2019;s
    (&#x201c;NEOs&#x201d;) as a group in the &#x201c;Total&#x201d; column of the SCT in each applicable year. There were no NEO&#x2019;s at
    the company during 2024 and 2023, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0024"
          xlink:to="Footnote000036"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0030"
          xlink:label="xdx2ixbrl0030"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0030"
          xlink:to="Footnote000036"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0025"
          xlink:label="xdx2ixbrl0025"
          xlink:type="locator"/>
        <link:footnote id="Footnote000037" xlink:label="Footnote000037" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
    amounts reported in this column represent the average amount of CAP to the Non-CEO NEOs as a group, as computed in accordance with
    Item 402(v) of Regulation S-K. Since there were no adjustments to be made for these NEO&#x2019;s, the amounts actually paid are equal
    to the SCT amounts calculated in the previous column.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0025"
          xlink:to="Footnote000037"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0031"
          xlink:label="xdx2ixbrl0031"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0031"
          xlink:to="Footnote000037"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000022"
          xlink:label="Fact000022"
          xlink:type="locator"/>
        <link:footnote id="Footnote000038" xlink:label="Footnote000038" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">This
    represents the year-end value of an initial $100 investment made at the beginning of the period.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000022"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000028"
          xlink:label="Fact000028"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000028"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
